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Foram Sanjaykumar Dave 
INVESTIGATING THE ROLE OF TAM (TYRO3, AXL AND MERTK) 
FAMILY RECEPTORS IN MERLIN DEFICIENT TUMOURS 
Abstract 
Mutations in the NF2 gene, which codes for the tumour suppressor Merlin, is 
responsible for the development of all Neurofibromatosis Type 2 (NF2)-related tumours 
including schwannomas, meningiomas and ependymomas. These tumours can also 
occur spontaneously in non-NF2 patients. The only available treatments for this group 
of tumours are surgery and radiosurgery/radiotherapy. Hence, there is an urgent need 
for new effective drug-based treatments. 
TAM (TYRO3, AXL and MERTK) family receptors are involved in tumour development, 
progression, metastasis and resistance to targeted therapies in several cancers. Our 
group previously showed overexpression and hyper-activation of all three TAM family 
receptors and their ligand Gas6 in schwannomas. The key role of AXL in promoting 
tumour development by altering proliferation, adhesion and survival of human 
schwannoma primary cells in vitro was also established. The aim of this project is to 
explore the role of TYRO3 and MERTK in schwannomas’ and all three TAM members in 
meningiomas’ pathogenesis. 
Western blotting demonstrated that AXL, MERTK, TYRO3 and their ligand Gas6 are 
highly expressed and activated in Merlin-deficient meningioma tissues and cells. The 
expression of AXL, MERTK and TYRO3, but not Gas6, appear to be Merlin-dependent in 
meningiomas. MERTK forms a complex with TYRO3 but not with AXL in both 
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meningioma and schwannoma tissues, and its expression is mandatory to maintain AXL 
and TYRO3 levels in both cell-types. 
MERTK and AXL contribute to increased proliferation and survival of schwannoma and 
meningioma cells in vitro. MERTK acts via JNK, FAK and cyclin-D1 in meningiomas, and 
via JNK, AKT, FAK and cyclin-D1 in schwannomas. Pathological proliferation and survival 
of both cell-types was successfully reversed by AXL inhibitor BGB324 and MERTK 
inhibitor UNC2025 in vitro, with UNC2025 being more effective. TYRO3 had no effect on 
cell proliferation of either schwannoma or meningioma cells.  
In conclusion, AXL and MERTK are important in schwannoma and meningioma 
pathogenesis and are potentially good therapeutic targets. MERTK inhibitor UNC2025 
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1.1 Neurofibromatosis  
Neurofibromatosis (NF) is an autosomal dominant genetic condition, primarily described 
by multiple cutaneous lesions and the tumours of central and peripheral nervous system. 
The term neurofibromatosis was first described by the German pathologist Friedrich 
Daniel von Recklinghausen in 1822 (Madigan and Shaw, 1988). In 1982, Riccardi 
classified the heterogenous disorder into eight categories with designations, clinical 
features and the pattern of an inheritance (Riccardi, 1982). Later, in 1987 National 
Institute of Health (NIH) published the basis for a current guideline of NF diagnosis. NIH 
consensus panel classified NF into two distinguish genetic conditions according to the 
characteristic features of each and numbered them as Neurofibromatosis type 1 (NF1), 
previously known as Recklinghausen's disease or peripheral neuroma and 
Neurofibromatosis type 2 (NF2), referred as central neurofibroma (NIH Consensus 
Development Conference, 1988)  
1.1.1 Neurofibromatosis type 1 (NF1) 
NF1 is the most common genetic condition, affecting 1 in 3500 individuals. The gene for 
NF1 is located on chromosome 17q11.2 and encodes the protein neurofibromin (Boyd et 
al., 2009). Neurofibromin is GTPase-activating protein (GAP) and is expressed by many 
cell-types including neurons, glial cells, Schwann cells and melanocytes (Boyd et al., 
2009). Neurofibromin maintains cell proliferation and differentiation by negatively 
regulating mitogenic RAS signaling. Hence, the loss of tumour suppressor neurofibromin 
leads to pathogenesis of NF1 by RAS stimulated RAF/MEK/ERK and PI3K/AKT/mTOR 
pathway (Bollag et al., 1996). The most common clinical features associated with the 
disease includes café-au-lait spots (CAL), neurofibromas, skin freckling, lisch nodules 
and optic gliomas. Neurofibromas originally arise from Schwann cells and café-au-lait 
spots from melanocytes. Both cell-types harbor mutation in both NF1 alleles, including a 
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germline and an acquired somatic mutation. In addition, patients can also exhibit other 
symptoms like learning disabilities, malignant peripheral nerve sheath tumours (MPNST) 
and bone deformities such as curvature of the spine (scoliosis) and congenital 
pseudarthrosis of the tibia (CPT) (Friedman, 2002). MPNST are highly aggressive 
malignancies with lifetime incidences in NF1 patients is 8-13% and the five years survival 
of only ~50% (Watson et al., 2017, Kahn et al., 2014).   
1.1.2 Neurofibromatosis type 2 (NF2) 
NF2 is characterized by the development of multiple benign (non-cancerous) tumours of 
nervous system. Bilateral vestibular schwannomas (BVS) of the eigth cranial nerve is a 
hallmark of the disease (Figure 1.1). Moreover, 50-60% of NF2 patients also develop 
intracranial meningiomas and 75% of patients develop spinal schwannomas, 
meningiomas and/or ependymomas. Since the initial guidelines of NF2 diagnosis criteria 
proposed in 1987, continuous revisions have been made over years as more knowledge 
about the condition and its genetics become available (NIH Consensus Statement, 1987) 
(Gutmann et al., 1997) (Baser et al., 2011). The most up-to-date, revised diagnostic 
criteria were presented in 2018 which involves mandatory molecular testing of 
individuals with unilateral vestibular schwannomas (UVS) for NF2 or Leucine-zipper-
like transcriptional regulator 1 (LZTR1) to rule out schwannomatosis associated 
schwannomas (more information in chapter-1.1.3) (Table-1.1). 
- 4 - 
 
  
Table 1. 1 - The Manchester Diagnostic criteria for NF2 (Evans et al., 2018). 
 
The estimated prevalence rate of NF2 is 1 in 25,000 individuals. Interestingly, despite not 
occurring as frequently as NF1, the tumour types associated with NF2 are the most 
common in neuro-oncology and can cause significant morbidity and mortality in majority 
of the patients depending on the size and location of the tumour (Gerber et al., 2009). 
Hearing impairment is a primary symptom of almost all NF2 patients and that attributes 
to vestibular schwannomas (VS). At the time of onset, hearing loss is mostly unilateral 
which may be accompanied or preceded by tinnitus. Many NF2 patients also experience 
dizziness and balance issues as primary symptoms of the disease. Other symptoms present 
in NF2 patients are due to intracranial meningiomas, spinal tumours and cutaneous 
schwannomas. Seizures, headaches, impaired vision and cognitive and behavioral 
problems are common indications associated with meningiomas. Spinal tumours usually 
cause muscle pain, weakness and paresthesia and many NF2 patients become wheelchair 
bound by adulthood. Vertigo, blindness, numbness, tingling, nausea and vomiting are less 
common symptoms in the beginning and usually evident of later stages of the disease 
(Evans et al., 1992, O'Shaughnessy and Bussieres, 2006). 
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1.1.3   Schwannomatosis  
Schwannomatosis shares significant clinical overlap with NF2 and is characterized by the 
development of multiple schwannomas but rarely meningiomas ((Merker et al., 2012). 
The estimated prevalence rate of schwannomatosis is 1/40,000-1/70,000 (Koontz et al., 
2013). Once considered as an attenuated form of NF2, schwannomatosis was recognized 
as genetically and clinically distinct form of NF in late 90’s (MacCollin et al., 1996, 
Jacoby et al., 1997).  
Most patients with schwannomatosis develop initial symptoms of the disease in second 
or third decade of their life, the majority of the cases being sporadic without any family 
history unlike NF2. Chronic pain is a hallmark of the disease and most often associated 
with depression and anxiety in many patients (Merker et al., 2012). Moreover, there is an 
increased concern of malignancy in patients with schwannomatosis compared to NF2, 
specifically for malignant peripheral nerve sheath tumour (MPNST) (Gonzalvo et al., 
2011).  
Schwannomas linked to schwannomatosis usually affect spine and peripheral nerves but 
are not associated with BVS, which is characteristic feature of NF2. Schwannomatosis 
patients may develop UVS and care should be taken not to misdiagnose it as NF2 (Smith 
et al., 2012). Moreover, intradermal schwannomas, ependymomas, cataract and retinal 
abnormalities that are commonly observed in NF2 patients, are absent in 
schwannomatosis (Smith et al., 2015). 
Recent molecular studies identified two novel genes SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) and LZTR1 
on chromosome 22 as responsible for the pathogenesis of schwannomatosis ((Piotrowski 
et al., 2014)). Moreover, NF2 somatic mutations affecting both alleles are often present, 
schwannomas linked to schwannomatosis lack classical NF2 genetic mutation seen in 
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NF2 patients. Tumourogenesis is believed to occur via four-hit, where patient carry 
germline mutation in SMARCB1 (1 hit), followed by loss of portion of chromosome 22 
which harbors second SMARCB1 allele and one NF2 allele (hit 2 and 3), subsequently 
mutation in the raminaing NF2 allele (hit 4) (Plotkin et al., 2013). The genetic differences 
in molecular etiology of two conditions provide the basis of molecular testing that 
distinguish NF2 and schwannomatosis from each other. Patient’s blood and tumour 
samples are now routinely checked for mutations in SMARCB1, LZRT1 and NF2 genes 
to improve diagnosis (Piotrowski et al., 2014, Sestini et al., 2008). 
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1.2 NF2 related tumours 
1.2.1 Schwannomas 
Schwannomas are benign and encapsulated tumours of peripheral nerves, composed 
purely of Schwann cells. They can arise as a part of the hereditary condition NF2, 
schwannomatosis or sporadically and account for about 20% of adult nervous system 
tumours. Schwannomas associated with NF2 affect less than 5% of population and more 
than 90% of patients develop unilateral sporadic schwannomas. The chances of 
schwannomas undergoing malignant transformation is very rare but may occur following 
therapeutic irradiation (Mahboubi et al., 2015, Hilton and Hanemann, 2014).  
VS of the eigth cranial nerve (CN) are the most common CN schwannoma, with overall 
lifetime risk of approximately 1 in 1000 (Figure 1.1) (Hanemann, 2008, Laws and Thapar, 
1993, Evans et al., 2005). Other CN rarely found affected by schwannoma involves; 
trigeminal nerve (CN V), the facial nerve (CN VII), glossopharyngeal (CN IX) the vagal 
(CN X), accessory (CN XI) or hypoglossal nerve (CN XII) (Laws and Thapar, 1993).  
Schwannomas arising from nerves within spinal canal are also very common and account 
for 3% of all spinal tumours with the annual incidences of 0.3-0.5/100,00 (Rustagi et al., 
2012, Conti et al., 2004). While the most cases of sporadic schwannomas are diagnosed 
between 50-60 years of age, NF2-related schwannomas affect individuals in their 20s or 
30s with no gender bias and often develop at multiple locations within the nervous system 
(Evans et al., 2005, Mahboubi et al., 2015).  
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Figure 1. 1: Images of vestibular schwannoma. Illustration showing small vestibular 
schwannoma arising from superior vestibular nerve in internal auditory meatus and protruding 
into posterior fossa (Image is taken from (Lam, 2016)) A); MRI image of a 28-year old male with 
bilateral vestibular schwannomas (BVS) (Image is taken from (L, 2019)) B).  
 
 
Histologically, schwannomas consist of two distinct cellular growth patterns: Antoni A 
regions described by highly dense cellular areas and Antoni B regions composed of 
loosely arranged tumour cells. Sometimes schwannomas show parallel arrays of two rows 
of palisading nuclei, forming the unique structure called Verocay bodies (Hilton and 
Hanemann, 2014).  Compared to normal healthy Schwann cells which are slim elongated 
and bipolar in nature; schwannoma cells in culture show increased spreading, multiple 
membrane extensions and enhanced cell-matrix adhesion (Figure 1.2) (Hanemann, 2008) 
. The tumour cells demonstrate strong and diffuse staining of S-100, a calcium binding 
protein and routinely used as a diagnostic marker for schwannomas (Boulagnon-Rombi 
et al., 2017). Small subsets of schwannomas are positive for glial fibrillary acid protein 
(GFAP) (Kawahara et al., 1988). Moreover, Sox-10, calretinin and podoplannin are also 
increasingly use as a positive marker for schwannomas (Choi et al., 2017, Jokinen et al., 
2008, Fine et al., 2004). Although mostly homogenous with limited range of cellular 
components, schwannomas still show few interesting histological diversities. 
Histological variants other than classical schwannomas reported so far involve; cellular 
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schwannomas, plexiform schwannomas and melanotic schwannomas (Hilton and 
Hanemann, 2014).  
 
Figure 1. 2: Electron microscopic pictures showing differences in cell shape of Schwann cells 
and schwannoma cells. Schwannoma cells (NF2-/-) show increased spreading and membrane 
ruffling (left panel) whereas schwann cells (NF2+/+) show thin, elongated bipolar structure (right 
panel) (Image is taken from (Hanemann, 2008)).  
 
Early cytogenetic analysis revealed partial or complete loss of chromosome 22 as the 
main characteristic feature of schwannomas and proposed NF2 as a candidate gene 
responsible for the formation of schwannomas (Stenman et al., 1991, Bijlsma et al., 1992). 
Other rare chromosomal changes observed to date by different investigators; involves loss 
of chromosome 9p, 1p, 11q,  13q and copy gains on chromosome 9q, 10q, 17q, 19p, 19q 
(Koutsimpelas et al., 2011, Leone et al., 1998, Warren et al., 2003). However, 
chromosome 22 is the only consistently reported genetic alteration associated with 
schwannomas; further clinical relevance of all other chromosomal changes is needed. 
The bi-allelic inactivating mutation of NF2 gene by Knudson’s two-hit model, which 
leads to complete loss of Merlin, is responsible for all NF2 related schwannomas as well 
as 30-60% of sporadic schwannomas (Lee et al., 2012, Ikeda et al., 2005). The recent 
genomic sequencing data reveals that at least ~40% of sporadic VS cases are due to a 
single mutation in NF2 gene and are associated with a less aggressive phenotype 
compared to their bi-allelic counterpart. Moreover, bi-allelic mutation or ‘two-hit’ is more 
common in younger individuals and may be responsible for the clinical progression of 
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the tumours (Chen et al., 2017). This newly published data provides biological 
background to the previously published reports which have shown the correlation 
between tumour growth speed and younger age (Mohyuddin et al., 2015). In addition to 
NF2, loss of chromatin-modifying genes AT-rich interactive domain-containing protein 
1A (ARID1A) and AT-rich interactive domain-containing protein 1B (ARID1B) as well as 
mutation in discoidin domain receptor family, member 1 (DDR1) genes were found to be 
responsible for around 29% and 11% of sporadic schwannoma cases respectively. The 
subset of schwannomas harbors the balanced chromosomal translocation on chromosome 
10q which results in a fusion of SH3PXD2A-HTR1A, with higher predominance in males 
and leads to increased proliferation and invasion of the tumour (Agnihotri et al., 2016). 
In addition to genetic factors, hay fever, exposure to high level of sounds, ionizing  and 
non-ionizing radiation are some of the environmental risk factors proposed to be 
responsible for schwannoma’s etiology (Corona et al., 2009).  
1.2.2 Meningiomas 
Meningiomas are the most common primary brain tumour and arise from the meningeal 
covering of the brain and spinal cord. The meniges are composed of three protective 
layers; the dura mater (the outermost layer), the arachnoid mater (the middle layer) and 
the pia mater (the innermost layer) (Haines D, 2018). Meningiomas are thought to 
originate from arachnoid cells of the meninges and may occur anywhere arachnoid cells 
are present (Figure 1.3).  
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Figure 1. 3: The structure of Meninges. Schematic representation of the meninges showing 
three layers; the dura mater, arachnoid mater and pia mater. Meningiomas are thought to 
originate from arachnoid cells (Image is taken from (Kolias et al., 2014)). 
 
Meningiomas account for 20-30% of primary intracranial tumours and high proportion of 
the meningiomas are found to be located in the region of convexity, parasagittal and 
sphenoid (Figure 1.4). Spinal location is rare but found to be a primary site in 12% of 
meningioma patients (Bondy and Ligon, 1996, Buetow et al., 1991) .  Meningiomas are 
mostly sporadic in nature but approximately 50% of meningiomas are associated with the 
genetic condition- NF2 (Smith et al., 2011). Females have a two-fold higher incidence of 
meningioma compared to males, except for atypical and anaplastic meningiomas which 
show higher predominance in males (Liang et al., 2014). The incidence of meningiomas 
increases with age in both males and females, with peak incidences reported after age 65. 
The correlation between age and grade of meningiomas is still a controversial topic with 
some reports suggesting that younger patients are more prone to higher grade 
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meningiomas. Liang et al. however, found no correlation between meningioma tumour 
grade and age (Wang et al., 2013, Liang et al., 2014)  
 
Figure 1. 4: Illustration of intracranial meningiomas. Schematic diagram shows the locations 
of skull base tumours (left) and the locations of parasagittal, falcine, covexity and intraventricular 
tumours (right) (Image is taken from (Nanda et al., 2017)).  
  
 
WHO (World Health Organization) classification categorizes meningiomas into 15 
different subtypes depending on the histological and biological diversity of the tumours 
(Table-1.2). The WHO grade I (G-I) comprises nine variants that represents 80% of all 
meningiomas with meningothelial, fibroblastic and transitional subtypes are being the 
most common. G-I meningiomas are histologically benign in nature with less than 4 
mitoses/10 microscopic high-power field (HPF) (Louis et al., 2007, Louis et al., 2016). 
The WHO grade-II (G-II) and grade-III (G-III) meningiomas have higher recurrence rates 
with aggressive tumour biology. WHO G-II or atypical meningiomas account for 15-20% 
of all cases and are characterized by increased mitotic activity; 4-19 mitoses/10 
microscopic HPF or the presence of 3 out 5 of the following features: sheet-like growth, 
spontaneous necrosis, high nuclear to cytoplasmic ratio, prominent nucleoli and tumour 
necrosis (Maier et al., 1992). Chordoid and clear-cell meningiomas are the variants of G-
II meningiomas (Zorludemir et al., 1995, Couce et al., 2000). Meningiomas with 20 or 
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more mitoses/10 HPF and resemblance to sarcoma or carcinoma, are considered as G-III 
or anaplastic meningiomas. G-III meningiomas involve rhabdoid and papillary subtypes 
with the incidence rate of only 1-2% but are associated with high recurrence rate (~50-
80% of cases) and usually cause death within two years of diagnosis (Perry et al., 1999, 
Pasquier et al., 1986, Kepes et al., 1998). 
In accordance with schwannomas, loss of chromosome 22 is the most consistent 
cytogenetic abnormality in meningiomas with ~50% of the tumours showing 
chromosome 22 monosomy (Zang, 2001). In addition, loss of chromosome 1p, 14q, 9p21 
and abnormality in chromosome 10 and 17q is frequently associated with tumorigenesis 
and progression to higher grade meningiomas (Alahmadi and Croul, 2011, Cai et al., 
2001). Especially, the loss of chromosome 1p is associated with high recurrence rate and 
is mostly found in meningiomas located at the convexity but not in skull base or spinal 
meningiomas (Ketter et al., 2008)  
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Table 1. 2 - Table showing histological subtypes, WHO diagnostic criteria, mutations and 
chromosomal alterations across meningiomas (Adapted from (Bi et al., 2016)). 
 
Mutations in the NF2 gene is responsible for 40-60% of sporadic meningiomas, in 
addition to familial meningiomas. The role of the NF2 gene in meningioma’s 
pathogenesis is still conflicting, with many reports suggesting NF2 mutation as an early 
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event in tumorigenesis (Perry et al., 2000, Menon et al., 1997). However, Peyre et al 
argued this, showing in NF2 knock-out mouse that NF2 cooperates with cdkn2ab and is 
responsible for progression of G-I meningioma to G- II/III (Peyre et al., 2013). Moreover, 
NF2 mutated meningiomas are prone to higher chromosomal instability during malignant 
progression and are larger in tumour size compared to their NF2-wild type counterparts 
(Goutagny et al., 2010, Yuzawa et al., 2016). In addition to NF2, chromosome 22 harbors 
genes like SMARCB1, checkpoint kinase 2 (CHEK2) and clathrin heavy chain 
polypeptide gene (CLH-22/CTCL1) which have been shown to be responsible for 
meningioma pathogenesis (Yang et al., 2012, van den Munckhof et al., 2012). Isolated 
cases of familial meningiomas have also been observed due to genetic mutation in 
SMARCE1 and SUFU gene, which causes multiple non-NF2 spinal and cranial 
meningiomas (Smith et al., 2014, Aavikko et al., 2012). 
The recent data from the next generation DNA sequencing has identified new somatic 
recurrent mutation responsible for benign meningiomas. These non-NF2 mutations are 
specific to G-I meningiomas and involve pro-apoptotic E3 ubiquitin ligase TNF receptor-
associated factor 7 (TRAF7), the proto-oncogene v-Akt murine thymoma viral oncogene 
homolog 1 (AKT1), the pluripotency transcription factor kruppel like factor 4 (KLF4), the 
Hedgehog pathway signaling member smoothened (SMO). In conclusion, non-NF2 
recurrent somatic mutations represent ~40% of sporadic meningioma cases and are 
enriched in the skull base tumours in contrast to NF2 tumours which are most commonly 
found in calvarium (Brastianos et al., 2013, Clark et al., 2013, Abedalthagafi et al., 2016, 
Yuzawa et al., 2016). A recurrent mutation in KLF4K409Q on chromosome 9q31 which 
results in a lysine to glutamine substitution at codon 409 has shown to be responsible for 
~15% of G-I meningiomas. KLF4K409Q is the second highest mutation after TRAF7 located 
on 16p13, which causes ~25% of benign meningiomas. The remaining AKT1 and SMO 
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mutations occur almost at similar frequencies and harbor ~5-8% of benign meningiomas 
(Clark et al., 2013, Abedalthagafi et al., 2016). TRAF7 mutations in most cases co-occur 
with mutations in KLF4 and AKT1 but independent of NF2 and SMO. Moreover, KLF4 
and AKT1 mutation occurs mutually exclusive of each other and mutations in all three 
genes (KLF4, AKT1 and TRAF7) are exclusive of SMO, NF2 or chromosome 22 loss 
(Figure-1.5) (Clark et al., 2013). 
 
Figure 1. 5- Graph showing distribution of NF2 and non-NF2 mutations in G-I 
meningiomas.  Mutation in TRAF7, KLF4, AKT1 and SMO occurs in mutually exclusive pattern 
of NF2. The proportion of overlap of AKT1 and KLF4 with TRAF7 has represented in Venn 
diagram (Image is taken from (Bi et al., 2016)).  
 
Mutations in certain genes have associated with higher grades of meningiomas. The 
mutation in telomerase reverse transcriptase (TERT) promoter that leads to higher 
expression of TERT protein is indicative of progression to higher grade meningiomas 
(Goutagny et al., 2014, Stogbauer et al., 2019, Collord et al., 2018). Transformation of 
atypical (G-II) meningiomas to the rhabdoid subtype, the most aggressive form of G-III 
meningiomas, is associated with lack of ARID1A protein due to frameshift deletion of 
ARID1A (Bujko et al., 2017). Higher expression of PPM1D in G-II and G-III 
meningiomas is the predictive marker for progression (Fukami et al., 2016). Recently, 
Vasudevan et al. linked the higher expression of forkhead box protein M1 (FOXM1), 
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which is negatively regulated by NF2, with poor clinical outcomes and aggressive forms 
of meningiomas (Vasudevan et al., 2018). 
The genetic alteration profile of meningiomas correlates to specific grade and histologic 
subtypes. NF2 mutation is a common occurrence in fibroblastic and transitional subtypes 
of G-I meningiomas while AKT1E17K is associated with meningothelial subtypes but 
rarely seen in G-II and G-III meningiomas (Wellenreuther et al., 1997, Sahm et al., 2013). 
Almost all cases of secretory meningiomas appeared to have mutation in TRAF7 and 
KLF4 K409Q. SMARCE1 is the signature mutation associated with cranial and spinal clear 
cell meningiomas (Smith et al., 2013, Smith et al., 2014). Multiple chromosomal 
polysomies on chromosome 5 are linked to angiomatous subtype of G-I meningiomas and 
unbalanced translocation between chromosome 1 and 3 is the marker for G-II chordoid 
meningiomas (Abedalthagafi et al., 2014, Steilen-Gimbel et al., 1999).  
Despite recent advances in the understanding of molecular markers for meningiomas, the 
current diagnosis of meningiomas grade is based solely on tumour histology. Although 
of high prognostic value, the current histology based WHO classification system for 
meningiomas many times results in interobserver and sampling bias in accurately 
determining the meningioma grade and to predict the associated risk of tumour recurrence 
for individual patients (Rogers et al., 2016). To solve this key problem, Sahm et al. 
recently classified meningiomas into six sub-groups based on DNA- methylation 
profiling by combine knowledge of histology and molecular markers. The methylation 
classes MC ben-1, MC ben-2, MC ben-3 and MC int-A are mostly composed of G-I 
tumours. MC ben G-I tumours have ~50-60% higher chances of progression free survival 
compared to MC int G-I tumours at 72 months. The grade-II tumours fall into MC int-A 
and MC int-B categories with a small subset belongs to MC ben. The progression free 
survival rate of G-II MC int-A and MC int-B at 72 months is ~28% and ~23% 
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respectively, whereas MC ben G-II tumours have 70% higher chances of being 
progression free at 72 months compared to MC int G-IIs. The probability of progression 
free survival for G-III tumours is only 15-18% at 24 months, these tumours belong to MC 
mal class of methylation (Sahm et al., 2017). This new innovative and precise DNA-based 
classification system may be a key turning point for the diagnosis and treatment decision-
making of meningiomas. 
In addition to genetic factors, ionizing radiation is the most consistently reported 
environmental factor known to increase the risk of meningiomas. Occupational exposure 
to certain metals like lead and iron increase the chances of meningiomas, especially in 
women (Sadetzki et al., 2016, Wesseling et al., 2002). Certain health conditionals like 
epilepsy, diabetes and hypertension have been linked to meningioma risk (Schwartzbaum 
et al., 2005, Schneider et al., 2005). Other common risk factors involve endogenous and 
exogenous hormone use, cell-phone use, cigarette smoking and allergies (Custer et al., 
2006, Schneider et al., 2005, Phillips et al., 2005). 
 
1.2.3 Ependymomas 
Ependymoma is a type of glioma, arising from the ependymal cells at different locations 
throughout the brain and spinal cord. It is the least frequent out of three tumours linked 
to NF2 condition and accounts for ~5% of all intracranial tumours. Approximately 29-
38% of ependymomas show mutation in NF2 or loss of heterozygosity (LOH) on 
chromosome arm 22q. NF2 mutation and Merlin loss is more common in spinal 
ependymomas than cranial (Hanemann, 2008). Ependymomas has not been studied in this 
project and will not be dicussed further, however, due to a common aetiology of subset 
of ependymomas with schwannomas and meningiomas, the findings presented in this 
study may also be relevant for NF2-mutated ependymomas. 
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1.3 Challenges in the management of NF2-related tumours 
The classical mainstay management options for schwannomas and meningiomas are 
surgery, radiosurgery/radiotherapy as well as ‘wait and scan’ strategy. Although drastic 
improvements in the diagnostic and surgical techniques have been made in last few 
decades, post-operative neurological complications based on tumour location are not rare. 
The preservation of hearing and facial nerve functions is the most common challenge 
while performing complete resection of tumours as well as with radiation treatment. The 
patients who undergo sub-total resection of tumour to preserve the nerve function or other 
complications face high recurrence rates compared to patients with total resected tumours. 
Furthermore, total resected tumours are not guaranteed to be recurrence free and up to 
60% of tumours come back after ~15 years. Post-operative cerebrospinal fluid (CSF) 
leaks may further complicate the patient’s condition and increases the chances of 
meningitis. In most cases, patients require re-operation and repair (Apra et al., 2018, 
Halliday et al., 2018) 
Surgery and radiosurgery/radiotherapy (RT) is an unattractive option for VS and 
meningiomas especially in NF2. NF2-related VS are multifocal and tend to grow faster 
compared to sporadic VS. The preservation of cochlear nerve is very difficult in NF2-
related VS and almost all NF2 patients become completely deaf (Evans, 2009). NF2-
related meningiomas located at the skull-base, cavernous sinuses and orbits are 
challenging to operate on and the success rate of RT is also limited (Blakeley and Plotkin, 
2016). Moreover, there are reports showing concern of increased chances of malignancy 
following RT in NF2 patients compared to patients with sporadic tumours (Evans et al., 
2006). Many patients with NF2 die or become wheel-chair bound by their early 20s or 
30s, adversely affecting the quality of life (Evans, 2009). This demands for new non-
invasive and effective drug-based treatments for NF2-related tumours. 
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As mutations in the NF2 gene is a common event of all NF2-related tumours, a better 
understanding of how NF2 mutation primes the upregulation of oncogenic signaling 
pathways and tumour development, will help us to define the best therapeutic target and 
treatment. 
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1.4 NF2 gene and Merlin 
NF2 was discovered in 1993, by two different groups individually, as an inactivated 
tumour suppressor gene, in the familial inherited disorder, Neurofibromatosis Type 2 
(NF2) (Rouleau et al., 1993, Trofatter et al., 1993). The ~95 kilobase pair (kb) NF2 gene 
consists of 17 exons and undergoes alternate splicing to generate multiple isoforms. 
Isoform I, which lacks exon 16 and isoform II that contains all 17 exons, are the most 
predominant isoforms of the gene. The diversity in NF2 isoforms are thought to be due 
to the presence of multiple polyadenylation sites (Chang et al., 2002) 
The wide variety of mutations in NF2 gene has been discovered which defines the severity 
of the disease. Protein truncating mutations such as frameshift insertion/deletion and 
nonsense mutations, which cause a severe phenotype with decreased survival rates 
amongst, NF2 patients, are the most common. Patients with constitutional missense 
mutations, large deletions and somatic mosaicism experience a comparatively milder 
phenotype. The germline NF2 splice-site mutation causes greater variability in the disease 
severity depending on the exons affected. Mutations in exons 13-15 cause a milder 
phenotype compared to mutations in exons 1-5 (Evans, 2009). In addition to mutational 
inactivation, loss of heterozygosity (LOH) and transcriptional inactivation are also major 
cause of NF2-related tumours. 60% of VS and 26% of sporadic meningiomas found to 
have methylation in NF2 promoter which correlate to decreased promoter activity and 
mRNA expression (Kino et al., 2001, Lomas et al., 2005). 
NF2 gene encodes the tumour suppressor protein Merlin (moesin ezrin radixin like 
protein). Merlin belongs to the protein 4.1 superfamily of cytoskeleton-associated 
proteins and has a high structural similarity to the other members of the family; Ezrin, 
Radixin, Moesin (ERM) proteins. Merlin is composed of three functional domains; an 
amino terminal (N-terminal) FERM domain which corresponds to exons 1-9, α helical 
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coil-coil domain corresponds to exons 10-13 and a carboxy terminal (C-terminal) domain 
corresponding to exons 14-17 of NF2 gene, mirroring the structure of ERM proteins 
(Figure-1.6). Unique from other ERM proteins however, Merlin interacts with the actin 
cytoskeleton through an actin-binding motif at the N-terminus instead of the C-terminus 
portion of the protein (Zhou and Hanemann, 2012). 
 
Figure 1. 6- The structure of protein Merlin. A schematic representation of the structure of 
protein Merlin shows the FERM domain in N-terminus followed by α-helical coil-coil region 
(CCR) and C-terminus domain (adapted from (Sun et al., 2002)).  
 
Merlin is ubiquitously expressed in all tissues during embryonic development. 
Homozygous deletion of NF2 in mice lead to embryonic failure (McClatchey et al., 1997), 
underlining the importance of Merlin in normal embryonic development. Expression of 
Merlin is restricted to certain tissues in adulthood including testis, ovaries, adrenal glands, 
lens, retina and neuronal tissues. In neuronal tissues, Merlin is expressed by both glial 
cells and neurons of CNS and PNS (Hanemann, 2008).  
In Schwann cells, the role of Merlin is not just restricted to a tumour suppressive function 
but is critical for organization of Schwann cell contacts. Here Merlin promotes the 
alignment of Schwann cells to axons thus, influencing myelin segment length. At a sub-
cellular level, Merlin is enriched in actin-rich cellular compartments like membrane 
ruffles and lamellipodia as well as cell-cell and cell-matrix contact sites in association 
with focal adhesion proteins (Hanemann, 2008, Schulz et al., 2014). 
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1.4.1 Merlin as a tumour suppressor 
Merlin works at multiple levels to regulate cellular proliferation. It acts as a tumour 
suppressor protein at the cell membrane by regulating the expression and activation of 
integrins and receptor tyrosine kinases (RTKs) and in the nucleus by suppressing the E3 
ubiquitin ligase CRL4DCAF1 (Figure-1.7) (Hanemann, 2008).  
1.4.1.1 Merlin’s role in contact dependent inhibition 
Merlin plays an important role in contact-dependent inhibition, the process by which 
normal cells undergo senescence and stop proliferating upon contact with neighbouring 
cells. Healthy cells recruit Merlin at cell-cell contacts where Merlin facilitates cadherin 
mediated cell-cell adhesion and inhibits the cell-growth (Lallemand et al., 2003). When 
Merlin is depleted, cadherin junctions are destabilized, Rac1 is recruited to the plasma 
membrane and there is an enhanced activity of RTK and Rac/PAK signaling, leading to 
tumour proliferation (Curto et al., 2007, Okada et al., 2005). In addition, Merlin can also 
associate with cluster of differentiation 44 (CD44) - hyaluronic acid receptor and paxillin 
to mediate contact-dependent cell inhibition of growth (Morrison et al., 2001, Fernandez-
Valle et al., 2002). 
1.4.1.2 Merlin’s role in regulation of RTKs and integrins 
RTKs are cell-surface receptors that mediate signaling pathways leading to cell-
proliferation, survival, differentiation and cell-migration. Over-expression and activation 
of RTKs is the most common event in the development of malignant as well as benign 
tumours, including Merlin-deficient tumours (Paul and Mukhopadhyay, 2004, 
Hanemann, 2008) 
A study in Drosophila shows that Merlin controls the availability of RTKs at the plasma 
membrane by regulating endocytosis. Defective endocytosis and degradation of RTKs 
due to loss of Merlin and the related tumour suppressor Expanded in Drosophila, leads to 
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upregulation of several RTKs including epidermal growth factor receptor (EGFR) (Maitra 
et al., 2006). Further direct evidence comes from a study in mouse primary Schwann cells, 
where Merlin restricts the delivery of several RTKs to plasma membrane. Loss of Merlin 
leads to accumulation of ErbB2, ErbB3, insulin-like growth factor receptor-1 (IGFR1) 
and platelet derived growth factor receptor 1 (PDGFR-1) at the plasma membrane in both 
NF-2 mutant mice and human NF2-deficient schwannomas (Lallemand et al., 
2009)(Ammoun et al., 2008). Both of these studies point to a complex level of regulation 
of RTKs by Merlin at the plasma membrane but helps to explain the link between loss of 
Merlin and overexpression/hyper activation of mitogenic signaling pathways such as 
Ras/Raf/MEK/ERK, PI3K/AKT, FAK/Src and Rac/PAK/JNK pathways downstream of 
RTKs in Merlin deficient tumours (Zhou and Hanemann, 2012, Ammoun and Hanemann, 
2011).  
Integrins are heterodimeric cell surface adhesion receptors. Integrin mediate adhesion to 
the extra-cellular matrix (ECM) is a crucial regulator of cell-proliferation, migration and 
survival (Schwartz and Assoian, 2001) Merlin is known to regulate the expression of 
integrins α6, β1 and β4 (Hanemann et al., 2006). High expression and activation of 
integrins in the absence of Merlin leads to a cascade of Rac/PAK/JNK, FAK/Src as well 
as mTORC1/Cyclin-D1 signaling. All of these pathways are known to enhance integrin-
mediated pathological adhesion, proliferation and survival (Xiao et al., 2002, Ammoun 
et al., 2012, Lopez-Lago et al., 2009).   
Co-operation between integrins and growth factor receptors is often essential to regulate 
cell proliferation and survival. In Merlin-deficient tumours, RTK mediated signaling and 
integrin mediated signaling every so often synergize. For example, in schwannoma cells 
activation of AXL receptor kinase and integrins, independently by their respective 
ligands, leads to phosphorylation of FAK molecule and increase in cell-proliferation, 
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adhesion and survival of schwannomas (Ammoun et al., 2012, Ammoun et al., 2014). In 
addition, to regulate the mitogenic signaling directly at plasma membrane, active Merlin 
can also enter the nucleus and indirectly regulate the activity of RTKs at the membrane 
by inhibiting promitogenic E3 ubiquitin ligase CRL4/DCAF1 in nucleus (Figure-1.3) (Li 
et al., 2010). 
As is clear from the above reports, RTKs are directly or indirectly involved in promoting 
key signaling pathways which leads to cell-proliferation, differentiation, migration and 
survival of Merlin-deficient tumours. Hence, targeting RTKs appears to be a good 
therapeutic strategy for these tumours.  
  




Figure 1. 7- A schematic diagram of Merlin’s role as tumor suppressor at the membrane 
and in nucleus; functional Merlin A) and loss of Merlin B). At the membrane Merlin inhibits 
RTK and integrin mediated Ras/Raf/MER/ERK, PI3K/AKT, FAK/Src and Rac/PAK/JNK 
signaling. In nucleus, it inhibits the E3 ubiquitin ligase CRL4/DCAF1 complex. CRL4/DCAF1 
can also regulate the expression of RTK and integrins and therefore is link to membrane signaling 
A); Loss of Merlin leads to upregulation of CRL4/DCAF1 in nucleus and membrane signaling of 
RTKs and integrins and enhances cell-proliferation, adhesion, survival and migration of cells B) 
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 1.5 Molecular targeted therapy for NF2 tumours 
Due to advances in the understanding of the molecular pathways responsible for the 
development of NF2-related tumours, many new potential therapeutic targets have 
recently emerged. It is now possible to reprofile many drug candidates which are already 
approved in the clinical setting for other conditions including but not exclusively, cancer, 
as well as to develop new therapeutic agents to benefit NF2 patients. Below I have 
summarised the candidates which are approved for or are currently in clinical trial for 
NF2-related tumours. 
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor 
(VEGF). VEGF and its receptor vascular endothelial growth factor receptor-1 (VEGFR-
1) are highly expressed in schwannomas and their expression corelate with increased 
tumour growth. The efficacy of bevacizumab was tested in small group of NF2 patients 
with progressive VS. Results showed that more than 50% of patients achieved 
radiographic response, defined as >20% decrease in tumour volume and audiological 
response, defined as significant increase in word-recognition score. 54% of patients had 
stable or decreased tumour size and 61% had stable or improved hearing after three years 
of treatment (Plotkin et al., 2012). Bevacizumab response in meningioma is poor but 
conversely, ependymomas responded impressively to the drug (Goutagny et al., 2011, 
Farschtschi et al., 2016). Long-term use of bevacizumab was associated with manageable 
toxicity including hypertension and proteinuria. However, one team reported the death of 
a patient due to cerebral hemorrhage, possibly linked to bevacizumab treatment. Despite 
good therapeutic response, close follow-up of NF2 patients treated with the drug is 
required to avoid long term drug related toxicity or further complications (Slusarz et al., 
2014, Alanin et al., 2015). VEGFR inhibitor- axitinib which demonstrated inhibition of 
tumour growth in a breast cancer xenograft model (Wilmes et al., 2007) and showed 
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partial responses in renal cell carcinoma patients (Karam et al., 2014) is now underway 
in a phase-II clinical trial for NF2 patients to determine the effect of the drug on NF2 
related tumours (NCT02129647). 
Since EGFR pathways are involved in the pathogenesis of all NF2-related tumours-
schwannomas, meningiomas and ependymomas, various EGFR kinase inhibitors have 
been investigated in pre-clinical and clinical studies. Erlotinib, an oral EGFR kinase 
inhibitor was administrated to 11 NF2 patients with progressive VS, who were poor 
candidates for standard therapy. Neither significant decrease in tumour volume nor 
improvement in hearing were observed. In fact, two patients developed progressive 
hearing loss whilst taking part in the trial (Plotkin et al., 2010). Results of erlotinib 
(NABTC 01-03) as well as another EGFR kinase inhibitor- gefitinib (NABTC 00-01) 
were discouraging also for meningiomas. Erlotinib is no longer in use for the treatment 
of NF2 patients. Icotinib another EGFR kinase inhibitor which has been shown to have 
modest therapeutic effect in non-small-cell lung cancer patients (Yang et al., 2017), is 
now in phase-II clinical trial for NF2 patients (NCT02934256). There are no published 
reports of EGFR inhibitors that have been or are being tested for ependymomas. 
Following promising results of pre-clinical study using human schwannoma primary cell 
model (Ammoun et al., 2010), lapatinib- a dual EGFR/ErbB2 kinase inhibitor was tested 
in phase-II clinical trial for NF2 patients with progressive VS (NCT00973739) and 
meningiomas (NCT00973739). 17 out of 21 VS patients experienced ≥15% decrease in 
tumour volume and nearly one third of evaluated patients had hearing improvement. 
However, ≥20% reduction in tumour volume is required to be considered as a significant 
response and hence, the trial results were categorized as a minor response (Karajannis et 
al., 2012). Karajannis et al suggested that combination therapy of lapatinib together with 
bevacizumab which has shown a good response in phase-II metastatic breast cancer trial 
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(Rugo et al., 2012), would be more efficient in NF2 patients. Progressive meningioma 
patients treated with lapatinib showed significant tumour shrinkage with best volumetric 
response of 26.1%. The drug was well tolerated among patients with minimum toxicity 
(Osorio et al., 2018).  
Mammalian target of rapamycin complex- 1 (mTORC1) is negatively regulated by 
Merlin. Activation of mTORC1 in the absence of Merlin is responsible for the growth of 
schwannomas and meningiomas in vitro and in vivo which can be reversed by 
mTORC1inhibitors- rapamycin and everolimus (James et al., 2009, Pachow et al., 2013, 
Giovannini et al., 2014). Based on pre-clinical data and safety profile of everolimus in 
other diseases, three phase-II clinical trials were conducted. In the first study, everolimus 
was administrated orally to 9 NF2 patients with progressive VS for 12 months. None of 
the 9 patients experienced volumetric or hearing response and the study concluded that 
everolimus did not have clinical anti-tumour activity against progressive VS in NF2 
patients (Karajannis et al., 2014). The second study showed that although unable to induce 
tumour shrinkage, everolimus maintained stable disease condition in 5 out of 9 patients 
with manageable mild toxicity. However, tumour resumed in this group of patients within 
3-6 months of treatment discontinuation (Goutagny et al., 2015). Third, phase-II study 
for everolimus (NCT01345136) is ongoing.  
AZD2014 is an mTORC1/mTORC2 dual kinase inhibitor. In the laboratory, AZD2014 
has proved its anti-tumour effect by blocking cellular pathways responsible for the growth 
and survival of meningiomas (Beauchamp et al., 2015). Although not approved by food 
and drug administration (FDA) yet, the first in human-pharmacokinetic and 
pharmacodynamic study of AZD2014 for multiple cancers have allowed investigators to 
determine the dose to achieve anti-tumour effect with minimum side effects (Basu et al., 
2015). Two phase-II clinical studies of AZD2014 are underway for NF2 patients with 
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progressive or symptomatic meningiomas (NCT02831257) and for patients with 
recurrent G-II and III meningiomas (NCT03071874). The main objective of both studies 
being to learn if AZD2014 can shrink or slow the tumour growth.  
Sorafenib (PDGFR/cRaf kinase inhibitor) and nilotinib (PDGFR kinase inhibitor) have 
been tested in human schwannomas in vitro by Ammoun et al in two separate studies. 
Both kinase inhibitors were able to decrease PDGFR-mediated ERK1/2 activity and 
proliferation of human schwannoma primary cells. Sorafenib was slightly more effective 
than the nilotinib in vitro which could be due to its inhibitory effect not only on PDGFR 
but also on the downstream Raf/MEK1/2/ERK1/2 pathway, which is activated in 
schwannomas not only by PDGF-DD but also by other growth factors released by 
schwannoma cells (Ammoun et al., 2008, Ammoun et al., 2011). Based on in vitro data, 
sorafenib has being assessed in phase 0 clinical trial (ISRCTN49989464) but was 
subsequently found to be insignificant (Ammoun et al., 2019). Due to the crucial role of 
Raf/MEK1/2/ERK1/2 pathway in schwannoma development, a combination of nilotinib 
and the MEK kinase inhibitor-selumitinib has also been tested in human schwannoma 
primary cells. Indeed, combination therapy of these two drugs resulted in a significant 
increase in the effectiveness of nilotinib towards decreasing schwannoma growth, 
suggesting nilotinib and selumitinib combination therapy could be beneficial for NF2 
patients (Ammoun et al., 2011). In 2017, a phase-II trial for selumitinib (NCT03095248) 
started recruiting patients with NF2-related tumours to determine if selumitinib is capable 
of inhibiting tumour growth, improve hearing and physical and emotional health in this 
group of patients. The trial is still ongoing with the results are scheduled to be released in 
2021. 
AR-42, a novel histone deacetylase (HDAC) inhibitor has gained attention for a treatment 
of schwannomas and meningiomas recently. Bush and colleagues showed that AR-42 
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inhibited cell-growth, induced apoptosis, decreased phosphorylation of AKT in Merlin-
deficient mouse and human schwannoma and meningioma primary cells as well as 
meningioma cell-line Ben-Men-I in vitro and schwannoma xenograft model in vivo (Bush 
et al., 2011). Subsequently AR-42 (NCT02282917) phase-0 clinical trial began for 
treatment of vestibular schwannomas and meningiomas in September 2015, the results of 
which are yet to be published.  
Recently, the effect of cabozantinib (XL184, CabometyxTM, Exelixis) and saracatinib 
(AZD0530, AstraZenca) was tested in Merlin-deficient primary mouse Schwann cells in 
vitro and in vivo. Cabozantinib is a c-Met inhibitor, FDA approved for the treatment of 
medullary thyroid cancer (Bentzien et al., 2013) and renal cell carcinoma (Singh et al., 
2017). It has previously shown great potential in inhibiting the growth of NF1-associated 
MPNST in vitro and in vivo (Torres et al., 2011, Lock et al., 2016). Saracatinib is a dual 
kinase inhibitor of c-Src and Abl which has shown excellent pre-clinical activity in 
bladder cancer (Green et al., 2009). Moreover, it enhanced the sensitivity to the c-Met 
inhibitor (PHA-665752) in gastric cancer (Bertotti et al., 2010). When Merlin-deficient 
mouse Schwann cells (MD-MSC) are treated with cabozantinib and saracatinib as single 
agents, the cells demonstrated cell-cycle arrest at G1 phase. However, when treated in 
combination, cabozantinib and saracatinib induced caspase-dependent apoptosis and 
more than ~80% inhibition in the cell growth compared to vehicle in MD-MSC orthotopic 
allograft mouse model. c-Met and Src dual inhibition could be a good potential therapy 
for the treatment of NF2-related schwannomas (Fuse et al., 2017).   
Although there have been advances in clinical therapeutics in recent years, there are not 
yet any FDA approved drug treatments for NF2 patients. Most of the drugs tested in 
clinical trials, have shown limited efficacy only in a small group of patients. Moreover, 
drug resistance due to activation of alternate signaling pathways is a major limitation in 
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cancer therapeutics (McCubrey et al., 2015). Therefore, comprehensive dissection of all 
signaling pathways involved in the pathogenesis of all NF2-related tumours is required 
for designing the most effective therapy that is simultaneously effective against all NF2-
related tumours- schwannomas, meningiomas and ependymomas. 
 
Figure 1. 8- A known drug targets in Merlin-deficient tumours. Figure shows the aberrant 
activation of multiple growth factor receptors and downstream signaling pathways in Merlin-
deficient tumour and kinase inhibitors with known effect in Merlin-deficient tumours (adapted 
from (Agarwal et al., 2014)).  
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1.6 TAM family receptor tyrosine kinases 
The TAM family of receptors are a recently identified family of receptor tyrosine kinases 
(RTK) that consist of three members; AXL, TYRO3 and MERTK. Interestingly, all 
members of TAM family were discovered in early 1990s in span of only three years. AXL 
was discovered in 1991 by three individual research groups. One group discovered the 
gene from chronic myelogenous leukemia (CML) and named AXL-anexelekto, meaning 
‘uncontrolled’ in Greek (O'Bryan et al., 1991). The second group identified the same gene 
from patients with myeloproliferative disorder and termed it UFO for its unknown 
function whilest the third group called it ark-adhesion related kinase (Janssen et al., 1991, 
Rescigno et al., 1991). In the same year, second member of the family-TYRO3 was 
discovered from rat cells in an effort search for novel genes that regulate neural 
development (Lai and Lemke, 1991). Later in 1993, another group cloned human TYRO3 
gene from human tetocarcinoma cells, bone marrow and melanocyte cDNA libraries 
(Polvi et al., 1993). In 1994, Graham et al cloned human ortholog of avian MERTK and 
named for its presence in monocytes, epithelial and reproductive tissues (Graham et al., 
1994).  
1.6.1 Structure and expression pattern of TAM receptors 
Like other RTKs, TAM family receptors are composed of an extracellular domain, a 
transmembrane and an intracellular tyrosine kinase domain (Figure-1.9). An extracellular 
domain structure of the TAM family members consists of two immunoglobulin (Ig)-like 
domains through which it binds to ligand and two fibronectin type-III (FN-III) domains 
that regulate ligand binding. The transmembrane domain consists of an α-helix chain, 
responsible for promoting the stabilization of the dimeric receptor chain. Finally, the 
intrinsic tyrosine kinase domain activates down-stream signaling pathways responsible 
for proliferation, survival, migration and invasion. The neural cell adhesion molecule 
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(NCAM)-like structure in the extra-cellular region and unique KW(I/L)A(I/L)ES 
conserved amino acid sequence in the tyrosine kinase domain, distinguishes TAM family 
receptors from other RTKs (Linger et al., 2008, Niu et al., 2019).  
Within the TAM family, AXL and TYRO3 have highly similar genomic structure sharing 
same number (20) and size of exons, whereas AXL and MERTK have the most similar 
amino acid sequence within tyrosine kinase domain. Overall, TAM family receptors share 
~30% amino acid sequence identity within the extracellular region and over 50% 
sequence identity within the tyrosine kinase domain. The full length TYRO3, AXL, and 
MERTK proteins consist of 890, 894, and 999 amino acids and have predicted protein 
sizes of 97, 98, and 110 kDa, respectively. However, actual molecular weight of the 
proteins varies due to post-translational modifications such as glycosylation, 
phosphorylation, and ubiquitination. The post-translation modification of the protein is 
accountable for variations in TAM family’s tissue and cell-specific function (Linger et 
al., 2008) 
 
Figure 1. 9- The structure of AXL/TYRO3/MERTK (TAM) receptor. The figure represents 
two Immunoglobulin (Ig)-like domains and two Fibronectin type-III (FNIII) domains in 
extracellular region, followed by transmembrane domain and intracellular tyrosine kinase 
domain. N= N terminal; C= C terminal (adapted from (Linger et al., 2008)). 
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TAM receptors have an overlapping but unique expression profile in adult tissues. All 
three receptors are expressed diversely by brain, heart, ovary, testis, lung, kidney and 
retina (Linger et al., 2008). Expression of AXL receptor is universal with prominent 
expression found in hippocampus and cerebellum. TYRO3 is highly expressed in nervous 
system and MERTK is rich in hematopoietic cells such as monocytes/macrophages, 
dendritic cells, natural-killer (NK) cells and platelets (Brandao et al., 2011). 
TAMs are widely distributed in the nervous system but TYRO3 is most highly expressed 
compared to AXL and MERTK. In brain, TYRO3 is abundantly expressed in the olfactory 
bulbs, cerebral cortex, and piriform cortex, all cortical layers of the cerebellum, the 
amygdala, and hippocampus. In addition, expression of TYRO3 increases during CNS 
development. All three receptors are expressed at variable level by non-neuronal cells of 
the CNS such as endothelial cells, oligodendrocytes, glia, Schwann cells and astrocytes 
(Pierce and Keating, 2014, Goudarzi et al., 2016). 
 
1.6.2 Function of TAM receptors in normal physiological processes  
At the cellular level, TAM family receptors play an important role in promoting 
phagocytosis of apoptotic cells, a process which is essential for maintaining normal tissue 
homeostasis. Even though they are expressed throughout embryonic development, TAM 
family receptors, appear not to play an important role in embryogenesis (Lu et al., 1999). 
This is evident from single, double and even triple knock-out mice that were born without 
any obvious signs of developmental birth defects. However, around four week of post-
birth, the mice start developing enlarged spleens and lymph nodes at an abnormal rate 
and by the age of one year, their spleen weights were on average 10 times higher 
compared to wild type. The triple mutant mice eventually developed autoimmunity, likely 
due to delayed clearance of apoptotic cells (Lu and Lemke, 2001). 
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TAM receptors involvement in the clearance of apoptotic cells is cell and tissue-type 
specific. Macrophage-mediated phagocytosis appears to involve all thee TAM receptors, 
but dendritic cells (DCs)-mediated phagocytosis, mainly involves only AXL or TYRO3. 
Moreover, MERTK but not AXL and TYRO3 appears essential for the maintenance of 
the retinal tissues (Seitz et al., 2007). This was in accordance with previous study 
reporting that MERTK knock-out mice developed retinitis pigmentosa due to defective 
phagocytosis of photoreceptors on the outer segment of the membrane of retinal pigment 
epithelium (RPE) (D'Cruz et al., 2000).  
Moreover, TAM family receptors also play an important role in the regulation of 
inflammatory responses. TAM triple knock-out mice produce elevated inflammatory 
response and hyperactivation of macrophages (Lu and Lemke, 2001). This was further 
supported by another group who showed that MERTK works by negatively regulating the 
activation of nuclear factor kappa B (NFκB) signaling in dendritic cells and dampens 
NFκB-mediated proinflammatory response by decreasing tumour necrosis factor alpha 
(TNFα) production (Sen et al., 2007).  
In the CNS, TAM family receptors play an important role in maintaining adult brain 
neurogenesis. TAM receptors are expressed by astrocytes and microglial-like immune 
cells in CNS where they regulate brain immunity. Microglial cells of TAM triple knock-
out mice produce high level of proinflammatory cytokines such as IL-1β, IL-6 and TNF-
α, which adversely affect the neurogenesis process. Furthermore, TAMs play a direct role 
in maintaining the neurogenesis process by supporting neural stem cells (NSCs) survival, 
proliferation and neuronal differentiation (Ji et al., 2013, Ji et al., 2014). Moreover, 
TYRO3 has been shown to be expressed in axons and dendritic compartments of cortical 
and hippocampal neurons where it thought to be important for neuronal plasticity via 
activation of MAPK and PI3K pathways (Prieto et al., 2007). 
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TAMs promote gonadotropin-releasing hormone (GnRH) neuronal survival and 
migration. GnRH neurons are brain cells that control reproduction and thus affect normal 
reproductive function (Pierce et al., 2008). AXL-mediated activation of ERK and PI3K 
pathways rescues GnRH neurons from cell death and promotes their migration in GnRH 
neuronal development (Allen et al., 2002). Loss of GnRH neurons in AXL/TYRO3 null 
mice resulted in an abnormal estrous cycle and reproductive malfunction due to impaired 
sex hormone-induced gonadotropin surge (Pierce et al., 2011). 
Another important role of TAM family receptors in nervous system involve the regulation 
of myelination process. Oligodendrocytes are myelin-producing cells of CNS whereas 
Schwann cells produce myelin for peripheral nervous system (PNS). Expression and 
activation of all three TAM receptors promotes survival and proliferation of 
oligodendrocytes and Schwann cells (Binder et al., 2008, Ammoun et al., 2014, Goudarzi 
et al., 2016). TAM family receptors are highly expressed and activated in white matter 
both before and during the myelination process (Binder and Kilpatrick, 2009). TYRO3 
has the largest pro-myelin effect of all the TAM family receptors. The loss of TYRO3 on 
oligodendrocytes and Schwann cells, impairs the pro-myelination process and results in 
delayed myelination and production of thinner myelin (Miyamoto et al., 2015, Goudarzi 
et al., 2016, Akkermann et al., 2017). AXL is not directly involved in either myelin or 
demyelination but is important for remyelination process. The loss of AXL causes 
delayed phagocytosis, delayed removal of myelin debris and enhanced inflammation 
which ultimately leads to the inhibition of remyelination and prolonged axonal damage 
(Hoehn et al., 2008). The role of MERTK in the myelination process has not well studied 
yet. 
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1.6.3 Regulation of TAM activity 
TAM family receptors were originally cloned from the cancer cells which manifests their 
oncogenic potential. All three members of the TAM receptor kinases are overexpressed 
in a broad spectrum of human cancers and non-cancerous tumours, including 
schwannomas, and their aberrant activation is related to cancer progression, metastasis 
and resistance to targeted therapies (Linger et al., 2008, Ammoun et al., 2014). Despite 
the high oncogenic potential of TAM receptors in many cancers, there is limited reseach 
in understanding the mechanisms that cause aberrant expression of TAM receptors. Some 
of the explored mechanism are described below. 
1.6.3.1 Genetic variation 
DNA copy number variation has emerged as a potential mechanism underlying the 
overexpression of TAM receptors in many cancers. Evidence supporting this notion 
comes from two separate studies around the similar time; one in GBM patients and 
another in lapatinib resistant breast cancer cell-line. Both studies showed that AXL gene 
amplification was the potential cause for overexpression of the protein (Margareto et al., 
2009, Liu et al., 2009). Additionally, fluorescence in situ hybridization (FISH) on AXL- 
expressing colorectal cancer (CRC) samples identified that AXL overexpression in 5.4% 
of cases were due to the gene amplification (Martinelli et al., 2015). Mutations in TAM 
family receptors have reported recently but the functional significance of these mutations 
in promoting malignancy are still not fully understood. Mutation within TYRO3 kinase 
domain has reported in primary tumour samples of colon cancer (M592I), lung cancer 
(N615K), melanoma (W708fs*5), brain cancer (A709T) and AML (C690R). Mutations 
in the extra-cellular region of TYRO3 have been found in melanoma (Q67 and H60Q) 
and lung cancer (E340) which result in a premature stop codon (Smart et al., 2018). Most 
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reported MERTK human mutations have been linked to retinal dystrophy and retinitis 
pigmentosa (Jinda et al., 2016).  MERTK missense mutations have been found in 5.8% of 
head and neck cancer (HNSCC) cases but the significance of this mutation in cancer 
development is not clear (von Massenhausen et al., 2016). However, a mutation in 
MERTK kinase domain in melanoma cell-lines (P802S) was found to be responsible for 
impaired phosphorylation of the MERTK receptor and affected melanoma cell motility 
(Tworkoski et al., 2013).  
1.6.3.2 Transcription regulation 
Several vital up-stream transcriptional regulators have been described for AXL, TYRO3 
and MERTK. Many studies showed that sp1/sp3, activating enhancer binding Protein 2 
alpha (AP-2α), myeloid zinc finger-1 (MZF1) and activator protein-1 (AP1) can directly 
interact with the AXL promoter and regulate the transcriptional activity of the gene 
(Mudduluru and Allgayer, 2008, Mudduluru et al., 2010a, Mudduluru et al., 2010b, Orso 
et al., 2009). In addition, the proximal region of AXL contains hypoxia-response element 
(HRE) binding sites for hypoxia-inducible factor 1 (HIF1) and hypoxia-inducible factor 
2 (HIF2). Rankin et al showed that HIF1 and HIF2 can activate the transcription of AXL 
in hypoxic renal cancer cells by direct binding to HRE sites in the promoter region 
(Rankin et al., 2014). AXL is believed to be a transcriptional target of Yes-associated 
protein (YAP). In hepatocellular carcinoma (HCC) and non-small cell lung cancer 
(NSCLC), AXL mediates YAP-dependent oncogenic function and knock-down or 
pharmacological inhibition of AXL decrease the proliferation and invasion of YAP-
expressing HCC and lung cancer cell-line (Xu et al., 2011, Ghiso et al., 2017). P53 has 
also been shown to regulate AXL gene expression directly or indirectly (Vaughan et al., 
2012). Circadian regulator nuclear receptor subfamily 1 group D membra 2 (NR1D2) has 
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recently been shown to directly bind the AXL promoter in GBM cells, resulting in 
increased proliferation and invasion (Yu et al., 2018).   
Since, the human MERTK promoter has not yet been completely characterized, most 
transcriptional regulators have been described for mouse Mertk gene which shares 
considerable homology with its human ortholog. Wong et al identified sp1, sp3 and E2F 
as transcription factors essential in regulating Mertk promoter activity (Wong and Lee, 
2002).  Liver C receptor (LXR) is another transcription factor described to be important 
for the direct induction of Mertk transcription activity in mouse macrophages and 
promoting clearance of apoptotic cells (N et al., 2009). 
Very little is known about transcription regulation of TYRO3 in human or in mouse. 
TYRO3 and AXL have been described as transcriptional targets for CXCR4/SDF-1 
(CXCL12) and the expression of AXL and TYRO3 corelate with CXCRL4 expression in 
thyroid carcinoma cell-line (Avilla et al., 2011).   
1.6.3.3 Epigenetic Regulation 
DNA methylation is an important epigenetic regulation known for its role in cell-cycle 
control, tumour suppression and embryonic development. Endogenous AXL gene 
expression is correlated to CpG methylation within the AXL promoter. A lower AXL-
expressing CRC cell-line had partially methylated CpG sites compared to a high AXL-
expressing CRC cell-line where no such methylated CpG sites were observed (Mudduluru 
and Allgayer, 2008). Consistent with these results, another separate study also corelated 
promoter hypomethylation with increased AXL expression in Kaposi’s sarcoma (Liu et 
al., 2010). Histone modification has also been linked to altered gene expression of AXL. 
In H1299 lung cancer cells, histone acetylation of the AXL promoter region increased the 
promoter activity likely by enhancing interaction of the transcription factors p300, CREB, 
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and E2F1 with their consensus binding sites on the AXL promoter (Vaughan et al., 2012). 
No such epigenetic regulation for MERTK and TYRO3 has reported. 
1.6.3.4 Post-transcriptional regulation 
MicroRNAs (miRNAs) are short non-coding RNA molecules which negatively regulate 
messenger RNA (mRNA) translation to protein. miRNA-34a and miRNA-155 have been 
shown to decrease the expression of AXL in blood monocytes (Kurowska-Stolarska et 
al., 2010). Another team also found that the expression of AXL is negatively regulated 
by miRNA-34a and miRNA-199a/b (Mudduluru et al., 2011). Although the exact 
mechanism of this regulation is not known, AXL has recently been shown to be 
autoregulated in a negative feedback loop by miRNA. AXL overexpression causes 
upregulation of miRNA-34a via the JNK/ELK1 signaling pathway and upregulated 
miRNA-34a in return, inhibits AXL expression by binding to the 3’UTR region within 
the AXL promoter. Malfunction of this regulatory loop is thought to contribute in 
resistance to apoptosis and metastatic invasion of lung cancer cells (Cho et al., 2016).  
Loss of miRNA-335 expression is responsible for an increase in metastatic invasion in 
breast cancer cells. A search for putative metastatic genes regulated by miRNA-335, 
found that the 3’UTR promoter region of MERTK is the direct target of miRNA-335. 
However, the study didn’t asses the direct effect of miRNA-335 modification on the level 
of MERTK protein expression (Tavazoie et al., 2008). miRNA-335 is the only miRNA 
discovered so far that is able to regulate the expression of MERTK. 
Finally, miRNA-7 has been recognized as direct regulator of TYRO3 gene expression. 
Overexpression of miRNA-7 in HCC and CRC, reduced the expression of TYRO3 at 
mRNA and protein levels and resulted in decreased proliferation, migration and 
invasiveness of cancer cells (Kabir et al., 2018, Qin and Qian, 2018). 
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1.6.4 Ligands for the TAM receptors 
Gas6 and Protein S are well characterized vitamin K-dependent ligands of the TAM 
family receptors that share ~40% sequence similarity and have similar domain 
organization. Both ligands comprise of 11 γ-carboxyglutamic acid residues (Gla), a loop 
region, which contains disulphide-bridged ring structure and four EGF-like repeats in N-
terminal region and sex hormone binding globulin (SHBG)-like structure composed of 
two globular laminin G (LG)-like domains in the C-terminal region (Figure-1.10 A). The 
N-terminal region of the Gla domain is formed after post-translation modification of 
glutamate residues in the endoplasmic reticulum by γ‐glutamyl carboxylase enzyme, 
requiring the presence vitamin K as a co-factor. Negatively charged glutamic acid (Gla) 
residues mediate binding to negatively charged phospholipid membranes such as 
phosphatidylserine (PS) on apoptotic cells through calcium binding. On the other hand, 
laminin G (LG) domains in C-terminal region promote binding of the ligand to TAM 
receptors thus promoting phagocytosis of targeted bodies by receptors (Figure-1.10 B) 
(Hafizi and Dahlback, 2006). 
A thrombin sensitive cleavage site in the loop region of proteins S, separates it from Gas6 
and is responsible for the characteristic of protein S as negative regulator of blood 
coagulation. Despite similarities in structure and activity, both ligands; Gas6 and Protein 
S, have different affinities for different TAM receptors. Gas6 can bind to all three 
receptors but has the highest affinity to AXL compared to TYRO3 and MERTK 
(AXL>TYRO3>MERTK). Whereas, Protein S specifically binds to TYRO3 and MERTK 
but not AXL (TYRO3>MERTK). Protein S is primarily produced and secreted by the 
liver. In contrast, Gas6 is locally produced in many tissues and expressed by many cells 
including capillary endothelial cells, vascular smooth muscle cells, and bone marrow cells 
but is absent from liver cells. Normal human plasma concentration of Gas6 is in the sub 
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nanomolar range of 0.16–0.28 nM which is 1000-fold lower than that of protein S plasma 
concentration. Interestingly, only ~40% of Proteins S circulates as free protein in blood 
plasma that can act as ligand for TAM receptors, ~60% is present as a bound complex 
with C4 binding protein (C4BP) and cannot activate TAM receptors (Hafizi and 
Dahlback, 2006, Balogh et al., 2005).  
Tubby and tubby like protein-1 (Tulp-1), members of tubby protein family, have recently 
emerged as novel ligands for the TAM family receptors. Like Gas6 and Protein S, Tubby 
and Tulp-1 have different affinity for TAM receptors. Tulp-1 interacts with all three 
members of TAM receptors while Tubby specifically binds to MERTK. The levels of 
circulating Tubby and Tulp-1 have not been quantified yet but their expression have been 
shown to be restricted to in adult retina and neuronal tissues. In 2012, the same team that 
established Tubby and Tulp-1 as ligands for TAM receptors, showed that MERTK induce 
phagocytosis of apoptotic cells and cellular debris via binding to Galectin-3 and added 
one more protein in the list of novel ligands for TAM receptors. However, affinity of 
Galectin-3 for AXL and TRYO3 has not yet been defined (Caberoy et al., 2010, Caberoy 
et al., 2012).  
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Figure 1. 10- The structure of TAM ligands; Gas6/Protein S and their binding to TAM 
receptor to mediate phagocytosis. The N-terminal consists of a Gla domain, followed by loop 
region, four EGF repeats and finally a C-terminal SHBG domain that consist of two LG repeats 
A); SHBG domain in C-terminal of ligand Gas6/Protein S mediated binding to N-terminal Ig 
domain of TAM receptor present on immune cells like dendritic cells and macrophages. N-
terminal Gla domain of the ligand binds to PS that is presented by outer plasma membrane of 
apoptotic cells B). (Gla- glutamic acid; EGF- epidermal growth factor; LG- laminin G; SHBG- 
sex hormone binding globulin) (Adapted from (Axelrod and Pienta, 2014, Lemke and Rothlin, 
2008)). 
 
1.6.5 Activation and deactivation of TAM receptors 
1.6.5.1 Ligand dependent activation of TAM receptors 
The typical activation of RTK involves, ligand binding to the extra-cellular region of the 
RTK, receptor dimerization and trans-autophosphorylation of tyrosine residues in the 
intra-cellular kinase domain (Figure-1.11 A). Following autophosphorylation, the 
activated RTK either leads to phosphorylation/activation of other substrates or recruits 
signaling molecules to the docking site thus creating macromolecular signaling complex 
(Linger et al., 2008).  
For the MERTK receptor, Y-749, Y-753 and Y-754 are the primary sites of 
autophosphorylation. For the full activation of the receptors, phosphorylation at all three 
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tyrosine residues in the kinase domain is essential with Y-749 being the preferred site of 
autophosphorylation (Ling et al., 1996). Y-749, Y-753 and Y-754 sequence of MERTK 
receptor are conserved among all three members of TAM receptors, corresponding to 
698, 702, 703 residues of AXL and 681, 685, 686 residues of TYRO3 kinase but there is 
no evidence implicating their role in autophosphorylation (Linger et al., 2008). Residues 
Y‐779, Y‐821, and Y‐866 that mediate the AXL receptor interaction with signaling 
molecules phospholipase C (PLC), phosphatidyl inositol 3 kinase (PI3K), and Grb2 
(Braunger et al., 1997) are thought to be the potential autophosphorylation site of AXL. 
However, in vivo study of mutant AXL without Y-821 showed normal Gas6 stimulated 
phosphorylation of the receptor, conflicting the results from in vitro study (Fridell et al., 
1996). Gas6 stimulation leads to phosphorylation of the residues Y702 and Y703 in AXL 
kinase domain (Pao-Chun et al., 2009), but further study is required to investigate 
signaling molecules that bind to these sites for AXL activation. 
 
1.6.5.2 Ligand independent activation of TAM receptors  
In addition to the conventional ligand-dependent activation, atypical ligand-independent 
activation of TAM receptors has also been reported. TAMs can be activated by ligand 
independent homophilic dimerization of receptor monomers on neighboring cells or on 
the same cell (Figure-1.11 B and Figure-1.11 C) and by receptor heterodimerization with 
other RTKs or with other members of TAM family (Figure-1.11 D and Figure-1.11 E). 
Overexpression of AXL causes cell-aggregation and ligand-independent receptor 
activation, via homophilic binding of the receptor on a neighboring cell. Moreover, cell-
aggregation and homophilic dimerization of the receptor was independent of tyrosine 
kinase activity (Bellosta et al., 1995). Another team also reported that over-expression of 
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TYRO3 was sufficient to induce phosphorylation and activation of the receptor in absence 
of the ligand (Taylor et al., 1995). Further evidence of ligand-independent receptor 
dimerization come from the crystal structure of TYRO3, further supporting the previous 
reports (Heiring et al., 2004). 
TAM family receptors can crosstalk with other receptors by forming heterotypic dimers. 
AXL has been reported to physically interact with RTK EGFR in glioblastoma 
multiforme (GBM) cell-line in a ligand independent manner. The treatment of GBM cells 
with EGF lead to trans-activation of the AXL receptor and activation of down-stream 
signaling pathways (Vouri et al., 2016). Although such heterotypic dimers for TYRO3 
and MERTK have not been reported, indirect molecular cross-talk between αvβ5 integrin 
and MERTK is reported to be essential for promoting phagocytosis of apoptotic cells (Wu 
et al., 2005).  
Heteromeric complex have also been reported among TAM family members. Co-
immunoprecipitation experiments in GnRH neuronal cells have showed that AXL and 
TYRO3 are closely related and can form complex irrespective of the presence of their 
ligand Gas6 (Pierce et al., 2008). A physical interaction between TYRO3 and AXL has 
also been reported in Rat2 fibroblast cells, where ectopic expression of TYRO3 but not 
‘kinase dead’ TYRO3 (kdTYRO3) enhanced Gas6-mediated activation of AXL. 
Similarly, overexpression of AXL induced the phosphorylation of kdTYRO3 receptor 
(Brown et al., 2012). Indeed, blocking Gas6-mediated phosphorylation of AXL also 
decreased the activation of TYRO3 in GBM cell-line (Vouri et al., 2015). One study has 
clearly demonstrated that Gas6-stimulated activation of any one TAM receptor requires 
the presence of one or both of remaining TAM receptors, further supporting the notion 
that TAM receptors co-operate in their activation response (Angelillo-Scherrer et al., 
2005). 
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Figure 1. 11- Mechanisms of TAM receptor activation.  Gas6-induced dimerization and 
activation of TAM receptor A); A ligand independent homophilic dimerization of receptors B); 
Ligand-independent homophilic binding of two receptors on neighboring cells C); Ligand-
independent dimerization of two different TAM receptors D); Ligand-independent dimerization 
of TAM receptor with non-TAM receptor E) (adapted from (Korshunov, 2012)). 
 
 
1.6.5.3 Mechanisms of deactivation of TAM receptors 
RTKs maintain normal physiological response by the tight regulation of mechanisms for 
receptor activation and deactivation. The attenuation and termination of RTK signaling 
may be induced by antagonistic ligands, hetero-oligomerization with receptor mutant, 
dephosphorylation by tyrosine phosphatase and by receptor endocytosis and degradation. 
Impaired RTK deactivation may lead to many pathological conditions including cancer 
(Schlessinger, 2000). Studies evaluting the mechanisms for TAM receptor deactivation 
are limited.  
Overexpression of C1 domain-containing phosphatase and TENsin homologue (C1-TEN) 
inhibited HEK-293 proliferation, migration and increased apoptosis of the cells in culture 
(Hafizi et al., 2005). C1-TEN has been shown to dephosphorylate Y612 of insulin 
receptor substrate 1 (IRS-1) and accelerate its degradation (Koh et al., 2013). AXL kinase 
domain has also been shown to bind to (C1-TEN) (Hafizi et al., 2002).  This binding may 
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lead to dephosphorylation of the AXL receptor, however there is no direct evidence 
demonstrating C1-TEN mediated dephosphorylation of AXL. Protein tyrosine 
phosphatase receptor type G (PTPG) has recently emerged as tyrosine phosphatase for 
AXL. A novel mechanism involving Gas6-mediated inactivation of AXL in the presence 
of tumour suppressor - opioid-binding protein/cell adhesion molecule-like (OPCML) was 
described. The study shows that OPCML enhances interaction between AXL and 
phosphatase PTPG which ultimately causes AXL dephosphorylation and inactivation 
(Antony et al., 2018). 
  
1.6.6 TAM receptor’s signaling in cancer 
TAM family receptors were originally cloned from cancer cells which manifests their 
oncogenic potential. All three members of the TAM receptor kinases are overexpressed 
in a broad spectrum of human cancers including schwannomas and their aberrant 
activation is related to cancer progression, metastasis and resistance to targeted therapies. 
Ligand-induced or ligand-independent phosphorylation of TAM intracellular kinase 
domain promotes a cascade of signaling molecules that subsequently leads to 
proliferation, survival and migration of the cells. Three important signaling pathways 
downstream of TAM family receptors involve MAPK, PI3K and PLCγ pathway (Figure-
1.12, Figure-1.13 and Figure-1.14) (Linger et al., 2008, Ammoun et al., 2014).  
All three receptors promote cell proliferation via the classical MAPK pathway. Ligand-
stimulated phosphorylation of AXL and MERTK lead to a cascade of Shc, GrB2, Ras, 
Raf, MEK1 and ERK1/2 signaling molecules. GrB2 can be activated by direct binding to 
AXL and MERTK kinase domain or indirectly by binding to Shc which is phosphorylated 
by activated AXL and MERTK (Linger et al., 2008). While the role of AXL and MERTK 
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is well defined in mediating the MAPK pathway, data indicating regulation of this 
pathway by TYRO3 are limited. However, ectopic expression of TYRO3 in Rat2 cells 
induced phosphorylation of MAPK (Brown et al., 2012). Similarly, TYRO3 was found 
to be responsible for the activation of ERK in breast cancer and hepatocellular carcinoma 
(HCC) cell-lines which was reversed upon genetic knock-down of TYRO3 (Ekyalongo 
et al., 2014, Duan et al., 2016). 
The intracellular phosphorylated kinase domains of AXL, TYRO3, and MERTK can 
directly interact with PI3K to promote cell survival via activation of multiple signaling 
pathways downstream of AKT. AXL and MERTK both have shown to activate classical 
AKT/S6K and AKT/NFkB pathways to promote cell survival. Additionally, AXL 
mediates survival of the cells by activating anti-apoptotic proteins such as Bad, Bcl‐2, 
and Bcl‐xL and by inhibiting pro-apoptotic proteins like caspase-3, downstream of AKT. 
The Gas6-AXL axis is also involved in AKT mediated activation of the JNK signaling 
pathway to enhance cell survival (Linger et al., 2008). AKT downstream of TYRO3 has 
also been reported to phosphorylate Bcl-2 associated death promoter (BAD) to promote 
the survival of neuronal cells (Guo et al., 2011). In Rat2 cells, TYRO3 mediated 
activation of AKT leads to phosphorylation of mTOR and ribosomal protein S6 kinase 
beta-1 (P70S6K) (Brown et al., 2012). 
In addition to PI3K and GrB2, phospholipase C gamma (PLCγ) can also directly bind to 
the AXL and MERTK kinase domains, resulting in increased migration of cells. 
Alternative cell migration signaling pathways involve AXL-mediated Ras, Rac, p38 
MAPK, MAPKAP kinase 2, and HSP25 pathways downstream of AKT and; Vav-1, Rac1 
and cdc42 pathway directly downstream of MERTK. AXL and MERTK have also been 
shown to stimulate Src-mediated phosphorylation of FAK, leading to cell migration. 
Although these are signaling pathways known to sit downstream of the TAM family, the 
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ultimate downstream targets of signaling pathways may differ depending on cell-type and 
tissue microenvironment (Linger et al., 2008, Ammoun et al., 2014).  
 
Figure 1. 12- Important oncogenic signaling pathways downstream of MERTK. Molecules 
in blue; PLC, Vav1, shc, Grb2 and PI3K, can directly or indirectly interact with phosphorylated 
MERTK kinase. Ras/ERK pathway- green, AKT pathway- grey, Rac1- yellow and FAK/Src 
pathway- in pink leads to cell proliferation, survival and migration. Phospho sites (dark orange 
circles) are mentioned at the side in a box (adapted from (Linger et al., 2008)). 
  




Figure 1. 13- Important oncogenic signaling pathways downstream of AXL. Molecules in 
blue can directly or indirectly interact with phosphorylated AXL kinase. Ras/ERK pathway- dark 
green, Ras/HSP25- light green, PI3K/AKT pathway- dark grey, PI3K/JNK pathway light grey 
leads to cell proliferation, survival and migration. Phospho sites (orange circle) are mentioned at 
the side in a box (adapted from (Linger et al., 2008)). 
 
 
Figure 1. 14- Important oncogenic signaling pathways downstream of TYRO3. Molecules in 
blue can directly or indirectly interact with phosphorylated TYRO3 kinase. ERK pathway- green, 
PI3K/AKT pathway- grey leads to cell proliferation, survival and migration. Specific phospho 
sites (orange circles) for TYRO3 are not known (adapted from (Linger et al., 2008)). 
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1.6.7 TAM family of receptors in drug resistance  
A large body of evidences suggests that activation of TAM family receptors is associated 
with resistance to conventional and targeted therapies in several cancers (Schoumacher 
and Burbridge, 2017). As previously described, TAMs can cross-talk, not only with the 
members of their own family but can also dimerize with non-TAM receptors to bypass 
the inhibitory effect of targeted kinase inhibitors (Meyer et al., 2013). Activation of 
TAMs promotes resistance to therapeutic agents and favors tumour growth by 
maintaining downstream signaling of targeted receptors by an alternative effector or by 
switching to alternate signaling pathway (Schoumacher and Burbridge, 2017).  
Acquired resistance to drugs targeting EGFR such as gefitinib and erlotinib in lung cancer 
(Bae et al., 2015, Zhang et al., 2012) and lapatinib and erlotinib in breast cancer is 
common due to AXL overexpression and activation (Meyer et al., 2013). Activation of 
AXL limits the response to EGFR-tyrosine kinase inhibitor in these cancers by 
compensating or amplifying downstream signaling of EGFR through association with 
and/or transactivation of other members of the EGFR family (Tian et al., 2016, Meyer et 
al., 2013). Increased AXL expression has also shown to be responsible for resistance to 
imatinib in gastrointestinal stromal tumours, and resistance to imatinib and nilotinib in 
CML cells (Mahadevan et al., 2007, Dufies et al., 2011). In acute myeloid leukemia 
(AML) cell-line, AXL mediates resistance to conventional chemotherapeutic drugs; 
doxorubicin, VP16 and cisplatin by activating compensatory survival signaling to favor 
tumour growth (Hong et al., 2008). Very recently, MERTK has also been reported to 
mediate resistance to EGFR inhibitors in non-small cell lung cancer (NSCLC) and to 
AXL kinase inhibitor in head and neck squamous cell carcinoma (HNSCC), triple-
negative breast cancer (TNBC) and NSCLC (Yan et al., 2018, McDaniel et al., 2018). 
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These studies highlight that TAMs could be attractive therapeutic target in cancer and 
drug resistance. 
Additionally, TAMs role as an immunosuppressor favors their oncogenic potential. 
Activation of TAM receptors dampen the inflammatory response by promoting activation 
of M2 state macrophages which secrete anti-inflammatory cytokines and limits expansion 
of CD8+ T cells. This immunosuppressive environment aids tumour growth by blocking 
the anti-tumour activity of cytotoxic T cells thus, potentially limiting the effectiveness of 
anticancer treatment (Cook et al., 2013). Indeed, in metastatic melanomas intrinsic 
resistance to programmed cell death protein 1 (PD-1) therapy has been demonstrated to 
be due to overexpression of AXL (Hugo et al., 2016). These reports further emphasize 
the importance of TAMs as therapeutic target in combination with immunotherapy. 
1.6.8 TAM receptors as therapeutic target 
Overexpression of TAM receptors in many cancers and the role of TAM family members 
in promoting cancer cell proliferation, survival, migration and drug resistance makes 
them an attractive therapeutic target in cancer. Due to advances in the understanding of 
their biology, several kinase inhibitors targeting TAM receptors have recently been 
developed and tested in a clinical setting. Below is the summary of TAM inhibitors that 
are in pre-clinical or in clinical trials (Table-1.3). 
Cabozantinib is a multi-kinase inhibitor with strong affinity for AXL. It has recently been 
approved by the FDA for the treatment of medullary thyroid cancer and renal cell 
carcinoma (Weitzman and Cabanillas, 2015, Grassi et al., 2016). Currently, it is in clinical 
trials for the treatment of multiple cancers including non-small cell lung cancer (NSCLC) 
(phase-II studies-NCT01639508, NCT02132598, NCT00596648, NCT01708954 and 
NCT01866410), breast cancer (phase-II NCT02260531, NCT03316586), ovarian cancer 
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(NCT02315430), metastatic melanoma (phase-II NCT01835145) and pancreatic cancer 
(phase-I NCT01663272, phase-II NCT01466036) as a monotherapy or in combination 
with other drugs. BPI-9016M is a dual kinase inhibitor with strong activity against c-
MET and AXL. BPI-9016M inhibits proliferation, migration and invasion of lung 
adenocarcinoma cells by disrupting kinase activity of c-MET and AXL and their 
downstream signaling pathways in vitro and in vivo (Zhang et al., 2018). BPI-9016M is 
now being tested in phase-I clinical trial for patients with advanced solid tumours to 
assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the drug 
(NCT02478866).  
BMS-777607 is another small kinase inhibitor with activity against AXL (IC50-1.1 nM), 
MERTK (IC50-14 nM), TYRO3 (IC50-4.0 nM) as well as inhibitory activity towards 
RON, MET, FLT3, Aurora B, Lck and VEGFR2. BMS777607 has showed an excellent 
oral bioavailability, tissue distribution, long half-life (4.5 hours in mouse, 4.8 hours in rat 
and 4.9 hours in dog) and low systemic clearance. It completely inhibited tumour growth 
in a Met-dependent gastric cancer xenograft model at 50 mg/kg (Cmax 43.7 μM) 
(Schroeder et al., 2009). Due to excellent in vivo pharmacokinetic properties and anti-
tumour efficacy, BMS777607 was tested in a phase-I multiple-dose escalation study for 
multiple advanced solid tumours (NCT01721148). The drug demonstrated an excellent 
safety profile and resulted in a partial response or stabilization of disease condition in a 
subset of tumour types (Roohullah et al., 2018).  
BGB324 (R428) is the first small molecule tyrosine kinase inhibitor developed for its 
potent activity against AXL (IC50-14nM) and it has >50 and >100-fold selectivity against 
AXL over MERTK and TYRO3 respectively. It successfully inhibited phosphorylation 
of AXL and downstream AKT signaling pathway with low nanomolar concentration in 
vitro (IC50 14 nM) and in vivo (IC50 0.1-1.0 µM). The drug showed a long plasma half-
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life in mice of 4 hours and 13 hours at 25 mg/kg and 75 mg/kg respectively. A twice daily 
dose of 25 mg/kg, 75 mg/kg and 100 mg/kg of BGB324 resulted in Cmax of 2.4, 6.8 and 
9.0 µM respectively and 7 mg/kg dose was sufficient to increase the survival of mice from 
52 days in vehicle-treated animals to >80 days in mice treated with BGB324. BGB324 
was well tolerated at all doses in mice and no significant compound-related weight loss, 
mortality or other adverse clinical signs were observed during the experiment (Hector et 
al., 2010, Holland et al., 2010). A phase-I clinical trial of BGB324 in acute myeloid 
leukemia (AML) patients showed that the drug is well-tolerated (Ben-Batalla et al., 2017). 
Based on pre-clinical and clinical data, BGB324 is currently undergoing phase-Ib trials 
for AML patients as a single agent or in the combination with chemotherapy drugs 
cytarabine or decitabine (NCT02488408). Two separate Phase-II trials of BGB324 have 
also been planned for NSCLC patients. One study is currently testing BGB324 in 
combination with erlotinib (NCT02424617) in stage III and IV NSCLC patients and 
another is testing BGB324 in combination with humanized PD-1 antibody-
pembrolizumab in advanced NSCLC patients (NCT03184571). Moreover, BGB324 has 
shown good tolerance in healthy volunteers at up to 1.5 g daily dose (Bergenbio, 2014, 
April 09).  
Moreover, a series of quinolone antibiotic derivatives have recently been developed with 
the aim of developing a new AXL-specific inhibitor. Of all designed compounds, 8i 
(nadifloxacin) was found to tightly bind to AXL with binding constant (Kd) value of 1.1 
nM and inhibit the kinase activity of AXL with IC50 of 26 nM, thought to be the most 
selective AXL inhibitor to date. The kinase inhibitory assay against a panel of 468 kinases 
at 1 µM (the concentration ~900 times higher than its Kd value against AXL) displayed 
excellent target selectivity of compound 8i for AXL except for FLT3, which was inhibited 
with IC50 of 50 nM. In addition, the compound also showed convincing pharmacological 
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properties in rats. A single oral dose of compound 8i of 25 mg/kg resulted in Cmax of 
2386.9 μg/L (3.6 µM) following 4.0 hours of dose administration which was 138 times 
higher than its IC50 values against AXL kinase and half-life of the compound was 5.68 
hours. The compound was well-tolerated, and no obvious toxicity was observed following 
200 mg/kg, 400 mg/kg or 800 mg/kg of doses (Tan et al., 2019). Other small molecule 
kinase inhibitors such as DP3975 and NA80xl- specifically targeting AXL, NPS-1034- 
targeting AXL and MET and LDC-1267 targeting all three members of the TAM family 
have also shown great pre-clinical activity and have the potential to be further tested in 
clinical trials (Ou et al., 2011, Rho et al., 2014, Paolino et al., 2014).  
In contrast to AXL, few MERTK-targeted small molecule inhibitors have advanced to 
clinical trials. One of the first reported MERTK-specific inhibitors is UNC569. Although 
efficient in reducing tumour growth and increasing sensitivity to chemotherapy drugs in 
acute lymphocytic leukemia (ALL), UNC569 failed in clinical trials due to its high off-
target activity towards human ether-a-go-go-related gene potassium channel (hERG) and 
suboptimal inhibitory activity towards MERTK (Christoph et al., 2013, Liu et al., 2013). 
Since then, a number of subsequent derivatives of UNC569 such as UNC1062, 
UNC1666, and UNC2025 have been developed to have increase potency against 
MERTK. Out of all three, UNC2025 is the most effective against MERTK (IC50- 2.7 nM) 
and it has almost equal potency against FLT3 (IC50-14.0 nM) in cell-based assays. A 
single oral dose of 3 mg/kg UNC2025 in leukemia xenograft mice model effectively 
decreased phosphorylation of MERTK by 90% and yielded Cmax of 1.6 μM with half life 
of 3.8 hours in mice. The compound was well tolerated with minimal side effects in the 
mice model (Zhang et al., 2014). Additionally, treatment with UNC2025 induced 
apoptosis, reduced colony-formation and suppressed proliferation in MERTK expressing 
ALL cell-lines (DeRyckere et al., 2017). A final derivative of this family, MRX-2843 
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which is an analogue of UNC2025 with a minor side chain substitution, similar PK 
properties and toxicity profile has recently entered in phase-I clinical trials for relapsed 
advanced metastatic tumours (NCT03510104). Like UNC2025, MRX-2843 induced 
apoptosis and inhibited colony formation of MERTK-expressing leukemia cells and both 
compounds were ~10 times more effective against patient derived AML cells compared 
to normal human cells, indicating MRX2843’s specificity to cancer cells as well as its 
therapeutic potential (DeRyckere et al., 2017, Minson et al., 2016).   
Additionally, other novel approaches to specifically target TAM receptors are in 
development. These include; the use of monoclonal antibody, antibody-drug conjugate 
(ADC) and aptamer. An AXL specific monoclonal antibody YW327.6S2 was tested in 
NSCLC and breast cancer xenograft model and showed successful attenuation of tumour 
growth via inhibition of Gas/AXL binding, thus downregulating expression and 
activation of both AXL and its downstream signaling pathways (Ye et al., 2010). In 2016, 
a phase-I/II clinical trial began recruiting a mixed population of patients with solid 
tumours to assess the safety and tolerance of a novel AXL specific antibody drug 
conjugate- HuMax-AXL-ADC (NCT02988817). A high affinity short nucleic acid 
aptamer that binds to the extra-cellular region of AXL. HuMax-AXL-ADC has been 
tested pre-clinically in NSCLC where it inhibited AXL activity and decreased tumour cell 
proliferation, migration and invasion in xenograft model (Cerchia et al., 2012).  
Monoclonal antibodies that bind to and inhibit MERTK and TYRO3 have also been 
developed. A novel MER590 monoclonal antibody reduced the cell surface and total 
MERTK expression by almost 90% and decreased colony-forming potential and 
chemoresistance in a NSCLC cell-line (Cummings et al., 2014). A TYRO3-specific 
monoclonal antibody was able to block TYRO3 and inhibited TYRO3-dependent survival 
signaling in a melanoma cell-line (Demarest et al., 2013).  
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A second generation high-affinity AXL decoy receptor, MYD1-72 Fc with an apparent 
affinity of 93 femtomolar (fm) to Gas6 has also been designed. MYD1-72 Fc specifically 
blocks AXL signaling at low concentrations and reduces tumour volume in AML mice 
with almost no toxicity described to-date (Kariolis et al., 2017). These novel strategies 
widen the therapeutic window of TAM inhibitors and show the potential of further clinical 
development of these novel molecules. All novel therapeutic strategies targeting TAM 
receptors that are undergoing clinical development are summarized in Table 1.3. 
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Table 1. 3- TAM inhibitors in clinical development. A summary of the drug candidates that are 
in clinical development for AXL, MERTK and TYRO3 receptors with their known IC50 values 
(adapted from(Myers et al., 2016)).  
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1.7 Project significance/Aims 
Our group has previously demonstrated that all three members of TAM family receptors; 
AXL, MERTK and TYRO3, as well as their ligand Gas6, are overexpressed in 
schwannomas and have recognized the role of AXL in mediating schwannoma cell 
proliferation, adhesion and survival (Ammoun et al., 2014). The overall aim of this project 
is to investigate, possible involvement of the other TAM family members; TYRO3 and 
MERTK in schwannoma pathology and all three TAM members in meningioma 
development and progression. The objectives of the research project are as follow; 
Firstly, to investigate the expression profile of AXL, MERTK, TYRO3 and their ligand 
Gas6 in Merlin-deficient human meningioma tissues and primary cells compared to 
normal controls. 
Secondly, to investigate the physical or functional interaction among AXL, MERTK and 
TYRO3 receptors in human schwannoma and meningioma tissues and primary cells. 
Thirdly, to investigate the role of TAM family members in pathological proliferation and 
survival of human primary schwannoma and meningioma cells via key signaling 
pathways that are already known to be involved in the tumours development. 
Finally, to test different drug candidates targeting TAM kinase receptors such as BGB324 
(R428)-AXL inhibitor, UNC2025-MERTK inhibitor and BMS777607-pan-TAM 
inhibitor to decide the best therapeutic target to take forward in a clinical study. 
 
  









Chapter 2.0 – Materials and methods 
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2.1 Cell-culture  
2.1.1 Tissue collection and ethics 
The sporadic or NF2-associated schwannoma and meningiomas used in this study were 
obtained with patient’s informed consent. The majority of schwannoma and meningioma 
samples used in this project were collected under ‘Molecular Target (MOT) 
identification’ project from Derriford Hospital, Plymouth (NHS Trust: R&D No: 
14/P/056) and Bristol Southmead Hospital (NHS Trust: R&D No: 3458) following 
national ethical approvals (Research ethics committee (REC) No: 14/SW/0119; IRAS 
project ID: 153351) and received a unique MN numbers. J and SS specimen were 
collected via Brain archieve and information network (BRAIN UK) under ethical 
approval (REC No: 14/SC/0098; IRAS project ID: 143874, BRAIN UK Ref: 15/011). 
The project is also granted approval by Faculty Research Ethics and Integrity Committee 
(FREIC number for MOT project is 14/15-401 and for BRAIN UK, 14/15-450) Two 
normal meninges used in this project were obtained from Analytical Biological Services 
Inc. as frozen tissues and one was purchased as human brain cerebral meninges whole 
tissue lysate from Novus Biologicals® (NB820-59183; lot B105014). 
2.1.2 Cell culture 
Schwannoma and meningioma tumour samples were transported from the operation 
theatre to the laboratory in DMEM (Thermofischer Scientific, MA, USA), 10% FBS 
(Sigma-Aldrich, MO, USA), 500U/ml Pen/Strep (Thermofischer Scientific, MA, USA) 
and 2.5 μg Amphotericin B (Sigma- Aldrich, MO, USA). Upon arrival, a small tumour 
piece was cut and snap frozen in liquid nitrogen before transferring to -80°C for later use. 
The remaining tumour was incubated for 24 hours in petri dish containing DMEM 
supplemented with 10% FBS, 500U/ml Penicillin/Streptomycin, and 2.5 μg 
Amphotericin B in a 37°C and 5% CO2. 
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On the next day, incubation media was replaced by digestion medium, containing 
DMEM, 10% FBS, 500U/ml pen/strep; 1.25 U/ml dispase and 160U/ml collagenase type 
– I for schwannomas and DMEM, 10% FBS, 100U/ml pen/strep and 40U/ml collagenase 
type – III for meningiomas. After overnight incubation in digestion medium, tumour 
samples were further mechanically dissociated with glass pipettes of decreasing diameter 
until a single-cell suspension was formed. The suspension was transferred to 50 ml falcon 
tubes and centrifuged for 5 minutes at 1200 rpm. The pellet was resuspended in respective 
media; DMEM, 10% FBS, 100U/ml pen/strep, 0.5 μM Forskolin (Tocris, Bristol, UK), 
2.5 μg/ml Amphotericin (Sigma- Aldrich, MO, USA), 2.5 μg/ml insulin (Thermofischer 
scientific, MA, USA) and 10 nM β1- heregulin and 0.5 mM 3-isobutyl-1-methylxanthine 
(IBMX-BioTechne, MN, USA) for schwannomas and seeded into PLL (10 mg/ml) and 
LA coated 6-well plates (Greiner, USA). Meningiomas cells were cultured in 10% FBS, 
1% glutamine, 1%  pen/strep and 1% glucose medium. The characteristics of clinical 
samples used in this study has been provided in supplementary chapter 7.5, table-S1. 
Ben-Men-I is a grade-I meningioma cell-line, originally created by Püttmann S et al via 
hTERT immortalization of meningioma cells derived from meningothelial meningioma 
attached to parietal falx of a 68-year old female (Puttmann et al., 2005). The cell-line was 
cultured in 10% FBS, 1% glutamine, 1% pen/strep and 1% glucose medium. A 
cryopreserved foetal derived human meningeal cells (HMCs), isolated from human 
leptomeninges, were bought from ScienCellTM at P0 and was cultured in the 
manufacturer’s recommended media, meningeal cell media, ScienCellTM. 
2.1.2 Passaging and freezing down of cells 
Primary cells and cell-lines were cultured in proliferation growth medium until confluent 
before being passaged. For passaging, cells were washed once in phosphate buffered 
saline (PBS) (Thermofischer Scientific, MA, USA) and then incubated with 
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trypsin/EDTA (Thermofischer Scientific, MA, USA) for 2 minutes at 37°C in incubator. 
Once the cells were detached, trypsin was neutralized with complete growth medium. 
Cells were collected and centrifuged for 5 minutes at 1200 rpm. The pellet was 
resuspended in an appropriate volume of culture medium and seeded in fresh flask/6-well 
plate. 
 
Figure 2. 1- Morphological appearances of the cells used in the project. Representative phase-
contrast microscopy images of meningioma primary cells A), B); schwannoma primary cells C), 
D); HMC E) and meningioma cell-line Ben-Men-I F). Scale bar 100 μM 
 
 
To freeze down the cells, pellet was resuspended in 1 ml of freezing medium (450 μl of 
complete media+450 μl of FBS and 100 μl of dimethyl sulphoxide (DMSO)). The 
resuspended cells were transferred to cryovial and stored at -80°C overnight in ‘Mr 
Frosty’ (Thermofischer Scientific, MA, USA) before transferring to the liquid nitrogen 
tank for long term storage.  
2.1.3 Recovery of cryopreserved cells 
The cryovial containing frozen cells were rapidly defrosted in 37°C water-bath by gentle 
swirling until small ice crystal remain in vial. The content of the whole vial was 
transferred gently to the bottom of 50ml sterile tube and then 11 ml of pre-warmed 
complete medium was added in a drop-wise manner to avoid any osmotic shock to the 
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cells. The cells were then seeded into a T75 flask. Media was changed next day with fresh 
medium to remove remaining DMSO.  
2.1.4 Cell counting 
To count the cells, pelleted cells were resuspended in 1 ml of media. 10 μl of cell-
suspension was loaded to a hemocytometer counting chamber. Cells in 4 sets of 16 
squares were counted under light microscope on 10X objective. Only the cells set within 
a square counted. The cell concentration was determined by diving total cell number by 
4 and multiplying with 104 to derive final cells per millilitre.  
2.2 Cell-treatments 
2.2.1 Detection of cell-death and viability using the CytoTox-Glo™ assay 
The CytoTox-Glo™ assay (Promega, Southampton, UK) is based on detection of the 
distinct intracellular protease activity which is released when cell-membrane is 
compromised. The membrane compromised ‘dead cell-protease’ cleaves a luminogenic 
peptide substrate - alanyl-alanylphenylalanyl-aminoluciferin (AAF) and produce a 
luminescence signal. Since the AAF substrate cannot cross the intact membrane of live 
cells and does not produce any appreciable signal from live and healthy cells, the amount 
of luminescence signal corresponds to the percentage of the cells undergoing cytotoxic 
stress. 
All reagents were thawed at 37°C in water bath and mixed properly to ensure the 
homogeneity before an experiment. CytoTox-Glo™ cytotoxicity assay reagent was 
prepared by transferring the content of one bottle of assay buffer to the CytoTox-Glo™ 
substrate bottle and the lysis reagent was prepared by transferring 33 μl of digitonin to 
the 5 ml of assay buffer. 
For the assay the cells were seeded into a white, flat, clear-bottomed 96 well plate at the 
desired number (2500 for schwannoma and meningioma primary cells, 1500 for Ben-
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Men-I cell-line) in at least triplicates. The following day, cells were treated with the 
desired drug concentrations plus a vehicle control (DMSO/EtOH) at a final volume of 
100 μl/well. Cells were incubated for either 72 hours or seven days before undergoing the 
Cyto Tox-GloTM assay. Cyto Tox-GloTM assay reagents were prepared as per 
manufacturer’s instructions. 50 μl of AAF-Cyto Tox-GloTM substrate mix was added per 
well, incubated 15 minutes at room temperature in the dark before quantifying 
luminescence corresponding to dead cell numbers with a microplate reader (BMG 
Labtech, Buckinghamshire, UK). 50 μl of prepared cell lysis digitonin mix was then 
applied to the wells before a further incubation of 15 minutes at room temperature in the 
dark. A second luminescence reading was taken corresponding to total cell numbers. Data 
was analyzed in Microsoft Excel. Total cell luminescence was determined as a percentage 
of control. Dead cells were determined as a percentage of total cells then as a percentage 
of control. 
 
2.3 Quantifying Gas6 release from cells using enzyme-linked 
immunosorbent assay (ELISA) 
HMC, Ben-Men-I and primary meningioma cells were cultured for seven days or until 
fully confluent in complete growth medium. Following that, medium was collected and 
centrifuged at 1500 rpm for 10 minutes at 4°C and concentrated 10x using Amicon ultra 
centrifugal filters (Millipore, Feltham, UK). Concentrated media samples were aliquoted 
and stored at -80°C until required. 100 μl of concentrated media samples or standards 
were loaded into each well (in duplicates) of Gas6 Enzyme-linked immune sorbent assay 
(ELISA) kit (RayBiotech- Catalog NO: ELH-GAS6) and incubated for 2.5 hours at room 
temperature with gentle shaking. Following that the wells were washed four times with 
1X wash buffer (provided in the kit) before incubating with biotinylated antibody for one 
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hour at room temperature. The wells were washed once again and 100 μl of Streptavidin 
solution was added for 45 minutes and incubated at room temperature. Following final 
wash with 1x wash buffer, 100 μl of TMB one-step Substrate reagent was added to each 
well and incubated for 30 minutes in dark. Finally, 50 μl of stop solution added to each 
well and   absorbance was read immediately at 450 nm using a microplate reader in order 
to gauge Gas6 concentration. 
2.4 Lentivirus production and infection 
2.4.1 Plasmid preparation 
Lentiviral vectors pGIPZ and PLKO.1 containing TYRO3 (TYRO3 shRNA438; Clone 
ID- V2LHS_56438 and TYRO3 shRNA476; Clone ID- V3LHS_637476) and MERTK 
shRNA sequences (MERTK shRNA62; Clone ID - TRCN0000000862 and MERTK 
shRNA65; Clone ID- TRCN0000000865) were obtained as bacterial cultures of E.Coli 
(DH5α) in 2x LB-Lennox broth (low salt) medium with 8% glycerol and 100 μg/ml 
carbenicillin on dry ice from GE Healthcare (Dharmacon, IL, USA). To prepare the 
plasmid DNA, a loopful of glycerol stock was streaked onto LB agar plate containing 100 
μg/ml carbenicillin (Sigma-Aldrich, MO, USA). Plates were incubated overnight in 
bacterial incubator at 37°C for the growth of antibiotic resistant colonies. The next day, 
single colony was picked from LB agar plate and amplified in 5 ml of LB broth containing 
100 μg/ml carbenicillin and incubated at 37ºC with shaking at 200-250 rpm for 12-16 
hours. Plasmid DNA was isolated from bacterial cells using Miniprep kit (Thermo 
scientific, MA, USA). Lentivirus particles containing a scrambled shRNA sequence were 
obtained from Dharmacon (RHS4348). 
2.4.2 Plasmid DNA isolation: Miniprep 
The GeneJET Plasmid Miniprep Kit (Thermo Scientific, MA, USA) was used for rapid 
preparation of high-quality plasmid DNA. The plasmid DNA was isolated and purified 
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using manufacturer’s instructions. In short, the 5 ml of bacterial culture was centrifuged 
at 8000 rpm for 2 minutes at room temperature and the pelleted cells were resuspended 
in 250 μl of the Resuspension Solution. The cells were lysed by adding 250 μl of Lysis 
Solution and neutralized by adding 350 μl of Neutralization Solution. Following that the 
lysate was centrifuged for 5 minutes to pellet cell debris and chromosomal DNA. The 
supernatant containing plasmid DNA was transferred to the supplied GeneJET spin 
column and the column was centrifuged for 1 minute, followed by 2-3 more washes of 
column with Wash Solution. In the end, flow-through was discarded and column was 
centrifuged for additional 1 minute to remove any residual ethanol from plasmid 
preparation. Finally, plasmid DNA was eluted by adding 50 μl of Elution Buffer to the 
centre of GeneJET column. All centrifugation steps in the protocol were carried out at 
12000 rpm, unless mentioned. The quantity and quality of isolated DNA was assessed 
using a Nano-drop (Thermo Scientific, MA,USA).  
2.4.3 Lentivirus packaging  
Both TYRO3 and MERTK shRNA constructs were packaged using second generation 
packaging plasmid. Low passage human embryonic kidney (HEK) 293FT cells 
(Thermofischer Scientific) were plated at a density around 2.5*106 and incubated at 37°C 
and 5% CO2 overnight in complete medium containing DMEM, 10% FBS, 500U/ml 
pen/strep; to achieve ~70-80% confluency on the day of transfection. HEK-293 cell-line 
is derived from human embryonic kidney (HEK) cells. 293FT cells are fast growing 
variant of 293 cell-line that contains SV-40 large T-antigen which allows the episomal 
replication of transfected plasmids containing the SV40 origin of replication (Oka et al., 
2010). 5 μg of pLenti-shRNA constructs (TYRO3/MERTK) and 6 μg of packaging mix 
(Dharmacon- TLP4606) were added into 500 μl of Opti-MEM (reduced serum media – 
Thermofischer scientific). In a separate labelled tube, 44 μl of MegaTran 1.0 (Origene, 
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MD, USA) transfection reagent was added into 500 μl of Opti-MEM (Thermo Fischer 
Scientific, MA, USA). The content of both vials was mixed, vortexed and incubated 15-
30 minutes at room temperature. Finally, the mixture of DNA and MegaTran were added 
directly to the 10cm dish of 293FT cells. After 12-18 hours of transfection, media was 
changed to reduced serum medium (complete growth medium containing 5% FBS). Viral 
particles were collected after 48 hours of medium change, centrifuged at 3000rpm to 
remove cellular debris, aliquoted and stored at -80°C until further use.  
The titer of home-made TYRO3 shRNA438 was calculated to 7.9*105 TU/ml and TYRO3 
shRNA476 was calculated to 8.5*105 TU/ml. Titration was performed by Dr Emmanuel 
Maze. The schwannoma cells were infected with multiplicity of infection (MOI of 10) in 
each case. Viral titer was unable to be determined for the home made MERTK shRNA 
(construct 862 and 865) lenti-viruses due to absence of GFP but 2 ml unconcentrated viral 
particles was sufficient for 80% knock-down of primary cells.    
2.4.4 Pre-made MERTK, AXL and TYRO3 shRNA lentivirus particles 
For infecting meningioma primary cells, I used commercially available MERTK 
shRNA1643 (clone-ID: V2LHS_1643), MERTK shRNA202 (clone ID: 
V3LHS_372202), MERTK shRNA205 (clone ID: V3LHS_372205), AXL shRNA030 
(clone-ID: V3LHS_404030), AXL shRNA652 (clone ID: V3LHS_329652), AXL 
shRNA653 (clone ID: V3LHS_329653) and TYRO3 shRNA438 (clone ID: 
V2LHS_56438) and TYRO3 shRNA476 (clone ID: V3LHS_637476) constructs from GE 
Dharmacon. The titre of each lentivirus particles was 1x108 TU/mL. I used 10 μl of pre-
made lenti-virus particles (MOI-10) to infect cells in a 6-well plate. MOI was calculated 
by following formula; Number of virus particles (TU)/number of cells.   
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2.4.5 Lentivirus infection 
Schwannoma and meningioma primary cells were split into 6-well plates (80,000 
cells/well) the day before infection. The wells were coated with Poly L lysine (PLL-
Sigma-Aldrich, MO, USA) and laminin (LA-Thermofischer Scientific, MA, USA) for 
schwannoma cells. Cells were infected with shRNA viral particles targeting AXL, 
MERTK and TYRO3 in the presence of 8 μg/ml protamine sulphate (Sigma-Aldrich, MO, 
USA)- polycation. Control cells were infected with non-targeted control or scrambled 
shRNA in the same manner. After infection cells were incubated at 10% CO2 for 72 hours 
after which they were selected with puromycin (10 mg/ml-Sigma-Aldrich, MO, USA). 
All experiments included a ‘non-infected’ control well, in order to monitor the cell death 
upon puromycin selection. After selection, cells were lysed to extract protein and run on 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to investigate 
the target gene knock-down. 
2.5 Adenovirus infection   
Human primary meningioma cells were plated a day before infection in 6-well plates 
according to an experiment. Cells were infected with either control GFP adenovirus or 
adenovirus expressing wild-type Merlin for 72 hours as described in (Ammoun et al., 
2014), followed by cells-lysis using RIPA lysis buffer. The lysates were run on SDS-
PAGE electrophoresis. Merlin (NF2) wild type (recombinant adenovirus AdNF2) and 
control GFP-containing vector adenoviruses were a kind gift from J. Testa (Xu and 
Gutmann, 1998).   
2.6 Western blot 
2.6.1 Protein extraction and quantification 
Cultured cells were washed with ice-cold PBS before the addition of 
radioimmunoprecipitation assay buffer (RIPA) lysis buffer (150 mM NaCl, 0.5% sodium 
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deoxycholate, 0.1% SDS, 1% NP40, 50nM tris-HCl; pH-8), containing 1% complete 
protease inhibitor (Thermo-Scientific, MA, USA) and, 1% phosphatase inhibitor cocktail 
B and 1% phosphatase cocktail inhibitor C (SantaCruz Biotechnology, TX, USA) on ice. 
The lysate was collected and incubated on ice for 5 minutes before centrifuging at 13,000 
rpm for 15 minutes at 4°C to remove cell debris. Following the centrifugation, the 
supernatant was transferred to a clean and labelled 1.5 ml Eppendorf tube and stored at -
80°C until requierd. Pierce bicinchoninic acid (BCA) assay kit (Thermo Scientific, MA, 
USA) was used to quantify total protein concentration. The concentration of unknown 
protein was determined with reference to the standard concentration of Bovine Serum 
Albumin (BSA–2mg/ml), provided in the kit. The content of one Albumin Standard 
(BSA) ampule (2mg/ml) used to create various stock concentrations of 0, 25, 125, 250, 
500, 750, 1000, 1500, 2000 μg/ml by diluting it into lysis reagent (RIPA/ low salt Triton 
X-100). The whole protein lysates were diluted to 1:5 and 12 μl of the standard and 
unknown protein samples were pipetted in duplicates into 96-well plate. 100 μl of 
working reagent (50:1, reagent A: B) was applied to each well containing sample or 
standard. Plate was briefly mixed on plate shaker for 30 seconds and incubated at 37°C 
for 30 minutes. The plate was allowed to cool at room temperature and absorbance was 
measured at 562 nM on microplate reader (BMG, Buckinghamshire, UK). The 
absorbance value (at 562 nM) of blank standard replicate was subtracted from the 
absorbance values of all other standard and unknown sample replicates.  The average 
blank corrected values of the absorbance were used to plot the standard curve for each 
BSA standard concentration, and the protein concentration of an unknown sample was 
determined using the linear equation based on standard curve using Micorsoft Excel. 
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2.6.2 Sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE)  
The proteins were separated according to size by an electrophoresis using discontinuous 
polyacrylamide gel system. A stacking gel of 4% (Table-2.1) and a resolving gel of 8% 
or 10% (Table-2.2) were used, throughout the experiments depending on the size of 
protein of interest. Spacer plate (1.5 mm) and short plate were fixed into the casting frame 
and placed into casting stand (Bio-Rad, Watford, UK). Firstly, the resolving gel was 
prepared and poured between the glass plates and layered with 50% isopropanol. Once 
the gel polymerised, isopropanol was removed, and gel surface was rinsed with distilled 
water before layering the stacking gel on top of the resolving gel. Comb was placed and 
allowed the gel to polymerise.  
20 μg of total protein per sample was mixed with 4X loading buffer (250 mM Tris-HCl 
(pH-6.8), 8% SDS, 40% glycerol, 200mM DTT and 0.4% bromophenol blue (all Sigma-
Aldrich, MO, USA) and boiled at 95°C for 5 minutes. The samples were allowed to cool 
at room temperature before loading into the gel and run at 120V for 100 minutes in 1X 
running buffer (200 ml 10X running buffer (Table-2.3) in 800ml of distilled water). 10 μl 
of precision plus prestained dual color protein ladder (Bio-Rad, Watford, UK) was loaded 
with samples as a standard size of protein. 
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10 ml 4%  
H2O 7.5 ml 
Tris HCl 1.5M (pH 6.8) 1.25 ml 
40% Acrylamide 1.0 ml  
10% SDS 100 µl 
10% APS 100 µl 
TEMED 10 µl 
Table 2. 1- Recipe for stacking gel.  
 
10 ml 5% (100-250) KDa 10% (30-150) KDa 
H2O 5.9 ml 4.8 ml  
Tris HCl 1.5M (pH 8.8) 2.8 ml 2.5 ml  
40% Acrylamide 1.25 ml  2.5 ml 
10% SDS 100 µl 100 µl 
10% APS 75 µl 75 µl 
TEMED 10 µl 10 µl 
Table 2. 2- Recipe for resolving gel.  
 
 Running buffer 5X Transfer buffer 10X 
Trizma base 22.7 g 45.5 g 
Glycine 108 g 108 g 
SDS 7.5 g - 
Distilled water Up to 1.5 L Up to 1.5 L 
Table 2. 3- Recipe for Running buffers and Transfer buffer stock 
 
2.6.3 Protein transfer and immunodetection 
Separated proteins were transferred onto the activated polyvinylidene fluoride (PVDF) 
membrane (Bio-Rad, Watford, UK) at 250 mA for 90 minutes in 1X transfer buffer 
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(100ml of 10X transfer buffer (Table 2.3) into 700ml of distilled water and 200ml of 
methanol) along with ice packs at 4°C. The membrane was then blocked for 1 hour with 
either 5% blocking milk (5% skim milk powder/ tris-buffered saline with 0.1% tween 
(TBST)) for total proteins or 5% BSA/TBST for phospho proteins. Following blocking, 
membrane was incubated with primary antibody (Table 2.4) of interest in 5% BSA/TBST 
at 4°C overnight on shaker. The following day, the membrane was washed three times 
for 10 minutes in TBST and incubated with corresponding secondary antibody (Table-
2.5) for one hour at room temperature. The membrane was again washed 3-4 times for 15 
minutes before detecting the protein bound antibody using enhanced chemical 
luminescence (ECL) detection system. In short, Pierce ECL western blotting substrate 
(Thermo- Scientific, MA, USA) or Pierce ECL Plus western blotting substrate (Thermo- 
Scientific, MA, USA) was poured onto membrane in the dark. After 3- 5 minutes, excess 
of ECL reagent was removed and the protein bands were detected using ECL hyper film 
(GE Healthcare, IL, USA) by exposing the films from few seconds to several minutes 
onto the membrane. ECL hyper films were developed using Xenograph compact X4 X-
ray film processor (Thermofischer scientific, MA, USA). 
Primary antibody Species Company  Catalogue 
NO 
Dilution 
AXL (C89E7) Rabbit CST, MA, USA #8661 1:1000 
TYRO3 (D38C6) Rabbit CST, MA, USA #5585 1:500 










Gas6 (D3A3G) Rabbit CST, MA, USA #67202 1:500 
Phospho MERTK Rabbit Fabgennix, TX, 
USA 
PMKT-140AP 1:500 
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Merlin (D1D8) Rabbit CST, MA, USA #6995 1:1000 
Phospho Merlin 
(Ser518) 
Rabbit CST, MA, USA #9163 1:500 











Rabbit CST, MA, USA #9101 1:1000 
p44/42 MAPK 
(Erk1/2) (137F5) 
Rabbit CST, MA, USA #4695 1:1000 
Phospho AKT 
(Ser473) (D9E) 
Rabbit CST, MA, USA #4060 1:1000 
AKT (pan) (C67E7) Rabbit CST, MA, USA #4691 1:1000 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
Rabbit CST, MA, USA #9251 1:1000 
SAPK/JNK  Rabbit CST, MA, USA #9252 1:1000 
Phospho FAK 
(Tyr397) (D20B1) 
Rabbit CST, MA, USA #8556 1:1000 
Total FAK Rabbit CST, MA, USA #3285 1:1000 
Cyclin-D1 (92G2) Rabbit CST, MA, USA #2978 1:1000 















Table 2. 5- Secondary antibodies used to detect primary antibodies in Western blot  
 
2.6.4 Densitometry method 
Films were scanned to create a digital image and Image-J software was used for 
densitometry quantification of protein band (Schneider et al., 2012). Blots were inverted 
prior to density measurement so that bands appear white on a black background. To take 
the measurments, rectangle tool was selected from Image J and adjusted to contain the 
whole of the largest band and was subsequently used to take densities of all other bands 
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across the row. The same frame was used to take the background measurement and was 
later substracted from each individual protein band measurement to get the net value of 
protein band of interest. All bands at the correct molecular weight ± approximately 5 kDa 
were measured for the target protein (uncropped Western blot images in chapter 7.4, 
Figure- S5). Any visible overlapping bands in this region were measured to ensure that 
the level of background signal substraction is appropriate to the background noise in the 
membrane and is not artificially affected by detected signal. Any other non-specific bands 
at different molecular weight was excluded. The same measurments were taken for 
loading control bands and their backgrounds correspond to each protein band. Finally, 
data normalization was performed by dividing the net value of target protein to the net 
value of loading control of that lane. 
2.7 Co-immunoprecipitation (CO-IP) 
2.7.1 Tissue homogenization 
Schwannoma and meningioma tumour tissues as well as Ben-Men-I cell-line, were used 
for co-immunoprecipitation experiments instead of primary cells due to the large amount 
of proteins requirement. On receiving, larger piece of frozen schwannoma tissue was cut 
into small pieces whilst keeping it on dry ice. Smaller pieces were transferred into cold 
and fresh 1.5 ml Eppendorf tubes and stored at -80°C until further use. To homogenize 
the tissue pieces, 500 μl of ice-cold low salt Triton X-100 lysis buffer was used (30 mM 
Tris (pH 8.0), 75mM NaCl, 10% glycerol and 1% Triton X-100) for approximately 10-
20 mg of tissue. The schwannoma tissue was added to pre-chilled homogenizer 
containing the low salt triton X-100 lysis buffer (supplemented with 1% complete 
protease inhibitor and 1% phosphatase cocktail B and phosphatase cocktail C and 
homogenized using up-down strokes of pestle on ice. Ben-Men-I cells were lysed using 
low salt triton X-100 as described in chapter-2.6.1. The tissue lysate was transferred to 
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fresh pre-chilled 1.5 ml eppendorf tube and centrifuged at 3000 rpm for 10 minutes at 
4°C to remove any cell-debris. The supernatant was collected in pre-chilled 1.5 ml 
eppendorf tube and protein concentration was determined using BCA assay or aliquoted 
and stored at -80°C until further use. 
2.7.2 Pre-IP bead washes and CO-IP incubation 
To each 1.5 ml eppendorf tubes, 20 μl of protein G Sepharose beads (GE Healthcare, IL, 
USA) were added to a tube and washed 3-4 times with 1 ml of low salt Triton X-100 lysis 
buffer at 2000 rpm for 2 minutes at 4°C. To the washed beads tissue lysate (1 mg/ml) and 
antibody (Table-2.6) was added, tubes were sealed with parafilm and incubated at 4°C 
overnight on rotor. IgG (1 μg) antibody of the same species as IP-antibody was used as a 
negative control.  
2.7.3 Post-IP bead washes and eluting the protein complex 
The next day, beads were washed again for 6-7 times with 1 ml of low salt Triton X-100 
lysis buffer at 2000 rpm for 2 minutes at 4°C to remove non-specific binding to beads 
other than IP-antibody/protein complex. The protein complex was eluted by boiling the 
beads at 95°C for 5 minutes in 40 μl 2X reducing sample buffer. The samples were 
allowed to cool at room temperature and finally centrifuged at 13000 rpm for 2 minutes 
to pellet the beads and supernatant was transferred to a fresh 1.5 ml of eppendorf tube. 
Samples were run using SDS-PAGE to detect the protein. 
IP Antibody Species Company Catalogue 
NO 
Dilution 
AXL-IP AXL Rabbit CST, MA, 
USA 
#8661 1 μg/mg of lysate 
TYRO3-IP TYRO3 Rabbit CST, MA, 
USA 
#5585 5 μg/mg of lysate 
MERTK-IP MERTK Rabbit CST, MA, 
USA 
#4319 1 μg/mg of lysate 
IgG-IP IgG Rabbit CST, MA, 
USA 
#2729 1 μg/mg of lysate 
Table 2. 6- List of primary antibodies used for co-immunoprecipitation 
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2.8 Immunohistochemistry (IHC) 
 
Formalin fixed paraffin embedded (FFPE) thin tissue sections (4 µm) were cut and 
sections were baked at 60⁰C for 10 minutes by the Department of Cellular and Anatomical 
Pathology at University Hospitals Plymouth. Sections were dewaxed and rehydrated by 
washing slides two times for five minutes in xylene (Thermo Fisher Scientific, MA, USA) 
and 100% ethanol (VWR®, PA, USA) respectively followed by wasing in running water 
for five minutes. The endogenous peroxidase activity is blocked by incubating slides in 
3% hydrogen peroxide in methanol for 30 minutes at RT. The slides were washed in 
running tap water for 10 minutes before antigen retrival by boiling slides in citrate buffer 
(pH 6.0) or EDTA buffer (pH 9.0) for 30 minutes. Following that slides were slides were 
quilibriated by washing them in TBST for five minuets and then blocked using 1% normal 
horse serum for 30 minutes before applying primary antibodies overnight.    
The next day slides were washed two times for five minutes and biotinylated secondary 
and tertiary antibodies applied according to manufacturer’s instructions (Vectastain 
Universal Elite ABC kit (Vector Laboratories Ltd, CA, USA). Slides were washed in 
TBST twice for five minutes and then 3,3'-diaminobenzidine (DAB (Sigma-Aldrich, MO, 
USA) solution was applied for five minutes. Slides were washed again in running tap 
water for five minutes before counterstained with Mayers Haemaatoxylin (Sigma-
Aldrich, MO, USA) for two minutes and excess of solution was removed washing slides 
in running tap water for 10 minutes. Finally, the slides were washed twice in 100% 
ethanol and xylene before mounting with DPX (Sigma-Aldrich, MO, USA). Images were 
acquired by Leica DMRB and the scoring of staining intensity was performed with the 
help of consultant neuropathologist, Dr David Hilton (Department of Cellular and 
Anatomical Pathology at University Hospitals Plymouth).  
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Antibody Species Company Catalogue NO Dilution 
AXL Rabbit Abnova, Taipei, 
Taiwan 
PAB2999 1:100 
pAXL (Y779) Rabbit  R&D system, 
MN, USA 
AF2228 1:500 
MERTK Rabbit Abcam, 
Cambridge, UK 
ab52968 1:1000 
pMERTK Rabbit FabGennix, TX, 
USA 
PMKT-140AP 1:250 




Table 2. 7- List of primary antibodies used for IHC 
 
2.9 Immunocytochemistry/immunofluorescence (ICC/IF)  
Schwannoma and meningioma primary cells were seeded on 8 chambered microscopic 
slides (Lab-Tek-Thermofischer scientific, MA, USA) until confluent in complete growth 
medium. To perform immunofluorescence staining, culture media was aspirated, and 
cells were washed with 1X PBS before fixing the cells with 4% paraformaldehyde (PFA) 
for 10 minutes at room temperature. Cells were permeabilized with 0.2% Triton X-100 
for 5 minutes at room temperature. Cells were again washed three times for 5 minutes at 
room temperature with PBS, followed by blocking using 10% normal goat serum (NGS) 
in 1% BSA for 60 minutes at room temperature to block non-specific binding of 
antibodies. After an hour cells were again washed once with PBS and incubated overnight 
with primary antibody (Table-2.8). The following day, any unbound primary antibody 
was removed by washing the cells three times with PBS for five minutes and then the 
cells were incubated with corresponding secondary antibodies (Table-2.9) in 1% BSA 
and nuclear stain DAPI at concentration of 1:500 for 1 hour in the dark at room 
temperature. Lab-Tek chamber was removed and coverslip was applied to cells using 
vectashield antifade mounting media and slides were sealed using nail vanish to prevent 
drying and movement under microscope. Slides were imagined using 20X or 40X 
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magnification with Zeiss confocal microscope LSM510 and images were taken with 
built-in CCD camera for digital imaging with LSM image software. 
Primary 
antibody 
Species Company  Catalogue NO Dilution 






Rabbit CST, MA, USA #9661 1:100 
AXL (C89E7)  Rabbit CST, MA, USA #8661 1:100 
TYRO3 Mouse Biorbyt, 
Cambridge, UK 
orb167076 1:50 




MERTK (D21F11) Rabbit CST, MA, USA #4319 1:100 




Type Company  Catalogue NO Dilution 








Table 2. 8- Secondary antibodies used to detect protein of interest in ICC 
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2.10    Data analysis 
GraphPad Prism data analysis software was used throughout the project to calculate 
statistical significance in each experiment. Experiments were performed at least in 
triplicates unless otherwise mentioned. For statistical analysis Mann-Whitney test (for 
comparison of two columns) and Kruskal-Wallis test (for comparison of more than two 
columns) with Dunn’s multiple comparison (to compare mean rank of each column to 
mean rank of every other column) or ANOVA with Dunnett’s multiple comparison test 
(to compare mean of every column to mean of control column) was used. The p value 
was used to determine the significance of the results where ns= non-significant >0.05, 






































Chapter 3 – Results 
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3a.1 Characterize the expression of TAM receptors and their ligand Gas6 in 
meningiomas 
Introduction 
As previously mentioned, meningiomas are the most common intracranial brain tumours, 
responsible for ~30-40% of all cases. Meningiomas can exhibit wide variety of genetic 
alterations but interestingly all NF2-related meningiomas and ~50-60% of spontaneous 
meningiomas are linked to mutation in NF2 and loss of protein Merlin (Riemenschneider 
et al., 2006). The large percentage of meningiomas, carrying NF2 mutations provides an 
ideal opportunity to identify a novel candidate that is deregulated in all Merlin-deficient 
tumours and hence can be used as a common therapeutic target for treatment of all NF2-
mutated tumours. 
TAM receptors and their agonist Gas6 are overexpressed in several cancers including 
Merlin-deficient schwannomas as well as mesotheliomas, gliomas, melanomas, breast, 
colorectal and prostate cancer (Ammoun et al., 2014, Pinato et al., 2013, Pierce and 
Keating, 2014, Schwartz and Assoian, 2001, Holland et al., 2010, Schmitz et al., 2016, 
Wu et al., 2004, Jung et al., 2016). All three TAMs and their ligand Gas6 are known to 
be overexpressed and aberrantly regulated in human schwannoma primary cells and 
tissues. Moreover, expression of Gas6 and AXL was correlated with pathological 
proliferation, adhesion and survival of schwannoma cells (Ammoun et al., 2014). By 
performing IHC, our team previously showed higher expression of AXL, MERTK, pAXL 
and Gas6 in meningioma tissues compared to control tissues (Hilton et al., 2016). 
However, detailed investigation of the role of AXL or any other TAM members in 
pathophysiology of meningioma was not carried out at that point and authors warranted 
further investigation to examine the role of these receptors in meningioma development.  
- 84 - 
 
The aim of this chapter is to characterize the expression and activation of TAM receptors 
as well as their ligand Gas6 in Merlin-deficient meningioma tissues, primary cells and a 
cell-line using Western blotting. The status of NF2 or Merlin expression was determined 
for each sample (including tissue and meningioma primary cell) by either NF2 sequencing 
at the Manchester Centre for Genomic Medicine, Mangen (Manchester Department of 
clinical genetics) or by a Western blotting in the laboratory. Detail of NF2 status and 
Merlin expression of all meningioma samples used in this chapter is described in 
supplementary section (supplementary chapter 7.5; table S1 and table S2).  
3a.1.1 TAM receptors are highly expressed and activated in meningiomas  
Firstly, I performed Western blot analysis to investigate the expression of total as well as 
phosphorylated form of AXL, TYRO3 and MERTK in Merlin-negative G (grade)-I, II 
and III meningioma tissues compared to normal meningeal tissue (NMT) as a control.  
Notably, Western blot analysis showed an increased expression and phosphorylation of 
AXL and MERTK in all three meningioma grades with significant increases observed in 
the expression and phosphorylation of AXL in G-I and in phosphorylation of MERTK in 
G-II compared to NMT. There was no striking change in the levels of either 
phosphorylated or total AXL and MERTK between different meningioma grades.  
Variable expression and phosphorylation of TYRO3 was also observed in all three 
meningioma grades with no significant difference compared to NMT or between the 
different grades (Figure - 3.1 A and Figure - 3.1 B).  
  




Figure 3. 1- AXL, MERTK and TYRO3 are highly expressed and activated in human 
Merlin-negative meningioma tissues. Western blot panel shows the expression and 
phosphorylation of AXL, MERTK and TYRO3 in different grades of Merlin-deficient 
meningioma tissues and NMT as a control. GAPDH was used as a loading control A);  A scatter 
plot shows the level of phosphorylated (left) and total (right) AXL, MERTK and TYRO3 in NMT 
(n=3), G-I (n=9), G-II (n=5) and G-III (n=3) meningioma tissues B). Each dot in a scatter plot 
represents the data for an individual patient; the bar represents median value of phospho and total 
AXL, MERTK and TYRO3. Statistical difference was calculated using Kruskal-Wallis test 
followed by Dunn’s multiple comparision test; * = p <0.05. NMT= normal meningeal tissue, G-
I= grade I, G-II= grade II and G-III= grade-III. Membranes were firstly probed with phospho 
TAM antibodies and developed with ECL plus followed by reprobing with total TAM antibodies 
and developed with normal ECL or ECL plus. Phospho antibodies required much longer exposure 
time compared to total. 
 
Additionally, I also examined the expression and phosphorylation status of TAM 
receptors in Merlin-negative, G-I meningioma primary cells and Ben-Men-I cell-line 
against normal human meningeal cells (HMC) as a positive control. HMCs are primary 
human meningeal cells, derived from healthy leptomeninges of foetus and Ben-Men-I is 
NF2 mutated, WHO G-I cell-line, developed by retrovirally transducing primary cells 
derived from meningothelial meningiomas to surpass cellular senescence (Puttmann et 
al., 2005). Cryopreserved HMC and Ben-Men-I cells at passage 0 (P0) were bought from 
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Science cell research laboratories (Carlsbad, CA, USA) and DSMZ (Brunswick, 
Germany) company respectively.  
Consistent with the results of tumour tissues, Merlin-negative G-I meningioma primary 
cells and a cell-line, Ben-Men-I displayed variable expression and phosphorylation of 
AXL, MERTK and TYRO3 receptors. Moreover, Merlin-deficient meningioma primary 
cells showed significantly higher phosphorylation of AXL and MERTK compared to 
Merlin-positive HMCs, whereas the Merlin-deficient meningioma cell-line, Ben-Men-I, 
showed prominently higher phosphorylation of these two proteins. However, this 
difference was statistically insignificant (Figure-3.2 A). There was no remarkable 
difference in the expression of AXL, MERTK and TYRO3 (Figure-3.2 B) or 
phosphorylation of TYRO3 (Figure-3.2 A) in Ben-Men-I and meningioma primary cells 
compared to HMC (Explanation of possible reasons in chapter-3.1.4). 
 
Figure 3. 2- Expression and phosphorylation of AXL, MERTK and TYRO3 in Merlin-
negative (NF2-/-) human meningioma cells. Western blot of normal human meningeal cells 
(HMC, n=3) as a positive control, Merlin- negative meningioma cell-line, Ben-Men-I (n=3) and 
Merlin-negative meningioma primary cells (MN (NF2-/-), n=6 to n=8) showing A) the 
phosphorylation of AXL, MERTK and TYRO3; and B) the expression of AXL, MERTK and 
TYRO3. Merlin status of the samples were detected using a Western blot. Scatter graphs were 
plotted using GraphPad Prism software and it represents the data of each sample as an individual 
dot; the bar represents median value of phospho and total AXL, MERTK and TYRO3.  Statistical 
difference for HMC vs Ben-Men-I and MN (NF2-/-) was calculated using Mann-Whitney test; 
* = p <0.05. GAPDH was used as a loading control. 
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3a.1.2 Gas6 is overexpressed and released from meningioma cells 
Since Gas6 is highly expressed and released from Merlin-negative human schwannoma 
primary cells, I wanted to investigate whether this is also the case for Merlin-negative 
human meningioma cells and tissues. Western blot analysis showed variable expression 
of Gas6 in all three grades of meningiomas as well as NMT. However, the expression of 
Gas6 was slightly higher in G-I compared to NMT, G-II and G-III (Figure-3.3 A). Due to 
heterogeneity of meningiomas, the number of tumour tissues analyzed for Gas6 
expression needs to be increased before drawing any conclusions. 
Consistent with this finding, remarkably higher expression of Gas6 was also observed in 
G-I Merlin-negative meningioma primary cells and a cell-line, Ben-Men-I compared to 
HMCs (Figure-3.3 B). 
  





Figure 3. 3- Gas6 expression in meningioma tissues and cells. Western blot shows Gas6 
expression in A) G-I (n=3), G-II (n=1) and G-III (n=3) Merlin-negative meningioma tissues 
compared to NMT (n=3); and B) Ben-Men-I (n=3) and Merlin-negative meningioma primary 
cells (n=6) compared to Merlin-positive HMC (n=3) as a positive control. Graphs are the 
quantification of band density, measured using Image J. Data were normalized to GAPDH. Bars 
represents the median value and statistical difference was calculated using Kruskal-Wallis and 
Dunn’s multiple comparision post-hoc test (G-II, Gas6 expression was not included in statistical 
test) or Mann-Whitney test; * = p <0.05, 
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Next, I performed a Gas6 ELISA on cell-culture supernatant of HMCs, Ben-Men-I and 
meningioma primary cells to check whether Gas6 is released into cell-culture media. The 
results showed higher release of Gas6 from meningioma primary cells and Ben-Men-I 
cells compared to HMC cells, although this difference was statistically non-significant 
(Figure-3.4).   
  
Figure 3. 4 - Gas6 release from meningioma cells. The graph shows the release of Gas6 from 
HMC (n=3) control, Ben-Men-I (n=3) and meningioma primary cells (n=5) by ELISA. Statistical 
difference for HMC vs Ben-Men-I and meningioma primary cells (MN (NF2-/-)) was calculated 
using Mann-Whitney test; ns=not significant.  
 
3a.1.3 Overexpression of AXL, MERTK and TYRO3 but not Gas6 is Merlin-
dependent in meningiomas 
Overexpression of AXL, TYRO3 and Gas6 were due to loss of Merlin in schwannoma 
primary cells (Ammoun et al., 2014). Hence, I looked whether the expression of TAMs 
and their ligand Gas6 are also under negative regulation of Merlin in meningioma cells. 
In order to investigate this, I reintroduced Merlin using adenovirus to Merlin-negative 
meningioma primary cells. Merlin overexpression in these cells decreased the expression 
of AXL, TYRO3 and MERTK nevertheless, the expression of Gas6 remain unaffected 
(Figure-3.5 A and Figure-3.5 B). Successful reintroduction of Merlin was tested in each 
experiment by probing the membrane with anti-Merlin (NF2) antibody.  




Figure 3. 5- Overexpression of AXL, TYRO3 and MERTK but not Gas6 is dependent on 
Merlin in Merlin-negative meningioma primary cells. Adenovirus containing GFP or NF2 
constructs were used to infect Merlin-negative meningioma primary cells. Cells were infected for 
three days before lysis. Proteins were separated then, transferred to PVDF membrane and probed 
with AXL, TYRO3, MERTK and Gas6 antibodies. Merlin reintroduction was checked each time 
by probing the membrane with a Merlin (NF2) antibody. A) A representative Western blot images 
of AXL, TYRO3, MERTK and Gas6 on Merlin-reintroduction. GAPDH was used as a loading 
control; B) Scatter plots shows significant reduction in expression of AXL (n=4), TYRO3 (n=4) 
and MERTK (n=4) but not of Gas6 (n=3) on Merlin reintroduction. Data are represented as mean 
± standard error of mean. Statistical calculations were carried out using ANOVA with Dunnett’s 
multiple comparison test; *** = p <0.001 and ns=non-significant. 
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3a.1.4 Discussion 
Like other cancers, high expression and activation of multiple growth factor receptors and 
their downstream signaling pathways is a signature event in the pathogenesis of 
meningiomas. Overexpression of TAM receptors and Gas6 has been associated with 
increased proliferation, survival, migration and multiple drug resistance in several cancers 
(Petrilli and Fernandez-Valle, 2016). The contribution of AXL in promoting pathogenesis 
of schwannomas has been previously established by our group, whereby, AXL, TYRO3, 
MERTK and Gas6 are all overexpressed and activated. The study also confirmed that the 
expression of AXL, TYRO3 and Gas6 but not MERTK, are under negative regulation of 
Merlin (Ammoun et al., 2014). Since, NF2 mutations leading to Merlin loss is also the 
cause of all NF2-related meningiomas and 50-60% of spontaneous meningiomas (Hilton 
et al., 2016), I investigated whether this family of receptors and their ligand are also 
aberrantly regulated in Merlin-deficient meningiomas just as in schwannomas. 
In search for growth factors and their receptors responsible for the development of 
meningiomas, Hilton et al broadly assessed the expression of several proteins in different 
grades of meningiomas and non-neoplastic meninges by performing 
immunohistochemistry (IHC). Interestingly, the authors found noteworthy differences in 
the staining of AXL, MERTK, Gas6 and pAXL between neoplastic and non-neoplastic 
meninges along with several other proteins (Hilton et al., 2016) and suggested further 
investigation of this important family receptors in meningioma pathogenesis. By 
performing Western blot analysis on different grades of meningioma tissues, I further 
verified the results of IHC and showed the higher expression and constitutional activation 
of all three TAM receptors as well as their ligand Gas6 in Merlin-deficient meningioma 
tissues compared to NMT (Figure-3.1 and Figure-3.3 A).  
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I further assessed the expression and phosphorylation of TAMs and Gas6 in Merlin- 
negative G-I meningioma cell-line; Ben-Men-I and in meningioma primary cells and 
found a wide spread expression of AXL, MERTK, TYRO3 and Gas6 in all primary 
meningioma samples and in Ben-Men-I (Figure-3.2 B and Figure-3.3 B). However, there 
was no significant difference in their expression except of Gas6, compared to HMCs. Of 
note, HMCs are derived from fetal leptomeninges and therefore may not recapitulate the 
real scenario of adult human tissue. Even though HMCs are not an ideal control for our 
adult primary meningioma cells, it was the only closest choice available during this 
project. Interestingly, further evaluation of phosphorylation status of TAMs in HMCs and 
meningioma cells revealed that TAMs, particularly AXL and MERTK, are present in an 
unphosphorylated form in HMC cells (Figure-3.2 A). Since the phosphorylation of RTKs 
is the major determinant of their activity compared to their expression, it can be concluded 
that all three TAM receptors are expressed and activated in Ben-Men-I and meningioma 
primary cells.  
Increased basal activation of TAM receptors in meningioma tissues and cells may 
attribute to higher expression and release of Gas6 from these cells (Figure-3.4). Gas6 is a 
universal ligand that can bind and phosphorylate to all three TAM receptors with different 
affinity and has been shown to be highly expressed in tumour cells of gastric cancer, 
ovarian cancer and GBM (Sawabu et al., 2007, Sun et al., 2004, Hutterer et al., 2008). In 
addition, Gas6 is also highly expressed in tumour-associated cells such as macrophages. 
In fact, in human colorectal cancer, Gas6 has been shown to be mostly expressed and 
secreted by tumour-associated macrophages and communicate with tumour cells to act 
on TAM receptors (Schmitz et al., 2016, Loges et al., 2010). High infiltration of 
macrophages has also been described as the big phenomenon of schwannoma and 
meningioma tumours (de Vries et al., 2013, Domingues et al., 2013). Therefore, it is safe 
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to say that Gas6 released by tumour cells or by tumour micro-environment may have a 
role in activating TAM receptors in an autocrine or in a paracrine manner.  
Again, the activation of TAM receptors is not exclusively due to only ligand Gas6. But 
proteins S, tubby, tulp-1, Galectin-3 have also been described to activate TAM receptors 
and their role in NF2-related tumours is completely unexplored (Caberoy et al., 2010, 
Caberoy et al., 2012). Alternatively, the possibility of ligand-independent activation of 
TAMs in NF2 tumours cannot be denied as many growth factors receptors such as EGFR, 
PDGFR, c-MET, HER2 with which TAMs have been shown to physically interact and 
trans-activate in a ligand-independent manner, are also over-expressed in schwannoma 
and meningioma tumours (Hilton et al., 2016, Hanemann, 2008).  
Furthermore, there is little research available on the mechanisms responsible for TAMs 
and Gas6 overexpression in cancer in general. However, the reduction in expression of 
AXL, MERTK and TYRO3 in Merin-deficient meningioma primary cells upon Merlin 
re-introduction (Figure-3.5), suggest that Merlin may directly or indirectly regulate the 
expression of this family of receptors in Merlin-deficient tumours. Similarly, Merlin re-
introduction also reduced the expression of AXL, TYRO3 and Gas6 in schwannoma 
primary cells but not of MERTK (Ammoun et al., 2014). In contrast, I found the 
expression of MERTK but not Gas6 is under negative regulation of Merlin in meningioma 
cells. 
In summary, this is the first study reporting the levels of all three members of TAM 
receptors, their ligand Gas6, and the potential link to Merlin in meningiomas. Although 
much more future work is needed to understand the factors/mechanisms behind the 
overexpression and activation of TAM family receptors in this group of tumours, this data 
shows that TAMs are highly expressed and activated, and their expression at least 
partially is regulated by Merlin in meningioma, just as in schwannomas. Because this 
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family of receptors are also overexpressed in variety of other NF2-mutated tumours as 
described before (Pinato et al., 2013, Pierce and Keating, 2014, Schlegel et al., 2013, 
Holland et al., 2010, Schmitz et al., 2016, Wu et al., 2004, Jung et al., 2016), it is likely 
that TAM overexpression in these tumours may also be linked directly to Merlin loss. 
 
Figure 3. 6- Overexpression of TAM receptors and Gas6 in Merlin-deficient meningiomas. 
AXL, TYRO3, MERTK and Gas6 are highly expressed and activated in Merlin-deficient 
meningioma cells and tissues. Merlin (directly or indirectly) regulates the expression of AXL, 
MERTK and TYRO3 but not of Gas6. Highly expressed Gas6 is released by meningioma tumour 
cells or from the tumour microenvironment which can potentially activate TAM family receptors 
in an autocrine or in a paracrine manner. 
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3a.2 Interaction among TAM family receptors 
Introduction  
RTKs are a class of cell-surface receptors that transduce signal across cell-membrane and 
are essential for normal cellular processes. Nevertheless, aberrant regulation of RTKs is 
the cause of many pathological conditions including cancer. When overexpressed, RTKs 
can form homo or hetero-dimers in a ligand-dependent or in an independent manner. Such 
hetero-dimeric interactions among RTKs may influence the down-stream signaling of a 
target molecule by modifying the kinetic properties of enzymes, altering the specificity 
of a protein for its substrate or by creating a new binding site for small effector molecule 
and/or by directly inactivating/suppressing the target proteins. All these alterations may 
have a direct impact on the success of a targeted drug therapy (Rao et al., 2014).  
Depending on the expression levels and membrane localization, TAM receptors have 
been shown to dimerize with non-TAM receptors. For example, AXL has been shown to 
physically interact with ErbB family members such as EGFR, HER2 and HER3 in several 
cancers including breast cancer, ovarian cancer, squamous cell-carcinoma and 
glioblastoma multiforme (Scaltriti et al., 2016, Vouri et al., 2016). Additionally, AXL is 
also reported to form a complex with other RTKs such as MET and PDGFR (Meyer et 
al., 2013). Through these physical interactions, AXL can amplify the down-stream 
signaling of its target protein or activate an alternate pathway to sustain tumour growth 
even in the presence of other tyrosine kinase inhibitors and thus may result in resistance 
to targeted drug therapy. Identifying protein-protein interaction and cross-talk among 
RTKs can therefore help deciding the suitable drug target or successfully predicting a 
combination drug therapy for patients. 
Although physical complex among TAM family receptors has long been assumed, 
evidences showing such interaction among TAMs are lacking in cancer. AXL and 
- 96 - 
 
TYRO3 were found in complex in a human gonadotropin releasing hormone (GnRH) 
neuronal cell-line and have been shown to be important for promoting survival of 
neuronal cells (Pierce et al., 2008). Moreover, two separate studies reported that Gas6-
mediated phosphorylation/activation of a TAM receptor requires the presence of one or 
both of the other TAM family members and that the surface expression of AXL is 
dramatically reduced in TYRO3 or MERTK knock-out platelet cells (Angelillo-Scherrer 
et al., 2005, Seitz et al., 2007). These evidences hint at the collaborative nature of TAM 
family receptors which appear to perform their actions as a team rather than working 
strictly individually. 
As all three members of the TAM family and their ligand Gas6 are overexpressed in 
meningiomas and in schwannomas, I decided to investigate whether collaborative cross-
talk among TAM family members exist in these tumours. This section explores the 
possibility of physical or functional dependency of TAMs on one another. 
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3a.2.1 MERTK forms a complex with TYRO3 in schwannoma and meningioma 
tissues 
To investigate, whether there is physical interaction among TAM family receptors in 
Merlin-deficient tumours, I performed co-immunoprecipitation (CO-IP) experiments on 
Merlin-deficient schwannoma and meningioma tissue lysates as well as on the 
meningioma cell-line, Ben-Men-I. CO-IP experiments revealed the physical interaction 
between TYRO3 and MERTK (Figure-3.7 A) but not between AXL and MERTK (Figure 
3.7 B) or AXL and TYRO3 (Figure 3.7 C) in schwannoma tissues  
 
Figure 3. 7– Physical interaction among TAM receptors in schwannomas. Western blot 
analysis of immunoprecipitated schwannoma tumour lysates shows physical interaction between 
A) MERTK (upper) and TYRO3 (lower) (n=6); but not between B) AXL (upper) and MERTK 
(lower) (n=7) or C) AXL (upper) and TYRO3 (lower) (n=5).  
 
 
TYRO3-MERTK complex was also confirmed in G-I, Merlin-deficient meningioma 
tissues (Figure-3.8 A) but not in Ben-Men-I cell-line (Figure-3.8 a), despite successful 
pull-down of the proteins. In addition, AXL and MERTK, as well as AXL and TYRO3, 
were also not in complex in either meningioma tissue lysates (Figure-3.8 B and Figure-
3.8 C) or in meningioma cell-line Ben-Men-I (Figure-3.8 b and Figure-3.8 c). 
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Figure 3. 8- Physical interaction among TAM receptors in meningiomas. Western blot 
analysis of immunoprecipitated Merlin-negative meningioma tumour lysates showed physical 
interaction between A) TYRO3 and MERTK but not between B) AXL-MERTK and C) AXL-
TYRO3. No physical interaction between a) MERTK-TYRO3, b) AXL-MERTK or c) AXL-
TYRO3 was observed in Ben-Men-I cell-line (n=3). 
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3a.2.2 Crosstalk among TAM family receptors 
After confirming the physical interaction between TYRO3 and MERTK, I decided to 
further investigate the functional interaction among TAM family receptors. Since reports 
suggest that TAM receptors work in co-operation and require the presence of one or both 
of its TAM family members to function (Angelillo-Scherrer et al., 2005, Seitz et al., 
2007), I checked whether the absence of one TAM receptor affects the expression of other 
TAMs in schwannoma and meningioma primary cells. To do so, I used home-made or 
commercially available lentivirus particles to knock-down the expression of a specific 
TAM receptor in primary cultured schwannoma and meningioma cells and analyzed the 
effect of knock-down on other TAM family members using a Western blot.  
3a.2.2.1 MERTK knock-down decreases the expression of AXL and TYRO3 
in schwannoma and meningioma primary cells 
Using home-made lentivirus particles with two different MERTK shRNA constructs 
(Dharmacon, Inc), I successfully knocked-down the expression of MERTK protein 
compared to control scrambled (scr) shRNA in primary schwannoma cells (Figure-3.9 A 
and B). Interestingly, MERTK knock-down also significantly reduced the expression of 
AXL and TYRO3 in the same samples (Figure-3.9 A and Figure-3.9 B). 
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Figure 3. 9– MERTK Knock-down significantly decreases the expression of AXL and 
TYRO3 in schwannoma primary cells. Western blot analysis of schwannoma primary cells 
infected with scramble shRNA (scr- negative control) and MERTK shRNA (construct 62 and 65). 
A) Representative immunoblot shows the expression of MERTK (top panel), AXL (second panel) 
and TYRO3 (third panel) upon MERTK knock-down. GAPDH was used as a loading control; B) 
Scatter plot shows the relative expression of MERTK (n=7), AXL (n=4) and TYRO3 (n=3 or 4) 
in MERTK shRNA cells (construct 62 and 65) compared to scr shRNA. Data were normalized to 
scr and each dot in scatter graph represents an individual patient’s knock-down data. Statistical 
calculations were performed with GraphPad Prism software using ANOVA with Dunnett’s 
multiple comparison test. ***p<0.001. 
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To check whether this is the case also in meningiomas, I infected four different 
meningioma primary cells to knock-down MERTK expression. I used ready-made- 
lentiviral particles with two different MERTK shRNA (Dharmacon, Inc) constructs for 
the experiment due to time constraints to produce more home-made viruses. 
Unfortunately, out of four only two meningioma primary cells survived puromycin 
selection. Western blot analysis of two successfully infected meningioma samples 
revealed effective knock-down in MERTK expression with only one shRNA construct 
(Figure-3.10). Interestingly, prominent decrease in the expression of AXL and partial 
decrease in the expression of TYRO3 was consistent with a reduction in the expression 
of MERTK (Figure-3.10) as seen in schwannoma primary cells. Therefore, it is 
reasonable to suggest that the levels of AXL and TYRO3 in schwannoma and 
meningioma cells depend on MERTK expression. 
 
Figure 3. 10- MERTK knock-down decreases the expression of AXL and TYRO3 in 
meningioma primary cells. Western blot analysis shows a decrease in the expression of MERTK 
in two different meningioma primary cells using MERTK shRNA construct-1643 compared to 
Scr shRNA (top panel). MERTK shRNA also decreased the expression of AXL and TYRO3 
(second and third panel respectively n=2). GAPDH was used as a loading control. The statistics 
was not performed due to small sample size.   
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3a.2.2.2 TYRO3 and AXL knock-down does not affect the expression of other 
TAM members in schwannoma and meningioma primary cells 
Since MERTK and TYRO3 form a physical complex (Figure-3.7 A and Figure-3.8 A) 
and MERTK shRNA in schwannoma and meningioma cells decreased the expression of 
TYRO3 and AXL (Figure-3.9 and Figure-3.10), I decided to knock-down the expression 
of TYRO3 and of AXL to check whether this effect is reciprocal.  
Western blot analysis of schwannoma primary cells infected with two different constructs 
(438 and 476) of TYRO3 shRNA confirmed prominent decrease in the expression of 
TYRO3 but reducing TYRO3 expression did not influence the expression of either AXL 
or MERTK (Figure-3.11). 
 
Figure 3. 11- TYRO3 knock-down does not affect the expression of AXL and MERTK in 
schwannoma primary cells. Schwannoma primary cells were infected with scramble shRNA 
(scr-negative control) and TYRO3 shRNA (constructs 438 and 476) for 72 hrs or until all cells 
were GFP-positive. Cells were lysed and run on an 8% SDS-PAGE. A) Immunoblot showing the 
expression of TYRO3 (top panel), AXL (second panel) and MERTK (third panel) upon TYRO3 
KD. GAPDH was used as a loading control; B) Scatter plot shows successful knock-down of 
TYRO3 (n=7 for 438 or n=5 for 476) and unaffected expression of AXL (n=4) and MERTK (n=4) 
upon TYRO3 knock-down. Each dot in scatter graph represents the knock-down data of an 
individual patient. Data were normalized to scr. ANOVA with Dunnett’s multiple comparison 
test was performed using GraphPad Prism software. ***p<0.001.  
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Like MERTK shRNA in meningiomas, similar difficulty was faced when I tried to knock-
down TYRO3 and AXL in meningioma primary cells using two different shRNA 
constructs.  Out of four different meningioma primary cells infected with TYRO3 and 
AXL shRNA, only one (MN 085) showed successful infection and knock-down of AXL 
and two (MN 085 and MN 143) gave efficient reduction in TYRO3 expression. 
In accordance with schwannoma primary cells, both TYRO3 shRNA constructs (438 and 
476) successfully knocked down the expression of TYRO3 in two different meningioma 
primary cells but did not influence the expression of either AXL or MERTK (Figure-
3.12).  
 
Figure 3. 12- TYRO3 knock-down does not affect the expression of AXL or MERTK in 
meningioma primary cells.  Infection of TYRO3 shRNA (438 and 476) in two different 
meningioma primary cells successfully decreased the expression of TYRO3 (top panel) compared 
to scr shRNA. Reducing TYRO3 expression did not influence the expression of either AXL 
(second panel) or MERTK (third panel), (n=2). GAPDH was used as a loading control.  The 
statistics was not performed due to small sample size.   
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AXL shRNA specifically reduced the expression of AXL in meningioma primary cell 
without affecting total TYRO3 or MERTK expression levels (Figure-3.13). This was in 
accordance with AXL shRNA data from schwannoma primary cells (Ammoun et al., 
2014).  
 
Figure 3. 13- AXL knock-down does not affect the expression of TYRO3 or MERTK in 
meningioma primary cells.  Western blot of meningioma primary cells infected with scr and 
AXL shRNA (construct 030, n=1). AXL knock-down reduces the expression of AXL (top panel) 
but does not affect the expression of TYRO3 (second panel) and MERTK (third panel). GAPDH 
was used as a loading control.   
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3a.2.3 Discussion 
Crosstalk among cell-surface receptors and their role in modulating extra-cellular stimuli 
to co-ordinate intrinsic cell response has been well documented in both physiological and 
pathological conditions. TAMs can communicate directly or indirectly with neighboring 
receptors and can be trans-activated by an alternate receptor in a ligand-dependent or 
independent manner to favor the tumour growth and survival. TAM family receptors are 
frequently involved in causing drug resistance by compensating the oncogenic signaling 
of a targeted receptor molecule in several cancers. In fact, AXL expression has been 
suggested as a strong predictor of resistance to ErbB family inhibitors (Meyer et al., 
2013). Due to the established role of AXL in multiple drug resistance, most of the 
crosstalk studies have often centered around this TAM family member, whereas the role 
of TYRO3 and MERTK has remained widely unexplored.  
When co-expressed in GnRH neuronal cells, AXL and TYRO3 coordinate their action to 
promote neuronal cell survival, migration and proliferation by forming a physical 
complex (Pierce et al., 2008).  TYRO3 overexpression in Rat2 fibroblast cell-line resulted 
in AXL-TYRO3 dimerization and increased Gas6-mediated phosphorylation of AXL 
kinase (Brown et al., 2012). Despite of strong evidence in several systems suggesting a 
co-operative nature and an extensive crosstalk among TAM family members for normal 
physiological functions (Angelillo-Scherrer et al., 2005, Seitz et al., 2007), it is surprising 
that not many reports have paid attention at the crosstalk among TAM family members 
in cancer. 
All three TAM receptors and their ligand Gas6 are highly expressed in Merlin-deficient 
schwannomas (Ammoun et al., 2014) and meningiomas (Figure-3.1, Figure-3.2 and 
Figure-3.3). In schwannomas, Ammoun et al showed the importance of AXL in 
mediating pathological proliferation and survival of the tumour cells but also anticipated 
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the involvement of other two members of this family in carrying out this action (Ammoun 
et al., 2014). Based on the previous data from our laboratory and from others, interaction 
or cross-talks among TAM members in schwannomas and menigniomas was suspected. 
I performed co-immunoprecipitation (CO-IP) to unravel any potential physical 
interaction among TAMs in schwannomas and meningiomas. As CO-IP experiments 
require a large concentration of proteins to begin with, I chose to use a small piece of 
tumour tissue over precious primary cells which can grow only up-to limited number of 
passages. Moreover, using tumour tissue provides the advantage of studying endogenous 
protein-protein associations in their native form (Mohammed and Carroll, 2013).  
CO-IP revealed a physical interaction between TYRO3 and MERTK in schwannoma and 
meningioma tissues. This is the first time that complex between TYRO3 and MERTK 
has been reported (Figure-3.7 A and Figure-3.8 A). In contrast to Merlin-deficient 
schwannoma and meningioma tissues, Merlin-deficient Ben-Men-I cell-line did not show 
physical interaction between TYRO3 and MERTK despite successful pull-down of both 
proteins (Figure-3.8 a). These differences may attribute to the tumour micro-environment. 
Schwannoma and meningioma tumours show significant infiltration by macrophages and 
to a lesser extent by lymphocytes, particularly T cells, NK cells and rarely B cells. In fact, 
macrophage infiltration is known to be pronounced in Merlin-deficient meningiomas 
compared to Merlin-positive (Domingues et al., 2016, de Vries et al., 2013). Infiltration 
of M2-polarized macrophages have also been confirmed in this study and showed that 
MERTK but not AXL or TYRO3 are highly expressed by M2-macrophages in 
meningiomas (supplementary chapter 7.3, Figure S3). The upregulation of MERTK, but 
not of AXL or TYRO3, has also been observed previously in tissue macrophages 
compared to circulating monocytes  (Malawista et al., 2016).Therefore, it is highly likely 
that MERTK located on tissue macrophages and on tumour cells (supplementary chapter 
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7.3, Figure-S3) may physically interact with TYRO3 present mostly on tumour cells 
(supplementary chapter 7.3, Figure-S3) in schwannoma and meningioma tissues. Since 
cell-line cultures are generally devoid of immune cells such as macrophages, it may not 
necessarily always replicate the in vivo scenario. Ideally, CO-IP experiment should be 
performed on schwannoma and meningioma primary cells at lower passages which 
represent the closer view of tumour micro-environment. However, the limited availability 
of the primary cells made this difficult.  
In addition, it has been reported that the physical interaction of endogenously expressed 
TYRO3 and AXL receptors is enhanced by stimulation of cells with Gas6 in glioblastoma 
multiforme (GBM) (Vouri et al., 2016). Since Gas6 is strongly expressed in both 
schwannoma (Ammoun et al., 2014) and meningioma tissues (Figure-3.3) it can 
potentially enhance TYRO3-MERTK complex formation in tissues, therefore, to prove 
this hypothesis the CO-IP in Ben-Men-I cells would need to be repeated in the presence 
of exogenously added Gas6. 
Next, to address the functional importance of TYRO3/MERTK physical interaction in 
schwannoma and meningioma cells, firstly I knocked down the expression of MERTK 
using MERTK shRNA and found that reducing MERTK expression compromised the 
expression of TYRO3 and AXL (Figure-3.9 and Figure-3.10). To ensure MERTK shRNA 
mediated reduction in AXL and TYRO3 expression was not due to an off-target effect, 
three different MERTK shRNA constructs (TRCN0000000862, TRCN0000000865 and 
V2LHS_1643) were used. The specificity of the shRNA sequence was also confirmed by 
the providing company. Moreover, knock-down of MERTK using two of the same 
MERTK shRNA constructs, TRCN0000000862 and TRCN0000000865, by a different 
group in A549 NSCLC cells did not affect the expression of AXL (Linger R et al., 2013).  
Contrarily,  lack of MERTK receptor has been shown to reduce the expression of AXL 
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on the surface of platelets (Angelillo-Scherrer et al., 2005) and TYRO3 in ratinal pigment 
epithelium (RPE) cells (Prasad et al., 2006), suggesting that the interdependent expression 
pattern of TAM receptors could be cell-specific.  
MERTK shRNA-mediated decreases in AXL and TYRO3 levels that have been observed 
in this study could be either due to the involvement of MERTK in maintaining the stability 
of AXL and TYRO3 or due to MERTK-mediated transcriptional regulation of AXL and 
TYRO3 in schwannoma and meningioma cells.  Firstly, to investigate if MERTK is 
involved in mediating the accumulation of AXL and TYRO3 at the plasma membrane, a 
surface biotinylating assay can be performed, a simple method to quantify total amount 
of cell-surface receptors (Arancibia-Carcamo et al., 2006). To examine the role of 
MERTK in maintaining the stability of these proteins cycloheximide chase assay can be 
done on MERTK knock-out and MERTK-expressing cells. Cycloheximide chase assay 
assess protein stability by blocking protein synthesis using cycloheximide and measuring 
the changes in the level of a protein of interest at different time points (Buchanan et al., 
2016). Alternatively, the control and MERTK knock-out cells can be treated with 
proteasomal degradation inhibitor MG132 followed by Western blotting to examine 
whether MERTK inhibits proteasomal degradation of AXL and TYRO3. 
To investigate if MERTK regulates the transcription of AXL and TYRO3, qPCR would 
need to be performed on cells infected with MERTK shRNA or control shRNA. Although 
there is no direct evidence suggesting an involvement of MERTK in regulating 
transcription of AXL and TYRO3, MERTK has been shown to phosphorylate 
transcription factor, cAMP response element-binding protein (CREB) and 
phosphorylated CREB has, in turn, been shown to regulate the transcription of AXL and 
TYRO3 by binding to their promoter (Linger et al., 2013, Kokkinaki et al., 2013, Schulz 
et al., 1993). Additionally, the presence of MERTK in nucleus of leukemia cells has been 
- 109 - 
 
reported recently, further raising the possibility of an undiscovered role of MERTK as a 
transcription factor (Migdall-Wilson et al., 2012). Therefore, I would like to study the 
possibility of above mentioned both mechanisms to get further insight into phenomenon 
observed in this study. 
In contrast to MERTK knock-down, reducing TYRO3 and AXL levels did not affect 
either the expression of MERTK or of each other in both schwannoma and meningioma 
cells (Figure-3.11, Figure-3.12 and Figure-3.13). Similarly, macrophages lacking AXL 
or TYRO3 had no effect on the expression of MERTK, but instead diminished MERTK 
phosphorylation (Seitz et al., 2007). In addition, when in complex, TAM receptors have 
been shown to cross-phosphorylate each other (Brown et al., 2012). Therefore, the role 
of AXL and TYRO3 in promoting the phosphorylation of MERTK as well as cross-
phosphorylation of each other in schwannoma and meningioma cells cannot be excluded. 
Next, it will be important to check the level of pMERTK in the absence of AXL and 
TYRO3; and the level of pAXL and pTYRO3 when the cells are infected with TYRO3 
shRNA and AXL shRNA respectively (Figure-3.14 b and c).  
Although this study did not explore the above-mentioned possibilities due to time and 
technical limitations, the results emphasize the co-operative nature of TAMs in 
schwannoma and meningioma tumours and highlight the need for future work in this area 
to unravel the crosstalk among TAMs and therefore gain a better understanding of their 
role in tumour biology. 
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Figure 3. 14 Interaction and crosstalk among TAM family receptors. Results showed that 
TYRO3 and MERTK form a complex A); Knock-down of MERTK decreases the expression of 
TYRO3 and AXL a); TYRO3 knock-down did not have effect on expression of either AXL or 
MERTK b); Expression of TYRO3 and MERTK remained unaffected upon AXL knock-down 
c). Dashed lines indicate reduced expression of the protein.   




















Chapter 3b – Targeting TAM receptors in Merlin-deficient tumours 
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3b.1 The role of TAM receptors in schwannoma and meningioma 
pathophysiology 
Introduction 
By reducing AXL expression using AXL shRNA, our group has previously shown its 
positive effect on reducing schwannoma cell growth in vitro (Ammoun et al., 2014). Here 
I wanted to investigate the role of remaining two members of the TAM family in 
schwannoma tumorigenesis and all three members in meningioma tumorigenesis. To 
determine the role of MERTK, AXL and TYRO3 in schwannoma and meningioma 
pathogenesis, firstly I specifically depleted each TAM receptor using lentivirus-mediated 
knock-down and looked for changes in proliferation of cells by detecting the expression 
of cyclin-D1 compared to control cells.  
Cyclin-D1 plays a central role in the regulation of proliferation via promoting the cell-
cycle progression through the G1/S phase. Merlin has been reported to exert its anti-
proliferative effect partly by repressing cyclin-D1 and causing cell-cycle arrest. Loss of 
Merlin has been shown to be responsible for increases cyclin-D1 expression and increased 
S-phase entry in mesothelioma cells (Xiao et al., 2005). Cyclin-D1 has thought to promote 
the proliferation and differentiation of breast cancer cells by shortening the G1/S phase 
transition (Colozza et al., 2005). Overexpression of cyclin-D1 has been also linked to 
Merlin-deficient schwannomas (Colozza et al., 2005, Zhou et al., 2011). However, the 
expression of cyclin-D1 is not clear in G-I Merlin-deficient meningiomas and therefore, 
firstly I checked the expression of cyclin-D1 in Merlin-deficient G-I meningioma cells 
compared to HMCs.  
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3b.1.1 Cyclin-D1 is highly expressed in G-I Merlin-deficient meningioma primary 
cells and Ben-Men-I cell-line 
Western blot analysis revealed a prominent increase in cyclin-D1 levels in Merlin-
deficient meningioma primary cells and Ben-Men-I cells compared to Merlin-positive 
HMC cells (Figure-3.15).  
 
Figure 3. 15- Expression of Cyclin-D1 in meningioma cells. Western blot analysis showed 
higher expression of cyclin-D1 in Ben-Men-I (n=3) and meningioma primary cells (n=5) 
compared to HMCs (n=3) as a control. Tubulin was used as a loading control. Bars represents the 
median value and statistical difference was calculated using Mann-Whitney test, *p<0.05 
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3b.1.2 Knock-down of MERTK and AXL but not TYRO3 decrease cyclin-D1 levels 
in schwannoma and meningioma primary cells.  
Western blot analysis showed that reducing the expression of MERTK using MERTK 
shRNA in primary schwannoma cells (Figure-3.16 A) and primary meningioma cells 
(Figure-3.16 B) led to a substantial reduction in cyclin-D1 expression.  
 
 
Figure 3. 16- Reducing MERTK expression decreases cyclin-D1 expression in schwannoma 
and meningioma primary cells. Representative Western blot showing knock-down of MERTK 
with MERTK shRNA (constructs 62, 65 and 1643) in schwannoma (n=3) A); and meningioma 
primary cells (n=2) B), resulted in decreases in cyclin-D1 levels. The successful knock-down of 
MERTK was achieved in all experiments (bottom panels). scramble (scr) was used as a negative 
control and tubulin as a loading control. Statistical significance for schwannoma primary cells 
were calculated by ANOVA with Dunnett’s multiple comparison test using GraphPad Prism 
analysis software, ***p<0.001 A); Statistical calculations were not carried out for meningioma 
primary cells due to small sample size B).  
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A successful AXL knock-down in meningioma primary cells using AXL shRNA 
(construct 030) also efficiently decreased the cyclin-D1 levels compared to control 
(Figure-3.17). This result was in accordance with AXL knock-down results in 
schwannomas although more repeats are required in meningioma cells before a firm 
conclusion can be drawn (Ammoun et al., 2014). 
 
Figure 3. 17- Reducing AXL expression decreases cyclin-D1 expression in meningioma cells. 
Western blot analysis shows that successful knock-down of AXL expression (shRNA construct 
30) in meningioma primary cells (bottom panel, n=1) led to decreased expression of cyclin-D1 
(top panel). Tubulin was used as a loading control (central panel). Statistical analysis was not 
possible due to the low sample size. 
 
 
In contrast to MERTK and AXL, TYRO3 knock-down did not affect the cyclin-D1 levels 
in either schwannoma (Figure-3.18 A) or meningioma primary cells (Figure-3.18 B).  
 
 
Figure 3. 18- Reducing TYRO3 expression did not have any effect on cyclin-D1 expression 
in schwannoma and meningioma primary cells. TYRO3 shRNA (construct 438 and 476) 
decreased TYRO3 expression in schwannoma primary cells (bottom panels, n=3 for 476 or n=4 
for 438) A) and meningioma primary cells (bottom panels, n=2) B), with no effect on the 
expression of cyclin-D1 (A and B, top panels). Tubulin was used as a loading control (A and B, 
central panels). ANOVA with Dunnett’s multiple comparison test was used to assess statistical 
significance for schwannoma primary cells, ns=non-significant (A); sample size was small to 
calculate statistical significance in meningioms (B).  
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3b.1.3 TAM inhibition by small molecule inhibitors decrease proliferation and 
survival of schwannoma and meningioma primary cells. 
Genetic knock-down of TAM receptors proposed that both MERTK and AXL are 
involved in the increased proliferation of schwannoma and meningioma primary cells via 
cyclin-D1 (Figure-3.16 and Figure-3.17), suggesting that both receptors may be potential 
therapeutic targets in these tumours. Therefore, I further tested the effect of 
MERTK/FLT3 inhibitor UNC2025, AXL specific inhibitor BGB324 and pan-TAM 
inhibitor BMS777607 on proliferation and survival of schwannoma and meningioma 
primary cells as well meningioma Ben-Men-I cell-line. 
3b.1.3.1 Cytotoxicity assay 
I performed high throughput screening (HTS) for UNC2025, BGB324 and BMS777607 
using Cyto-Tox GloTM (Promega) assay to assess the effectiveness of these compounds 
in Merlin-deficient schwannoma and meningioma primary cells as well as cell-line, Ben-
Men-I. The assay measures the number of dead cells and total cells following an exposure 
to a test compound.   
3b.1.3.1.1 UNC2025 
UNC2025 significantly inhibited schwannoma cell growth by 50% at 3.96 μM with a 
concomitant increase in number of dead cells following 72 hrs of treatment. Prolonged 
treatment of schwannoma primary cells with UNC2025 for 7 days further slightly 
decreased the number of total cells  with IC50 of 3.09 μM with no additional cytotoxicity 
(Figure-3.19 A and Figure-3.19 a). 
UNC2025 was more effective at inhibiting meningioma cell growth compared to 
schwannoma. It potently reduced Ben-Men-I and meningioma primary total cell number 
with IC50 of 1.95 μM and 1.45 μM respectively, which was almost half the concentration 
required to inhibit schwannoma cell numbers by 50% after 72 hrs. Interestingly, after 72 
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hrs, the drug did not induce cell-death in meningioma primary cells but only in Ben-Men-
I cells which showed significant increase in dead cells at 3 μM, suggesting that UNC2025 
is cytostatic to meningioma primary cells at shorter time period. UNC2025 was cytotoxic 
to both Ben-Men-I and meningioma primary cells at higher concentrations after 7 days 
and led to further decreases in total cell numbers (IC50 Ben-Men-I- 1.08 μM and IC50 
meningioma primary cells- 0.47 μM) (Figure-3.19 B and b) (Figure-3.19 C and c). 





Figure 3. 19- Characterization of sensitivity of schwannoma and meningioma cells to 
MERTK inhibitor UNC2025. The tumour cells were treated with a single dose of UNC2025 at 
the indicated concentrations for 72 hrs (black) and 7 days (red). Reduction in total cell numbers 
for schwannomas A), Ben-Men-I (BM-I) B) and meningioma primary cells C) and an increase in 
dead cell numbers for schwannomas a), BM-I b) and meningioma primary cells c); were reported 
using CytoTox-GloTM assay. Tumour cells cultured in media only were used as a negative control 
and ethanol (EtOH) used as a vehicle control. The error bar indicates the standard error of mean 
for schwannoma primary cells (n=4), BM-I cell-line (n=3) and meningioma primary cells (n=4) 
performed in triplicates. ANOVA with Dunnett’s multiple comparison test was used to calculate 
statistical significance; *p<0.05, **p<0.01 and ***p<0.001. IC50 was calculated using GraphPad 
Prism analysis software.    
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3b.1.3.1.2 BGB324  
Incubation of schwannoma primary cells with BGB324 for 72 hrs resulted in a decrease 
in total cell number from 0.3 μM with significant reduction observed at 1 μM. However, 
higher concentrations of the drug had only negligible additional effect on cell growth and 
the highest concentration of 10 μM failed to decrease total cells by 50%. A treatment of 
schwannoma primary cells for 7 days with BGB324 (IC50-14.30 μM) did not have a much 
additional effect on reducing schwannoma total cell numbers. BGB324 caused a dose-
dependent increase in cytotoxicity and led to significant schwannoma cell-death at 10 μM 
after both time points (Figure-3.20 A and Figure-3.20 a). 
The treatment of Ben-Men-I and meningioma primary cells with 0.3 μM of BGB324 
decreased cell growth only a little, while the concentrations ≥1.0 μM strongly diminished 
the number of total cells after 72 hrs. The IC50 of BGB324 for Ben-Men-I and 
meningioma primary cells were calculated to 2.35 μM and 3.70 μM respectively after 72 
hrs. BGB324 was even more effective following 7 days of treatment and reduced Ben-
Men-I and meningioma primary total cell number with an IC50 of 0.03 μM and 0.13 μM 
respectively. The concentration of 5 μM nearly completely abolished the cell growth after 
7 days of drug treatment in both cell-types. Strikingly, despite significant reduction in 
total cell number at 1 μM, neither Ben-Men-I nor meningioma primary cells showed 
increase in cell death at this concentration after 72 hrs of drug treatment. A dose-
dependent increase in cell death was observed from 3 μM which was stronger in Ben-
Men-I compared to meningioma primary cells. BGB324 was moderately cytotoxic at all 
concentration to meningioma primary cells and Ben-Men-I cells after 7 days (Figure-3.20 
B and b) (Figure-3.20 C and c).  





Figure 3. 20- Characterization of sensitivity of schwannoma and meningioma cells to AXL 
specific inhibitor BGB324. AXL inhibitor BGB324 decreased the total cell numbers of 
schwannoma primary cells A), BM-I B) and meningioma primary cells C); with concomitant 
increase in dead cells a), b) and c) shown by Cyto-Tox gloTM cytotoxicity assay. DMSO was used 
as a vehicle control and cells with media as a negative control. The tumour cells were treated with 
a single dose of BGB324 in technical triplicates for 72 hrs (black) and 7 days (red). Error bars 
indicates standard error of mean (schwannomas-72 hrs and 7 days (n=4); BM-I- 72 hrs and 7 days 
(n=3) and meningioma primary cells- 72 hrs and 7 days (n=4)). IC50 was calculated using 
GraphPad Prism analysis software. ANOVA with Dunnett’s multiple comparison was used for 
statistical evaluation; *p<0.05, **p<0.01 and ***p<0.001. 
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3b.1.3.1.3 BMS777607 
The highest concentration of BMS777607 (100 μM) was insufficient to decrease 
schwannoma total cell number by half following 72 hrs of treatment. Additional 7 days 
treatment of schwannoma primary cells with BMS777607 did not further reduce total cell 
number. The approximate IC50 of BMS777607 was calculated to be 127 μM for 
schwannoma primary cells following 7 days treatment (Figure-3.21 A and Figure-3.21 a).  
BMS777607-mediated increase in dead cells and decrease in total cell number was 
apparent only from 80 μM in Ben-Men-I (Figure-3.21 B and Figure-3.21 b) and 
meningioma cells (Figure-3.21 C and Figure-3.21 c) following 72 hrs treatment. Further, 
7 days treatment of meningioma primary cells with BMS777607 had only a slight 
additional reduction in the total cell number with IC50 of 63.85 μM. 
   





Figure 3. 21- Characterization of sensitivity of schwannoma and meningioma cells to pan-
TAM inhibitor BMS777607. Schwannoma primary cells A), a); BM-I B), b); and meningioma 
primary cells C), c) were treated with a single dose of BMS777607 for 72 hrs (black) and 7 days 
(red). The graphs represent the effect of BMS777607 on total cell number A), B), C) and dead 
cells a), b) and c) evaluated by Cyto-Tox GloTM assay compared to DMSO (vehicle control). Cells 
with media was used as a negative control. ANOVA with Dunnett’s multiple comparison test was 
used to calculate statistical significance; *p<0.05, **p<0.01 and ***p<0.001. IC50 was calculated 
using GraphPad Prism analysis software. (Schwannomas- 72 hrs and 7 days (n=3); BM-I- 72 hrs 
(n=3) and 7 days (n=1); meningioma primary cells- 72 hrs and 7 days (n=3)). 
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3b.1.3.2 Ki67 and Caspase-3 staining 
Ki67 is a nuclear protein that is present in all proliferating cells but is absent from 
quiescent or resting cells, making it a good marker of cell proliferation (Jurikova et al., 
2016). The active form of caspase-3, cleaved caspase-3, is associated with initiation of a 
programmed cell death cascade and has been used as an apoptosis marker. The evaluation 
of cleaved caspase-3 levels is used to determine the cytotoxic effectiveness and strength 
of therapeutic agents (Jelinek et al., 2015). 
To support the results of cyclin-D1 achieved following shRNA knock-down of TAM 
receptors and the results of cytotoxicity assay obtained after treatment with TAM kinase 
inhibitors, I performed Ki67 and cleaved caspase-3 staining to assess the proliferative and 
apoptotic status of schwannoma and meningioma primary cells before and after treatment 
with anti-TAM drugs.   
3b.1.3.2.1 UNC2025 
Schwannoma primary cells treated with various concentration of UNC2025 for 72 hrs led 
to a dose-dependent decrease in proliferation, as reflected from decline in Ki67-positive 
(red) (IC50-0.17 μM) cells as well as an increase in apoptosis as demonstrated by increase 
in cleaved caspsase-3-positive (green) cells at higher concentrations of the drug (Figure-
3.22). 
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Figure 3. 22- UNC2025 decreases proliferation and induces apoptosis of schwannoma 
primary cells. Schwannoma primary cells were treated with EtOH (vehicle control) or indicated 
concentrations of UNC2025 (0.03-6.0 μM) for 72 hrs. Following that cells were fixed and stained 
with primary antibodies Ki67 (red) and cleaved caspase-3 (green). The percentage of proliferating 
and apoptotic cells were calculated by dividing Ki67 and cleaved caspase-3 positive cells to total 
number of cells (DAPI-blue). Graphs represent mean ± standard error of mean of three individual 
experiments (n=3). Statistical significance was calculated using ANOVA with Dunnett’s multiple 




A dose-dependent decrease in proliferation was also observed in meningioma primary 
cells after treatment of the cells with UNC2025, again measured by Ki67 (IC50-0.19 μM) 
as well as by cyclin-D1 (IC50-0.31 μM) detected by Western blotting after 72 hrs. 
UNC2025 induced apoptosis demonstrated by increased cleaved caspase-3 positive cells 
compared to vehicle (EtOH). However, this increase was non-significant (Figure-3.23 A 
and Figure-3.23 B). 




Figure 3. 23- UNC2025 decreases proliferation and induces apoptosis of meningioma 
primary cells. Meningioma primary cells were treated with EtOH (vehicle control) or indicated 
concentrations of UNC2025 (0.03-3.0 μM) for 72 hrs. Following that cells were fixed and stained 
with primary antibodies Ki67 (red) and cleaved caspase-3 (green). Immunofluorescence staining 
shows a dose-dependent decrease in proliferating cells by Ki67 staining (red) and increase in 
apoptotic cells by cleaved caspase-3 staining (green) after 72 hrs incubation of meningioma 
primary cells with UNC2025 (n=3). DAPI (blue) was used as a nuclear stain A); Western blot 
analysis further confirmed a significant decrease in expression of cyclin-D1 levels compared to 
EtOH (vehicle control) and media (negative control)  (n=3). Tubulin was used as a loading control 
B). Graphs represent mean ± standard error of mean. IC50 and statistical calculations were 
performed by GraphPad Prism analysis software. ANOVA with Dunnett’s multiple comparison 
test; *p<0.05 and ***p<0.001. 
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3b.1.3.2.2 BGB324 
BGB324 significantly inhibited fast dividing Ki67-positive schwannoma primary cells 
with an IC50 of 0.48 μM and showed dose-dependent increase in cleaved caspase-3 
positive apoptotic cells following 72 hrs of drug treatment (Figure-3.24).  
 
Figure 3. 24- BGB324 decreases proliferation and increases apoptosis of schwannoma 
primary cells. Ki67 (red) is significantly reduced and cleaved caspase-3 (green) is increased in a 
dose-dependent manner compared to DMSO (vehicle control) and cells containing only media 
(negative control) upon treatment of schwannoma primary cells with BGB324 (0.3-10.0 μM) for 
72 hrs. DAPI (blue) was used as a nuclear stain. Graphs represent mean ± standard error of mean 
of three individual experiments (n=3). IC50 and statistical calculations were performed using 
GraphPad Prism analysis software, ANOVA with Dunnett’s multiple comparison test *p<0.05 
and **p<0.01.  
 
BGB324 also successfully inhibited proliferation of meningioma primary cells by 
inducing cytotoxicity as seen from dose-dependent decreases in Ki67 staining (IC50-0.42 
μM) and cyclin-D1 (IC50-1.41 μM) and increase in apoptotic cells as measured by cleaved 
caspase-3 positive cells after 72 hrs treatment (Figure-3.25 A and Figure-3.25 B).  
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Figure 3. 25- BGB324 decreases proliferation and induces apoptosis of meningioma primary 
cells. Meningioma primary cells treated with AXL inhibitor BGB324 with indicated 
concentrations (0.3-5.0 μM) or DMSO (vehicle) showed concentration-dependent decrease in 
proliferation of cells assessed by Ki67 (red) and increase in apoptotic cells measured by cleaved 
caspase-3 (green). DAPI was used as a nuclear stain (n=3) A); Reduction in proliferation was also 
confirmed using Western blot by measuring cyclin-D1 levels compared to vehicle and media 
(n=4). Tubulin was used as a loading control B). Graphs represent mean ± standard error of mean. 
Calculations for IC50 and statistical significance were carried out using GraphPad Prism analysis 
software. ANOVA with Dunnett’s multiple comparison test *p<0.05, **p<0.01 and ***p<0.001.  
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3b.1.3.2.3 BMS777607 
Treatment of schwannoma primary cells with pan-TAM inhibitor BMS777607 for 72 hrs 
significantly decreased the number of Ki67-positive cells with an IC50 of 10.62 μM and 
increased Cleaved caspase-3 positive cells from 40 μM (Figure-3.26)  
 
Figure 3. 26- BMS777607 decreases proliferation and increases apoptosis of schwannoma 
primary cells. Incubation of schwannoma primary cells with BMS777607 (5.0-100.0 μM) for 72 
hrs led to a significant decrease in Ki67 positive (red) cells and an increase in cleaved caspase-3 
positive (green) cells in a dose-dependent manner. DMSO was used as a vehicle control and cells 
with media only as a negative control. DAPI (blue) was used as a nuclear stain. Graphs represent 
mean ± standard error of mean of three individual experiments (n=3). Calculations for IC50 and 
statistical significance were carried out using GraphPad Prism analysis software. ANOVA with 
Dunnett’s multiple comparison test *p<0.05, **p<0.01 and ***p<0.001.  
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The treatment of meningioma primary cells with BMS777607 caused dose dependent 
decrease in Ki67-positive cells with a concomitant increase in cleaved caspase-3 positive 
apoptotic cells from 40 μM (Figure-3.29 A). In aggrement with this, Western blot analysis 
showed a significant decrease in Cyclin-D1 expression from 40 μM with an IC50 of 78.73 
μM (Figure-3.27 B). 
 
 
Figure 3. 27- BMS777607 decreases proliferation and increases apoptosis of meningioma 
primary cells. Incubation of meningioma primary cells with various concentrations of 
BMS777607 (5.0 μM – 100 μM) reduced the numbers of Ki67-positive cells (red) and increased 
the numbers of apoptotic cells (cleaved caspase-3, green) in a concentration-dependent manner. 
DMSO was used as a vehicle. Meningioma primary cells with complete growth factor media was 
used as a negative control. DAPI (blue) was used as a nuclear stain (n=1) A); A representative 
Western blot shows that BMS77607 also decreased the expression of cyclin-D1 in a 
concentration-dependent manner. Tubulin was used as a negative control. Graphs represent mean 
± standard error of mean of three individual experiments (n=3) B). ANOVA with Dunnett’s 
multiple comparison test was used to calculate the statistical significance. **p<0.01.   
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3b.1.4 Comparative efficacy of TAM inhibitors for inhibition of TAM receptors in 
schwannoma and meningioma primary cells. 
UNC2025, BGB324 and BMS777607 can dephosphorylate their respective kinases and 
inhibit downstream signaling pathways in vitro, showing effects from within a few 
minutes to up an hour (Zhang et al., 2014, Oien et al., 2017). Therefore, most published 
studies have reported the effect of these inhibitors against their respective kinases only at 
a shorter time period while their long-term effects on related kinases or on total protein 
levels remain unrecorded. 
Schwannomas and meningiomas are mostly benign tumours and patients may need to be 
treated for a prolonged period of time, sometimes for years. Therefore, a better 
understanding of kinase inhibitor’s long-term effects on other related kinases or on the 
total protein levels in vitro may possibly help in preventing compensatory activation of 
alternate signaling pathways or inhibitor-mediated unwanted effects. TAM receptors 
share a high structural homology and demonstrate an extensive cross-talk in both 
schwannomas and meningiomas, therefore I compared the efficacy of TAM inhibitors for 
inhibition of all three TAM receptors.  
I treated meningioma primary cells with different concentrations of MERTK inhibitor 
UNC2025, AXL inhibitor BGB324 and pan-TAM inhibitor BMS777607 for two time 
points; 1 hr (shorter) and 72 hrs (longer). The limited availability of primary schwannoma 
cell material meant that I was restricted to just one timepoint of one-hour as this timepoint 
is well documented in literature. 
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3b.1.4.1 UNC2025 inhibits MERTK activity in schwannoma and meningioma 
primary cells 
Incubation of schwannoma primary cells with UNC2025 for one-hour led to successful 
inhibition of MERTK phosphorylation from 3 μM with IC50 of 3.19 μM (Figure-3.28 A). 
Interestingly, UNC2025 also inhibited the phosphorylation of AXL with similar potency 
as of MERTK with IC50 of 3.96 μM (Figure-3.28 B) but had no effect on the 
phosphorylation of TYRO3 (Figure-3.28 C). In addition, the total levels of MERTK, AXL 
and TYRO3 also remain unaffected by UNC2025 after one-hour of treatment (Figure-
3.28 A, Figure-3.28 B and Figure-3.28 C).  
  






Figure 3. 28- Comparative efficacy of UNC2025 for inhibition of TAM receptors in 
schwannoma primary cells. Western blot of phosphorylated and total MERTK A), AXL B) and 
TYRO3 C) in schwannoma primary cells following one-hour UNC2025 treatment with indicated 
(1.0-6.0 μM) concentrations.  EtOH was used as a vehicle control and cells with media as a 
negative control. GAPDH was used as a loading control. Densitometry of Western blot of 
pMERTK/MERTK and MERTK/GAPDH (n=4); pAXL/AXL and AXL/GAPDH (n=3); 
pTYRO3/TYRO3 and TYRO3/GAPDH (n=3), graphs represent mean ±standard error of mean 
of individual schwannoma primary cells. ANOVA with Dunnett’s multiple comparison test was 
performed to calculate statistical significance *p<0.05 and **p<0.01. IC50 was calculated using 
Graphpad Prism analysis software. 
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UNC2025 successfully inhibited the phosphorylation of MERTK with IC50 of 0.93 μM 
but did not affect the expression following one-hour of treatment in meningioma primary 
cells. Further incubation of meningioma primary cells with UNC2025 for 72 hrs led to 
prominent decrease in the levels of phospho-MERTK (IC50-2.81) as well as total 
MERTK; however, there was no statistically significant difference in the ratio of 
phosphorylated MERTK vs total MERTK (Figure-3.29 A). There was no significant 
difference in phospho-AXL or total AXL expression levels compared to control following 
one-hour of UNC2025 treatment. However, a significant increase in relative 
phosphorylation of AXL was observed following 72 hrs of treatment (Figure-3.29 B). No 
remarkable changes in the phosphorylation and expression of total TYRO3 observed at 














   
Figure 3. 29- Comparative efficacy of UNC2025 for inhibition of TAM receptors in 
meningioma primary cells. Western blot of phosphorylated and total MERTK A), AXL B) and 
TYRO3 C) in meningioma primary cells following 1 hr and 72 hrs treatments of UNC2025 with 
indicated concentrations (0.03- 3.0 μM). EtOH was used as vehicle control and cells with media 
as a negative control. GAPDH was used as a loading control. Densitometry of Western blot of 
pMERTK/MERTK and MERTK/GAPDH (1hr and 72 hrs- n=3); pAXL/AXL and AXL/GAPDH 
(1 hr and 72 hrs-n=3); pTYRO3/TYRO3 and TYRO3/GAPDH (1 hr and 72 hrs-n=3), graphs 
represent mean ±standard error of mean of individual meningioma primary cells. ANOVA with 
Dunnett’s multiple comparison test was performed to calculate statistical significance *p<0.05 
and **p<0.01. IC50 was calculated using Graphpad Prism analysis software. 
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3b.1.4.2 BGB324 inhibits AXL activity in meningioma primary cells 
Unlike UNC2025 in schwannomas (Figure-3.28), one-hour treatment of BGB324 was not 
enough to inhibit the activation of AXL and even up to 40 μM concentration of the kinase 
inhibitor failed to successfully inhibit phospho-AXL (Figure-3.30 A). In addition, 
BGB324 did not have any effect on either phospho-MERTK (Figure-3.30 B) or phospho-
TYRO3 (Figure-3.30 C) at this time point. Since 72 hrs treatment of schwannoma primary 
cells with BGB324 significantly reduced the total cell numbers (Figure-3.20 A) and 
decreased the proliferation by inducing apoptosis (Figure-3.24), the inhibitory effect of 
BGB324 was checked on phosphorylation of AXL at this time-point. Western blot 
analysis showed that while BGB324 failed to decrease levels of phospho-AXL at one-
hour, it remarkably inhibited phosphorylation of AXL at 72 hrs (Supplementary figure 
S2-top panel).  
  





Figure 3. 30C- Comparative efficacy of BGB324 for inhibition of TAM receptors in 
schwannoma primary cells. AXL inhibitor BGB324 (5.0-40.0 μM) did not inhibit the 
activity/phosphorylation of AXL A), TYRO3 B), or MERTK C) following one-hour treatment of 
schwannoma primary cells. DMSO was used as a vehicle control and cells with media as a 
negative control. GAPDH was used as a loading control. Graphs represent mean ± standard error 
of mean of three individual schwannoma primary cells (n=3). ANOVA with Dunnett’s multiple 
comparison test was performed to calculate statistical significance difference (See supplementary 
figure S2 for BGB324 mediated inhibition of pAXL at 72 hrs). 
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One-hour treatment of meningioma primary cells with BGB324 proficiently decreased 
the levels of phosphorylated AXL with an IC50 of 2.98 μM but did not affect the 
expression of total AXL. Further 72 hrs treatment of the cells with BGB324 led to dose-
dependent decrease in the expression of both total-AXL (IC50-0.28) and phospho-AXL 
but the ratio of phospho/total AXL remain unchanged (Figure-3.31 A). No changes were 
observed in the levels of either phosphorylated or total MERTK and TYRO3 following 
one-hour of BGB324 treatment. Moreover, there was no difference in the ratio of 
phosphorylated vs total MERTK and TYRO3 following 72 hrs of treatment but BGB324 
prominently decreased the expression of both total MERTK (IC50 – 1.04) and TYRO3 
(IC50 – 0.43) following 72 hrs of BGB324 treatment (Figure-3.31 B and Figure-3.31 C).    
  





Figure 3. 31- Comparative efficacy of BGB324 for inhibition of TAM receptors in 
meningioma primary cells. Representative Western blot of phosphorylated and total AXL A), 
MERTK B) and TYRO3 C) in meningioma primary cells following 1 hr and 72 hrs treatments of 
BGB324 (0.3-5.0 μM). DMSO was used as a vehicle control. Media with cells was used as a 
negative control. Densitometry of Western blot of pAXL/AXL and AXL/GAPDH (1hr and 72 
hrs- n=3); pMERTK/MERTK and MERTK/GAPDH (1 hr and 72 hrs- n=3); pTYRO3/TYRO3 
and TYRO3/GAPDH (1hr and 72 hrs- n=3), graphs represent mean ± standard error of mean of 
individual meningioma primary cells. ANOVA with Dunnett’s multiple comparison test was 
performed to calculate statistical significance *p<0.05, **p<0.01 and ***p<0.001. IC50 was 
calculated using Graphpad Prism analysis software. 
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3b.1.4.3 BMS777607 inhibits AXL activity in schwannoma and meningioma 
primary cells.   
BMS777607 treatment of schwannoma primary cells for one-hour reduced relative 
phosphorylation of AXL by 50% at 0.84 μM and nearly abolished activity of the receptor 
at 10 μM without affecting its expression level (Figure-3.32 A). There was no difference 
in the ratio of phosphorylated MERTK to total MERTK or phosphorylated TYRO3 to 
total TYRO3 between BMS777607 treated and vehicle (DMSO) treated or media only 
schwannoma cells, but the expression of total MERTK and TYRO3 were decreased in 
dose-dependent manner (Figure-3.32 B and Figure-3.32 C).  
  





Figure 3. 32- Comparative efficacy of BMS777607 for inhibition of TAM receptors in 
schwannoma primary cells. Schwannoma primary cells were incubated with BMS777607 (10.0-
100.0 μM) or DMSO (vehicle) for 1 hr before cells were lysed and lysates were run on. 8% SDS-
PAGE. Membranes were probed with phospho and total AXL A); MERTK B), and TYRO3 C) 
antibodies. GAPDH was used as a loading control. Densitometry of Western blot of phospho/total 
AXL and AXL/GAPDH (n=3); phospho/total MERTK and MERTK/GAPDH (n=2); 
phospho/total TYRO3 and TYRO3/GAPDH (n=1), graphs represent mean ± standard error of 
mean of individual schwannoma primary cells. IC50 and statistical calculations were carried out 
using GraphPad Prism analysis software. ANOVA with Dunnett’s multiple comparison test was 
used to determine statistical significance, ***p<0.001.  
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Meningioma primary cells treated with BMS777607 demonstrated a strong inhibition in 
the levels of phosphorylated AXL at very low concentrations with IC50 of 0.09 μM after 
one-hour of treatment. Surprisingly, the level of phospho-AXL raised back to basal 
following 72 hrs of BMS777607 treatment which again started dropping from 40 μM, 
increasing the IC50 value from 0.09 μM to 23.78 μM. BMS777607 did not affect the 
expression of total AXL at either time points (Figure-3.33 A). There were no apparent 
change in relative phosphorylation and expression of MERTK at either time-points of 
BMS777607 treatment (Figure-3.33 B). Moreover, BMS777607 did not affect the relative 
phosphorylation of TYRO3 following one-hour of treatment but decrease in phospho 
TYRO3/TYRO3 was apparent following 72 hrs of treatment (and Figure-3.33 C). More 
experiments would need to be performed for TYRO3 and MERTK at both time-points to 
conclude as to whether these changes are significant. 
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Figure 3. 33- Comparative efficacy of BMS777607 for inhibition of TAM receptors in 
meningioma primary cells. Western blot of phosphorylated and total levels of AXL A); MERTK 
B); and TYRO3 C) in meningioma primary cells, treated with BMS777607 (5.0-100.0 μM) at 
two different time points; 1 hr (black bars) and 72 hrs (green bars). GAPDH was used as a loading 
control and cells with media only as a negative control. Densitometry of Western blot of 
phospho/total AXL (1hr- n=3, 72 hrs- n=2); phospho/total MERTK (1hr- n=1, 72 hrs- n=2); 
phospho/total TYRO3 (1hr- n=1, 72hrs- n=2), graphs represent mean ± standard error of mean of 
individual meningioma primary cells. ANOVA with Dunnett’s multiple comparison test was used 
to calculate statistical significance, ***p<0.001.  
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3b.1.5 Discussion 
Increased expression and activation of TAM receptors has been linked to increase cell 
growth and resistance to apoptosis in several cancers (Linger et al., 2008) which are also 
the key features of both schwannomas and meningiomas. TAM receptors are highly 
expressed and activated in these Merlin-deficient tumours; and in schwannomas, Gas6-
mediated activation of AXL has been shown to be responsible for pathological 
proliferation and survival of the tumour cells (Ammoun et al., 2014). Here I further 
investigated the role of TAM family receptors in the pathogenesis of schwannomas and 
meningiomas by using shRNA-mediated gene knock-down and TAM kinase inhibitors.   
MERTK inhibitor UNC2025, AXL inhibitor BGB324 and pan-TAM inhibitor 
BMS777607 have already proved their antitumorigenic potency in clinical or pre-clinical 
trials for other cancers (Zhang et al., 2014, Holland et al., 2010, Roohullah et al., 2018). 
I tested the effectiveness of UNC2025, BGB324 and BMS777607 in regulating 
schwannoma and meningioma cell growth in vitro firstly by using CytoTox-GloTM 
cytotoxicity assay. As described before, CytoTox-GloTM counts dead cells and total cell 
numbers in culture media by measuring the proteases released from membrane 
compromised cells. In addition, live cells can be calculated by subtracting dead cells from 
total cell numbers and hence allowing an opportunity to measure live cells and dead cells 
in the same well. The data from the experiment therefore provides the valuable 
information on if the test compound has an effect on cell growth/proliferation or induce 
direct cytotoxic effect that leads eventually to cell death (Niles et al., 2009).  
UNC2025 (IC50 3.96 μM- 72 hrs and IC50 3.09 μM- 7 days for schwannoma; IC50 1.45 
μM- 72 hrs and IC50 0.47 μM- 7 days for meningioma) and BGB324 (IC50 14.30 μM- 7 
days for schwannoma and IC50 3.70 μM- 72 hrs and 0.13 μM- 7 days for meningioma) 
both successfully inhibited their respective kinase and reduced the total cell number of 
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schwannoma and meningioma cells in culture (Figure-3.19 A and C and Figure-3.20 A 
and C, Figure-3.28, Figure-3.29, Figure-S2 and Figure-3.31). However, BGB324 was 
more effective in reducing meningioma cell numbers as compared to schwannoma cells, 
whereas UNC2025 effectively inhibited the oncogenic growth of both schwannoma and 
meningioma cells in vitro (see table-3.1 for IC50 comparison). Of note, in contrast to 
schwannoma, meningioma cells demonstrated that the inhibitory effect of UNC2025 and 
BGB324 was more cytostatic rather than cytotoxic at shorter time point (72 hrs) and 
significant increases in dead cells were observed only after prolonged treatment of 
meningioma cells for 7 days (Figure-3.19 a and c; Figure-3.20 a and c). BMS777607 (IC50 
127 μM – 7 days for schwannoma and IC50 63.85 μM – 7 days for meningioma) was the 
least effective kinase inhibitor out of all three tested inhibitors in both schwannoma and 
meningioma cells (Figure-3.21).  
While the cytotoxicity assay gives a general overview on the effect of the test molecule 
on cell proliferation and survival in a quick and reliable manner, it is not a standard 
technique to measure the cell proliferation. Therefore, I further assessed the effect of 
UNC2025, BGB324 and BMS777607 on proliferation of schwannoma and meningioma 
cells by performing Ki67 staining. Indeed, UNC2025 (IC50-0.17 μM for schwannoma and 
IC50-0.19 μM for meningioma) and BGB324 (IC50-0.48 μM for schwannoma and IC50 
0.43 μM for meningioma) successfully inhibited fast dividing Ki67 positive cells 
following 72 hrs treatment (Figure-3.22, Figure-3.23, Figure-3.24 and Figure-3.25). 
However, BMS777607 required ~62-fold higher concentration than UNC2025 and ~22-
fold higher concentration than BGB324 to inhibit proliferating schwannoma cell by 50% 
(Figure-3.26) (see table-3.1 for IC50).  
One mechanism by which tumour cells sustain continuous proliferation is by altering the 
expression and/or activity of cell cycle-related proteins such as cyclin-D1. Cyclin-D1 is 
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an important regulator of cell-cycle progression through G1 to S phase. In normal 
conditions, its level is regulated by ubiquitin-dependent proteasomal degradation. 
Inefficient degradation or genetic upregulation leads to overexpression of cyclin-D1 in 
several cancers including breast, esophagus, bladder and lung cancer. In breast cancer, 
overexpression of cyclin-D1 has also linked to development of resistance to endocrine 
therapy targeting estrogen receptor (ER) (Alao, 2007).  
Aberrant expression of cyclin-D1 has also been reported in schwannoma primary cells 
compared to normal Schwann cells (Zhou et al., 2011) which can be reversed by 
knocking-down the expression of AXL (Ammoun et al., 2014).  Here, I again 
demonstrated increased level of cyclin-D1 in meningioma cells compared to normal 
human meningeal cells (Figure-3.15). In addition, reducing MERTK and AXL expression 
(Figure-3.16 and Figure-3.17) but not TYRO3 expression (Figure-3.18) using shRNA led 
to a significant decrease in cyclin-D1 levels in both schwannoma and meningioma cells. 
Knock-down results were further supported by MERTK inhibitor UNC2025 (IC50-0.31 
μM) and AXL inhibitor BGB324 (IC50-1.41 μM) in meningioma, both of which showed 
a successful reduction in cyclin-D1 levels (Figure-3.23 B and Figure-3.25 B). Consistent 
with cytotoxicity assay data, the pan-TAM inhibitor- BMS777607 (IC50-78.73 μM) was 
the least effective in decreasing cyclin-D1 levels (Figure-3.27 B).  
While BMS777607 inhibited the kinase activity of AXL by 50% in both tumour cell-
types with minimal concentrations of 0.84 μM or below after one-hour, it had a negligible 
effect on TYRO3 and MERTK kinase activity even at 100 μM (Figure-3.32 and Figure-
3.33). Importantly, reduced phospho-AXL levels following one-hour incubation of 
meningioma cells with BMS777607 returned to basal levels or even increased at lower 
concentration (5.0 µM) following 72 hrs treatment and with the IC50 of BMS777607 for 
AXL inhibition increased to 23.78 μM (Figure-3.33 A). This could potentially be due to 
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acquired resistance to the drug, possiebly by feedback activation of an alternative receptor 
or signaling pathway. Similar results have been reported recently whereupon 
BMS777607-mediated inhibition of pMET following 24 hours treatment of triple-
negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) cells led, in turn, 
to increase in pAXL levels with concomitant increase in total AXL, TYRO3, MERTK 
and Gas6 expression (Baumann et al., 2017).  
Furthermore, in breast cancer cells, BMS777607 has been shown to increase the 
resistance to cytotoxic agents including doxorubicin, bleomycin, paclitaxel, and 
methotrexate by inducing a polyploidy. Polyploidy is the presence of more than two 
copies of a single gene that has been linked to pathologies including drug resistance in 
cancer by inducing division in senescent cells (Sharma et al., 2013, Mosieniak and Sikora, 
2010). BMS777607 was also shown to only partially decrease tumour growth in vivo at 
the dose of 6.25 mg/kg (Cmax- 4.5 μM), further increases in dose up to 50 mg/kg (Cmax- 
43.7 μM) was required for complete inhibition of tumour growth (Schroeder et al., 2009). 
Consistent with these reports, even 100 μM concentration of the inhibitor failed to reduce 
schwannoma total cell numbers by 50% and concentration of over 60 μM was required 
to decrease meningioma cell numbers by half after seven days (Figure-3.21 A and C).  
Taking published reports and our in vitro data into consideration, BMS777607 does not 
seem to be an ideal candidate to take forward for the treatment of schwannomas and 
meningiomas.  
In addition to increased proliferation, increased resistance to apoptosis is another 
hallmark feature of both schwannomas and meningiomas. Schwannoma cells cultured in 
serum-free media for five days, only showed negligible cell death. Moreover, Gas6- 
mediated activation of TAM receptors further decreased cell death by activation of 
survivin (Ammoun et al., 2014). My results showed that treatment of schwannoma and 
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meningioma cells with MERTK and AXL small molecule inhibitors decreases the 
survival of tumour cells by increasing the levels of pro-apoptotic protein, cleaved caspase-
3 (Figure-3.22, Figure-3.23, Figure-3.24, Figure-3.25, Figure-3.26 and Figure-3.27). 
Of note, genetic knock-down of MERTK in schwannoma and meningioma primary cells 
reduced the expression of AXL (Figure-3.9 and Figure-3.10) and treatment with MERTK 
inhibitor UNC2025 led to decrease in the phosphorylation of AXL after one-hour in 
schwannoma primary cells (Figure-3.28 B). Similarly, incubation of meningioma primary 
cells with BGB324 for 72 hrs concomitantly reduced the expression of TYRO3 and 
MERTK along with AXL (Figure-3.31). Although it has yet remained to determine 
whether these observed effects are due to a cross-talk among these receptors, there are 
evidences suggesting that TAM receptors can cross-phosphorylate each other and that the 
absence of one receptor may adversely affect the activity of remaining TAM members 
(Angelillo-Scherrer et al., 2005, Brown et al., 2012). In addition, direct evidence comes 
from GBM, where inhibition of phosphorylated AXL by BGB324 also reduced the 
activity of TYRO3 (Vouri et al., 2015).  In short, due to an extensive cross-talk among 
TAM family members it is difficult to identify the role of individual TAM receptors in 
promoting tumorigenesis, but I can conclude from my data that AXL and MERTK work 
together and play a concerted role in promoting the proliferation and survival of 
schwannoma and meningioma cells in vitro which can be successfully inhibited using 
UNC2025 and BGB324. 
Interestingly, meningioma cells were overall more sensitive to all three tested inhibitors 
compared to schwannoma cells (Table-3.1). The limited efficacy of most drug treatments 
in schwannoma primary cells could be attributed to the intrinsic drug resistance mediated 
by multiple drug resistance proteins such as p-glycoprotein (p-gp). P-gp is a cell-
membrane protein responsible for causing an efflux of many important anti-cancer drugs 
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and develop resistance in many cancers. Merlin-deficient schwannoma cells reported to 
have an endogenous high level of p-gp compared to Schwann cells (Provenzano, 2018). 
The p-gp inhibitor PSC833 (Valspodar) has been shown to have a beneficial effect in 
combination with anti-cancer drugs in several cancers by reversing the effect of p-gp 
(Baekelandt et al., 2001, Fracasso et al., 2005). It remains to be seen whether a 
combination treatment of TAM inhibitors with PSC833 would have an additional 
beneficial effect in reducing schwannoma growth.  
Importantly, when cells were treated with UNC2025 and BGB324 for a prolonged period 
(72 hrs), reduction in total MERTK, AXL and TYRO3 levels were observed but not at 
the shorter treatment (one-hour) (Figure-3.29 and Figure-3.31). Therefore, a question 
remains whether this reduction is due to inhibitor-mediated dephosphorylation or 
inhibitor-mediated conformation changes leading to receptor internalization and 
degradation, or both. Since kinase inhibitors induce the dephosphorylation of their 
respective kinase within short time frame (up to 60 minutes), not many reports have 
studied the effect of kinase inhibitors at longer time periods. Recently emerging studies 
show that degradation of RTKs is a better therapeutic strategy as it provides complete 
blockage of downstream signaling compared to only inhibition of the kinase activity 
where receptor can still act as scaffold for cross-talk with another receptor (Bae et al., 
2015, Burslem et al., 2018). In this context, it is essential to understand whether the 
UNC2025- and BGB324-induced reduction in total TAM protein levels is of beneficial 
rather an unwanted effect in these tumours before pursuing these drugs as a therapeutic 
strategy. Future experiments should be conducted by incubating schwannoma and 
meningioma cells with proteasome inhibitor such as MG132 or lysosomal inhibitor 
chloroquine along with TAM kinase inhibitors UNC2025 and BGB324 to get further 
insight into the mechanism by which these drugs act to reduce protein levels.  
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In conclusion, this is the first report describing the therapeutic importance of TAM 
receptors in schwannomas and meningiomas by successfully targeting them with novel 
tyrosine kinase inhibitors, UNC2025 and BGB324. Blocking the expression and 
activation of MERTK and AXL reduces the proliferation of schwannoma and 
meningioma primary cells probably by cell-cycle arrest at G1 phase as well as inducing 
apoptosis. In addition, this report highlights the importance of not drawing conclusions 
of the anti-tumor effect of a specific TAM tyrosine kinase inhibitor at longer treatment 
(24 hrs, 48 hrs or 72 hrs) while studying their specificity only on a shorter time period 
(few minutes to an hour), especially when the TAM receptors are co-expressed in the 
cells of interest. 
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Table 3.1- Summary of IC50 values of UNC2025, BGB324 and BMS777607. IC50 values were 
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3b.2 TAM down-stream signaling pathways 
Introduction 
 
I further investigated the role of MERTK, AXL and TYRO3 in schwannoma and 
meningioma cell proliferation and survival by dissecting their relevant down-stream 
signaling pathways. TAM family receptors signal via multiple pathways to mediate their 
oncogenic effect on target cell/tissues. Nevertheless, Ras/Raf/MEK/ERK, PI3K/AKT, 
Rac/PAK/JNK and Src/FAK pathways have repeatedly been described down-stream of 
TAM receptors in multiple cancers (Linger et al., 2008). Interestingly, all these pathways 
are highly activated and have shown to be important for both schwannoma and 
meningioma development (Ammoun et al., 2008, Hilton et al., 2016). In addition, the 
stimulation of Merlin-deficient schwannoma primary cells with Gas6 strongly activated 
pERK, pAKT, pJNK, pFAK and pSrc within five minutes (Ammoun et al., 2014).  
ERK-1/2 is a protein serine-threonine kinase which, when activated, phosphorylates other 
protein kinases and transcription factors to promote multiple cellular processes such as 
cell-cycle progression, proliferation, adhesion, migration, survival and differentiation 
(Roskoski, 2012). In schwannomas and meningiomas, strong nuclear expression of 
pMEK and pERK1/2 is associated with increased cell proliferation (Ammoun et al., 2008, 
Hilton et al., 2009, Hilton et al., 2016). The c-Jun N-termianal kinase (JNK) is also a 
member of MAPK family. JNK can act as either a tumour promoter or a tumour 
suppressor depending on the tissue and cell type. However, persistent activation of JNK 
has been reported to play a pro-tumorigenic role in several cancers including brain 
tumour, GBM (Bubici and Papa, 2014). The hyper-phosphorylated form of JNK has also 
been detected in the nucleus of schwannoma and meningioma primary cells where, in 
schwannoma, it was shown to promote Schwann cell de-differentiation (Kaempchen et 
al., 2003, Parkinson et al., 2004, Hilton et al., 2016). 
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Another two important molecules regulated by Merlin are AKT and focal adhesion kinase 
(FAK). The aberrant activity of both signaling molecules in schwannoma and 
meningioma is evident from their high expression and phosphorylation and presence in 
the nucleus (Jacob et al., 2008, Hilton et al., 2016, Ammoun et al., 2012, Wang et al., 
2012). Nuclear AKT and FAK provides a proliferation and survival advantage to 
schwannoma cells by inducing degradation of the tumour supperessor protein p53 
(Ammoun et al., 2015).  
I investigated the role of TAM family receptors in mediating the signaling of the above-
mentioned pathways in schwannomas and meningiomas using kinase specific inhibitors 
or shRNA-mediated genetic knock-down. As explained above, due to time constraints 
and difficulty in achieving successful knock-down in meningioma primary cells, only the 
results of one or two successful knock-down are presented here. 
3b.2.1 The role of MERTK in the regulation of downstream oncogenic signaling in 
schwannoma and meningioma primary cells 
MERTK knock-down in schwannoma and meningioma primary cells (Figure-3.9 and 
Figure-3.10), which also strongly reduced AXL and TYRO3 in both cell types, 
profoundly decreased pAKT, pJNK and pFAK levels in schwannoma primary cells 
(Figure-3.34 A) and pJNK and pFAK levels in meningioma primary cells (Figure-3.34 
B). Interestingly, MERTK shRNA65 construct was less effective in inhibiting pJNK 
levels compared to MERTK shRNA62 in schwannoma cells (Figure-3.34 A). 
 




Figure 3. 34- The effect of MERTK knock-down on downstream oncogenic signaling in 
schwannoma and meningioma primary cells . MERTK knock-down decreased the levels of 
pAKT (n=4 for 62 and 65), pJNK (construct-62) (n=4 for 62 and n=3 for 65) and pFAK (n=4 for 
62 and n=3 for 65) but not of pERK (n=4 for 62 and 65) in schwannoma primary cells. Error bar 
indicates the standard error of mean of individual experiments, each dot in a scatter plot represents 
an individual data set. ANOVA with Dunnett’s multiple comparison test was used to calculate 
statistical difference, *p<0.05 and ***p<0.0001 A). MERTK shRNA decreased the levels of 
pJNK and pFAK in two different meningioma cells but not pERK and pAKT (n=2) B). GAPDH 
was used as a loading control.  
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Treatment of schwannoma and meningioma primary cells with MERTK inhibitor 
UNC2025 for one-hour caused a dose-dependent decrease in phosphorylated ERK and 
AKT but does not affect the expression of either total ERK or AKT. UNC2025 decreased 
the levels of total JNK in both cell-types following one-hour of treatment.  A decrease in 
phospho JNK/total JNK ratio was also observed in both cell-types; however, this 
difference was not statistically significant. UNC2025 did not affect phospho-FAK 
signaling in either cell-types following one-hour of treatment (Figure-3.35 A and Figure-
3.35 B).  
  




Figure 3. 35- The effect of MERTK inhibition by UNC2025 on downstream signaling 
molecules responsible for schwannoma and meningioma development. Representative 
Western blot of phosphorylated and total ERK, AKT, JNK and FAK in schwannoma A) and 
meningioma B) primary cells following one-hour of UNC2025 treatment. GAPDH was used as a 
loading control. Densitometry of Western blot of pERK/ERK and ERK/GAPDH (n=4-
schwannomas; n=5-meningiomas); pAKT/AKT and AKT/GAPDH (n=3-schwannoma; n=4-
meningiomas); pJNK/JNK and JNK/GAPDH (n=3-schwannomas; n=2-meningiomas); 
pFAK/FAK and FAK/GAPDH (n=2-schwannomas; n=1 meningiomas). Data were normalized to 
EtOH (vehicle) and media (cells containing normal growth medium)  was used as a negative 
control, graphs represent mean ±SEM.  ANOVA with Dunnett’s multiple comparison test was 
performed using GraphPad Prism analysis software to calculate statistical significance;  *p<0.05, 
**p<0.01 and ***p<0.001.   
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3b.2.2 The role of AXL in the regulation of downstream oncogenic signaling in 
meningioma primary cells  
Genetic knock-down of AXL, which did not affect the expression of MERTK and TYRO3 
in either schwannoma (Ammoun et al., 2014) or meningioma primary cells (Figure-3.13), 
impeded phospho-FAK signaling in schwannoma primary cells (Ammoun et al., 2014). 
A partial decrease in pFAK levels were also observed in meningioma primary cells on 
AXL knock-down. In addition, AXL shRNA also reduced pAKT levels in meningioma 
primary cells (Figure-3.36). 
 
Figure 3. 36- The effect of AXL knock-down on downstream oncogenic signaling in 
schwannoma and meningioma primary cells. Western blot analysis shows that AXL knock-
down in meningioma primary cells led to clear decrease in levels of pAKT and slight decrease in 
pFAK but has no effect on pERK levels (n=1). GAPDH was used as a loading control.  
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Incubation of meningioma primary cells with BGB324 for one-hour caused dose-
dependent decrease in the relative phosphorylation of ERK, AKT and JNK signaling 
molecules in meningioma primary cells (Figure-3.37). BGB324 also slightly reduced total 
JNK levels in meningioma primary cells compared to vehicle; however, this difference 
was non-significant. BGB324 did not inhibit phospho-FAK and total FAK exprssion 
levels after one-hour of treatment (Figure-3.37). 
 
Figure 3. 37- The effect of AXL inhibition by BGB324 on downstream oncogenic signaling 
in meningioma primary cells. Representative Western blots of phosphorylated and total ERK, 
AKT, JNK and FAK following one-hour treatment of meningioma primary cells with BGB324. 
GAPDH was used as a loading control. Densitometry of Western blot of pERK/ERK and 
ERK/GAPDH (n=3); pAKT/AKT and AKT/GAPDH (n=3); pJNK/JNK and JNK/GAPDH (n=3); 
pFAK/FAK and FAK/GAPDH (n=1); graphs represent mean ±SEM. Data were normalized to 
DMSO (vehicle) and media (cells containing normal growth medium) was used as a negative 
control. GraphPad Prism analysis software was used to calculate statistical significance using 
ANOVA with Dunnett’s multiple comparison test, *p<0.05 and **p<0.01. 
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Whilst BGB324 failed to effectively reduce phospho-AXL levels in schwannoma primary 
cells following one-hour treatment (Figure-3.30 A), BMS777607 almost completely 
abolished phospho-AXL in schwannoma primary cells at 10 μM after one-hour of 
treatment (Figure-3.32 A). Therefore, I decided to use BMS777607 to dissect down-
stream signaling of AXL receptor in schwannoma primary cells. BMS777607 mediated 
dose-dependent decrease in phospho-AKT levels from 10 μM. BMS777607 also led to 
dose-dependent decrease in the expression and phosphorylation of JNK; however, there 
was no noticeable difference in phospho JNK/JNK ratio compared to vehicle. 
BMS777607 did not affect either phosphorylated or total levels of ERK and FAK 
signaling molecules in schwannoma primary cells following one-hour of drug treatment 
(Figure-3.38). More repeats of this experiment will need to be performed to firmly 
conclude any data.  
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Figure 3. 38- The effect of AXL inhibition by BMS777607 on downstream oncogenic 
signaling in schwannoma primary cells. Representative Western blot of phosphorylated and 
total ERK, AKT, JNK and FAK following one-hour treatement of schwannoma primary cells 
with BMS77760. Schwannoma primary cells were treated with increasing concentration of 
BMS777607 (10.0-100.0 μM) or DMSO (vehicle control) for one-hour. GAPDH was used as a 
loading control. Densitometry of Western blot of pERK/ERK and ERK/GAPDH (n=1); 
pAKT/AKT and AKT/GAPDH (n=1); pJNK/JNK and JNK/GAPDH (n=2); pFAK/FAK and 
FAK/GAPDH (n=2), graphs represent mean ±SEM. Statistical calculation was not performed due 
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3b.2.3 The role of TYRO3 in the regulation of downstream oncogenic signaling in 
schwannoma and meningioma primary cells 
Although TYRO3 knock-down did not decrease the levels of cyclin-D1 in either 
schwannoma or meningioma primary cells (Figure - 3.18), strong expression and 
activation of the protein was previously observed in schwannoma primary cells (Ammoun 
et al., 2014) and in meningioma tissues and cells (Figure - 3.1 and Figure - 3.2). Hence, I 
decided to further explore an oncogenic potential of the receptor in these tumours using 
knock-down approach.   
Indeed, a lentivirus mediated knock-down of TYRO3 in schwannoma primary cells led to 
significant reduction of phospho-AKT and phospho-JNK levels and partial decrease in 
phospho-ERK levels (Figure-3.39 A). Conversely, in meningioma primary cells, TYRO3 
reduction showed very inconclusive results and no consistent change in any downstream 
signaling pathways were detected (Figure-3.39 B). 
  





Figure 3. 39- The effect of TYRO3 knock-down on downstream oncogenic signaling in 
schwannoma and meningioma primary cells. Knock-down of TYRO3 using two shRNA 
constructs, 438 and 476, in schwannoma cells lead to a significant decrease in the levels of pAKT 
(n=4 for 438 and 476) and pJNK (n=5 for 438 and n=4 for 476). A partial decrease in the levels 
of pERK (n=6 for 438 and n=5 for 476) was observed but the levels of pFAK were not affected 
(n=5 for 438 and n=4 for 476). ANOVA with Dunnett’s multiple comparison test was used to 
calculate statistical significance; *p<0.05, **p<0.01 and ***p<0.001 A). No change in the levels 
of pERK pAKT, pJNK or pFAK was seen in Western blots of meningioma cells infected with 
TYRO3 shRNA (n=2) B). GAPDH was used as a loading control. 
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3b.2.4 Discussion 
The co-operative nature of TAM family members poses a challenge for dissecting the 
role of individual TAM receptor in promoting tumour development. A genetic knock-
down of MERTK decreased total levels of AXL and TYRO3 in both schwannoma and 
meningioma primary cells (Figure-3.9 and Figure-3.11) but TYRO3 and AXL shRNA 
did not affect either expression of MERTK or of each other (Figure-3.11, Figure-3.12 and 
Figure-3.13). In schwannoma primary cells, UNC2025 decreased pAXL along with 
pMERTK after one-hour (Figure-3.28) but it was specific to pMERTK inhibition in 
meningioma cells (Figure-3.29). In addition, while BGB324 failed to inhibit pAXL after 
one-hour of treatment in schwannoma cells (Figure-3.31), it specifically inhibited pAXL 
in meningioma cells at the same time point (Figure-3.32). Capitalizing on the 
discrepancies between the modes of action of shRNA-mediated knock-down and kinase 
inhibitors, I looked at the role of TAM receptors on the activation of key downstream 
signaling pathways in schwannoma and meningioma primary cells as an individual entity 
or in a concert.  
I previously determined that reducing the expression and activation of MERTK and AXL, 
by shRNA knock-down and kinase inhibitors, decreases proliferation of schwannoma and 
meningioma primary cells in culture via reducing cyclin-D1 (Figure-3.16 to Figure-3.17 
and Figure-3.23 B, Figure-3.25 B). In prostate cancer, MEK/ERK specific inhibitor, 
PD098059 reduced cyclin-D1 levels by decreasing MEK/ERK/Jun pathway (Lee et al., 
2016), signifying that ERK is upstream of cyclin-D1. Consistent with this finding, I 
showed that the inhibition of MERTK and AXL phosphorylation by UNC2025 and 
BGB324 in schwannoma and meningioma cells reduced pERK levels in a dose-dependent 
manner (Figure-3.35 and Figure-3.37), suggesting that a similar mechanism may play a 
role in decreasing cyclin-D1 levels downstream of ERK in schwannoma and meningioma 
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cells. Other studies have also demonstrated that treatments with UNC2025 and BGB324 
lead to significant reductions in pERK-mediated proliferation in leukemia cells and 
NSCLC in vitro (DeRyckere et al., 2017, Cummings et al., 2015, Ben-Batalla et al., 2017).   
However, genetic knock-down of MERTK and AXL did not affect pERK levels in either 
cell-types (Figure-3.34 and Figure-3.36). These results suggest that an ERK-independent 
mechanism could be driving MERTK and AXL-mediated proliferation in schwannomas 
and meningiomas. Comparable results have also been reported previously in head and 
neck cancer where pERK levels were efficiently reduced by MERTK inhibitor UNC1062 
but remain completely unaffected upon MERTK genetic knock-down (von Massenhausen 
et al., 2016). Similarly, in liposarcomas AXL genetic knock-down decreased the cell 
proliferation but did not affect pERK levels (May et al., 2015). However, in many other 
tumour cell-types MERTK and AXL shRNA decreased pERK levels (Martinelli et al., 
2015, Keating et al., 2010), pointing towards differences in MERTK and AXL-induced 
signaling depending on the cell-type and tumour microenvironment.  
Fms-like tyrosine kinase 3 (FLT3) is a type-III, RTK with familiar oncogenic role in 
hematopoietic malignancies. In AML, it activates the classical Ras/Raf/Mek/ERK1/2 
signaling pathway to promote cell proliferation (Takahashi, 2011). A relatively high 
abundance of FLT3 has also been reported in meningiomas and astrocytic tumours such 
as GBM (Essbach et al., 2013). However, the importance of this receptor has not been 
further studied in these tumours. To recall that UNC2025 is a dual kinase inhibitor with 
equal potency against FLT3 and MERTK (Zhang et al., 2014). Moreover, BGB324 which 
has been considered as an AXL specific kinase inhibitor, has recently been shown to 
inhibit FLT3 with equivalent potency (Myers et al., 2018). Preliminary Western blots 
performed to check the effect of UNC2025 and BGB324 on pFLT3 showed successful 
inhibition of this kinase by both kinase inhibitors in these tumour cells (supplementary 
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figure-S1 and S2). Therefore, the involvement of FLT3 in debilitating pERK1/2 signaling 
by UNC2025 and BGB324 in schwannoma and meningioma primary cells cannot be 
dismissed. A detailed assessment of the role of the FLT3 receptor in tumour biology of 
schwannoma and meningioma is requied before either UNC2025 or BGB324 can be 
considered for the treatment of these tumours. 
In addition to Ras/Raf/MEK/ERK pathway, Rac/PAK/JNK and PI3K/AKT cascades are 
also responsible for enhancing proliferation and survival of Merlin-deficient schwannoma 
and meningioma cells by inhibiting caspase-dependent apoptosis (Petrilli and Fernandez-
Valle, 2016). I earlier showed that the inhibition of MERTK and AXL phosphorylation 
by UNC2025 and BGB324 in schwannomas and meningiomas increases the levels of 
cleaved caspase-3 and thus promotes apoptotic cell death (Figure-3.22 to Figure-3.25) 
which likely occurs via inhibition of pJNK and pAKT signaling molecules (Figure-3.35 
and Figure-3.37).  
JNK has been shown to play a vital role in both cell proliferation and apoptosis depending 
on the cell-type and a stimulus. In schwannoma primary cells, increased JNK/Jun 
signaling has been associated with Schwann cells de-differentiation and proliferation 
(Hilton et al., 2009). JNK can phosphorylate the transcription factor c-Jun, leading to 
increases in cyclin-D1 levels and subsequently to increased cell proliferation. JNK also 
enhances the survival of schwannoma cells by preventing the accumulation of reactive 
oxygen species (ROS) and inhibiting JNK confers sensitivity to γ-irradiation and 
increases apoptosis (Yue et al., 2013). Reducing MERTK expression in both 
schwannomas and meningiomas (Figure-3.34) and AXL expression in meningiomas 
(Figure-3.36) using MERTK shRNA and AXL shRNA respectively decreases pJNK 
levels. A dose-dependent decrease in pJNK was also observed upon treatment of 
schwannoma and meningioma primary cells with UNC2025 (Figure-3.35) and BGB324 
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(Figure-3.37), suggesting that UNC2025 and BGB324 blocks pJNK signaling by 
inhibiting pMERTK, pAXL and likely also pFLT3 as pFLT3 has also been shown to 
signal via pJNK in other cancers (Hartman et al., 2006). 
PI3K/AKT signaling also plays an important role in promoting cell survival and cell 
proliferation by directly inhibiting apoptosis or by an indirect interaction with key 
mediators of proliferation such as cyclin-D1. In several cancers, activated MERTK and 
AXL bind to PI3K and phosphorylate AKT to protect cells from apoptotic cell death via 
various mechanisms (Cummings et al., 2013, Hasanbasic et al., 2004, Goruppi et al., 
1997). AKT inhibits the pro-apoptotic protein caspase-3 and phosphorylates nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) which in turn can activate 
anti-apoptotic proteins such as B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra-
large (Bcl-xL) (Hasanbasic et al., 2004). In NSCLC, UNC2025-mediated inhibition of 
pMERTK blocks basal and Gas6-induced phosphorylation of AKT and induces apoptotic 
cell death (Cummings et al., 2015). Similarly, genetic knock-down of MERTK and AXL 
reduced the survival of astrocytoma and melanoma cells by blocking the activation of 
AKT and its downstream effector mTOR (Keating et al., 2010, Tworkoski et al., 2013). 
In accordance with these reports, blocking the expression and activation of MERTK and 
AXL in schwannoma primary cells successfully inhibited pAKT signaling (Figure-3.34 
A, Figure-3.35 A). Inhibition of pAKT was also observed in meningioma cells after 
genetic knock-down of AXL as well as after treatment with BGB324 (Figure-3.36 and 
Figure-3.37). Again, since MERTK does not engage pAKT signaling in meningioma 
cells, decreases in pAKT level after treatment with UNC2025 in meningioma could be 
due to FLT3 (Brandts et al., 2005). 
FAK is another important signaling molecule in schwannoma and meningioma 
development. It plays a significant role in cell-matrix adhesion but when translocate to 
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nucleus, it can also regulate the cell proliferation by inhibiting the tumour suppressor 
activity of p53 in schwannoma cells (Ammoun et al., 2012). AXL receptor has been 
shown to signal via Src and FAK in schwannoma cells, when stimulated with Gas6 
(Ammoun et al., 2014). In anaplastic meningioma cells, increased expression and 
phosphorylation of FAK facilitates cell migration (Wang et al., 2012). In melanoma cells, 
Gas6-induced activation of MERTK increased the phosphorylation of FAK and reducing 
the expression of MERTK impaired the migration and invasion of the tumour cells 
(Schlegel et al., 2013, Tworkoski et al., 2013). In head and neck cancer, inhibition of 
MERTK using UNC1062 decreased pFAK levels and reduced migration and invasion of 
the tumour cells (von Massenhausen et al., 2016). Similarly, my data shows that the 
genetic knock-down of MERTK and AXL disrupts the phosphorylation/activation of 
FAK in both schwannoma and meningioma primary cells (Figure-3.34 and Figure-3.36). 
However, all three TAM inhibitors failed to reduce pFAK levels following one-hour 
treatment of schwannoma and meningioma cells (Figure-3.35, Figure-3.37 and Figure-
3.38). I would like to perform all signaling pathway experiments also at 72 hrs to see the 
long-term effect of kinase inhibitor on downstream signaling.  
Out of three TAM members, TYRO3 is the least studied RTK in cancer. Only very 
recently, few publications have recognized the transforming potential of TYRO3 in 
promoting breast, colon, melanoma, and ovarian cancer (Chien et al., 2016, Ekyalongo et 
al., 2014, Kim et al., 2015, Smart et al., 2018). This is likely the reason that there have 
been only few efforts to develop TYRO3-specific inhibitor yet. Regardless of no change 
in cyclin-D1 levels (Figure-3.18), a genetic knock-down of TYRO3 caused a small but 
clear decrease in pERK and a significant decrease in pJNK levels in schwannoma cells 
(Figure-3.39). Since elevated activity of JNK is also related to higher cell-matrix adhesion 
and the fact that AXL has previously been shown to be responsible for increased cell-
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matrix adhesion of schwannoma primary cells, I would like to investigate if TYRO3 is 
also involved in pathological cell-matrix adhesion of Merlin negative schwannoma cells 
via JNK signaling by performing adhesion assay as previously described in (Ammoun et 
al., 2014). In addition, a role of TYRO3 in promoting apoptosis also needs to be 
investigated further by performing cleaved caspase-3 staining on TYRO3 knock-down 
cells. Knock-down of TYRO3 in a melanoma cell-line has been shown to induce 
apoptosis in cells treated with TYRO3 shRNA cells compared to control shRNA 
(Demarest et al., 2013). Similarly, thyroid cells also showed enhanced apoptosis on 
siTYRO3 exposure (Avilla et al., 2011). Another group showed increased apoptosis in 
colorectal cancer cell-line and colorectal cancer patient cells upon treatment with a 
neutralizing TYRO3 antibody (Chien et al., 2016). In this regard, it is possible that 
TYRO3 may be important for increased cell survival and cell-matrix adhesion rather than 
proliferation in at least schwannoma cells as no consistent change in pJNK levels were 
observed on TYRO3 knock-down in meningioma cells.  
Furthermore, genetic knock-down of TYRO3 also reduced pAKT in schwannoma primary 
cells (Figure-3.39). Likewise, activation of PI3K/AKT signaling has been shown to be 
interrupted in platelets from TYRO3-/- mice (Angelillo-Scherrer et al., 2005). 
Importantly, phosphorylation of AXL was also inhibited in this TYRO3-/- mice and 
therefore it is difficult to say if inhibition of pAKT is due to TYRO3-/- or due to pAXL 
inhibition or both. Although ectopic expression TYRO3 in Rat2 cells led to enhanced 
activation of the AKT/mammalian target of rapamycin (mTOR)/ribosomal protein S6 
kinase beta-1 (P70S6K) cascade suggesting that PI3K/AKT signaling is downstream of 
TYRO3 (Brown et al., 2012). Moreover, in rat hippocampal neurons, AKT 
phosphorylation was corelated with TYRO3 expression and was inhibited in TYRO3-/- 
mice (Guo et al., 2011, Zhong et al., 2010).  
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In summary, in meningioma primary cells, MERTK engages pJNK and pFAK whereas 
AXL engages pAKT, pJNK and pFAK signaling molecules. In schwannoma primary 
cells MERTK acts via pAKT, pJNK and pFAK; AXL acts via pSrc and pFAK (Ammoun 
et al., 2014); and TYRO3 acts via pERK, pAKT and pJNK. Both AXL and MERTK 
contribute to increased proliferation and survival of schwannoma and meningioma 
primary cells. The contribution of TYRO3 is yet to be determined for both tumour types. 
TAM receptor-mediated signaling can be successfully reversed using AXL inhibitor 
BGB324 and MERTK inhibitor UNC2025. 
 
Table 3.2- A summary of shRNA and kinase inhibitor mediated inhibition of TAM receptors 
and their downsteam signaling effectors.  








Chapter 4.0 - Conclusions 
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Conclusions 
• MERTK, AXL and TYRO3 receptors and their ligand Gas6 are highly expressed 
and activated in Merlin-deficient meningioma tissues compared to normal control.  
• Although there was no significant difference in the expression of TAM receptors 
in Merlin-deficient G-I meningioma cell-line Ben-Men-I and meningioma 
primary cells compared to HMCs, these receptors (except TYRO3) were highly 
phosphorylated in meningioma cells.  
• The expression of all three TAM receptors were Merlin-dependent but Gas6 
expression was not.  
• MERTK and TYRO3 form a complex in schwannoma and meningioma tissues 
but not in Ben-Men-I cell-line and the expression of TYRO3 is dependent on the 
expression of MERTK in both tumour types. 
• Although AXL and MERTK are not in complex either in schwannomas or 
meningiomas, expression of AXL is dependent on MERTK in both tumours. 
• In meningioma cells, MERTK signals via pJNK and pFAK; AXL signals via 
pAKT, pJNK and pFAK.  
• In schwannoma cells, MERTK signals via pAKT, pJNK and pFAK; TYRO3 
activates pERK, pAKT and pJNK.  
• UNC2025 is the most effective TAM family inhibitor tested in inhibiting the cell 
growth of both tumours and has the potential to be used as a common drug for 
treating schwannomas and meningiomas. 
• BGB324 effectively inhibits meningioma cell growth at low concentrations but 
comparatively higher concentrations were required in order to have the same 
effect on schwannoma cell growth in vitro.  
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• In vitro BMS777607 was the least effective at inhibiting schwannoma and 
meningioma tumour cell growth and should not be considered for a further clinical 
development for either of the tumours studied in this report. 
  









Chapter 5.0 – General discussion and future work 
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5.1 TAMs in schwannomas and meningiomas 
TAM family receptors have been implicated in several cancers including but not limited 
to leukemia, colorectal cancer, gliomas, breast cancer, hepatocellular carcinoma and 
prostate cancer (Lemke, 2013). Our group has previously reported an elevated expression 
and activation of TYRO3, AXL and MERTK as well as their ligand Gas6 in Merlin-
deficient schwannoma cells and tissues. Gas6-mediated activation of AXL receptor has 
been shown to play a role in the pathological proliferation, cell-matrix adhesion and 
survival of schwannoma cells (Ammoun et al., 2014). However, a role of the rest of the 
TAM family members has not been previously investigated. Moreover, IHC staining in 
search for differences in the expression and activation of growth factors, growth factor 
receptors and downstream signaling pathways between meningioma tissues and non-
neoplastic meninges revealed significantly stronger staining of AXL, MERTK, Gas6 and 
pAXL along with multiple other molecules in meningioma tissues (Hilton et al., 2016). 
To my knowledge, no previous detailed studies have been carried out to understand the 
role of this family receptors in meningioma pathology. In this project, I have focused on 
Merlin-negative schwannoma and meningioma tumours since our previous results 
demonstrated a strong link between Merlin deficiency and the expression of TAMs and 
their agonist Gas6 in schwannoma (Ammoun et al., 2014). Here, I evaluated the 
expression and activation of AXL, MERTK and TYRO3 as well as their ligand Gas6 in 
Merlin-negative meningioma tissues and cells using Western blot. I also investigated the 
interaction and a cross-talk among TAM family members as well as their potential role 
as therapeutic targets by performing in vitro inhibition and knock-down experiments in 
both schwannoma and meningioma primary cells. 
By analyzing protein expression and phosphorylation of AXL, MERTK and TYRO3 
across meningioma tissues, I found an overexpression and activation of all three TAM 
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receptors and Gas6 in Merlin-deficient meningioma tissues (Figure-3.1 and Figure-3.3 
A). To prove whether this upregulation is at the transcription level, I could have further 
performed qPCR. However, kinase inhibitors target protein itself and protein expression 
is more important to determine the therapeutic response (von Massenhausen et al., 2016), 
I only investigated protein levels of these receptors in this study due to time restraints and 
limited materials. Moreover, increased basal activation of TAM receptors were also 
detected in G-I Merlin-deficient meningioma primary cells and Ben-Men-I cell line which 
could be due to either paracrine/autocrine activation by released Gas6, or Gas6-dependent 
and/or independent complex formation with other types of receptors such as EGFR or 
PDGFR (Meyer et al., 2016, Vouri et al., 2016)   
Although the exact mechanism of overexpression of these receptors is not yet clear, their 
expression seems to be partly regulated by the NF2 gene since ectopic expression of 
Merlin significantly decreased TAM family expression levels in meningioma cells as was 
seen previously in schwannomas (Ammoun et al., 2014). However, not all TAM 
overexpressing tumours are Merlin-deficient i.e gastric cancer, head and neck cancer. 
Moreover, only a partial reduction (~50%) in the expression of AXL, MERTK and 
TYRO3 was achieved upon Merlin reintroduction and therefore an involvement of other 
regulatory genes or mechanisms in governing the expression of these receptors cannot be 
denied. Probably this is likely the reason why there was no significant difference in pAXL 
levels between Merlin-deficient and Merlin-expressing meningiomas (Hilton et al., 
2016).  
Ammoun et al previously established the importance of AXL in mediating schwannoma 
cell proliferation, survival and cell-matrix adhesion (Ammoun et al., 2014). By using in 
vitro knock-down and kinase inhibition experiments, here I further showed that not only 
AXL but also MERTK plays a vital role in mediating proliferation and survival of 
- 175 - 
 
schwannoma and meningioma cells. BGB324-mediated AXL and UNC2025-mediated 
MERTK inhibition represent novel therapeutic approaches in NF2-related tumours which 
have also been shown to enhance the efficacy of standard anti-cancer treatments in several 
other tumours including glioblastoma multiforme, non-small cell lung cancer, and breast 
cancer (Vouri et al., 2015, Sufit et al., 2016, Okimoto and Bivona, 2015, Li et al., 2009). 
Recently, TYRO3 has also emerged as an important modulator of tumorigenesis and 
many literatures have shown a benificial effect of targeting TYRO3 receptor (Smart et 
al., 2018). Although TYRO3 was not directly involved in mediating proliferation of 
schwannomas and meningioma cells, reducing TYRO3 expression in schwannoma 
significantly decreased pAKT and pJNK signaling. Therefore, the role of TYRO3 in 
promoting survival, cell-matrix adhesion and migration of these tumour should be further 
investigated in future. 
An important finding of this study is the identification of the endogenous complex 
between TYRO3 and MERTK in schwannoma and meningioma tissues (Figure-3.7 A 
and Figure-3.8 A). Although physical interaction between AXL and TYRO3 has been 
reported in Rat2 cells, GnRH expressing neuronal cell-line and GBM cell-line (Brown et 
al., 2012, Vouri et al., 2016), this is the first study to report a complex between TYRO3 
and MERTK. This interaction between TYRO3 and MERTK could be ligand dependent 
or independent. In GBM cell-line, endogenous interaction between AXL and TYRO3 was 
slightly enhanced upon stimulation of cells with Gas6 (Vouri et al., 2016). Although, this 
effect was deemed negligible. Moreover, structural studies revealed that TYRO3 can 
form a homo or heterocomplex in the absence of a ligand (Heiring et al., 2004). I show 
higher expression and release of Gas6 in meningioma cells as well in as Ben-Men-I cell-
line. However, the physical interaction was only detected in schwannoma and 
meningioma tissue samples but not in the cell-line, suggesting that Gas6 may or may not 
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be important in complying TYRO3-MERTK complex formation in these tumours. As 
mentioned previously, CO-IP experiments of Ben-Men-I cells in culture both in the 
presence and absence of Gas6 would need to be carried out for this to be fully elucidated. 
Although the importance of TYRO3-MERTK complex in these tumours is not clear yet, 
it seems that MERTK, AXL and TYRO3 all co-operate and signal via multiple cascades 
such as AKT, JNK, FAK and cyclin-D1 to enhance schwannoma and meningioma cells 
proliferation and survival. Therefore, inhibitors of common downstream signaling 
pathways, as described in previous studies by our research group and by others, in 
schwannomas and meningiomas could also be used as therapeutic target for these tumours 
(Ammoun et al., 2008, Ammoun et al., 2010, Ammoun et al., 2011, Ammoun et al., 2012). 
Since RAS-RAF-MEK pathway and PI3K-AKT-mTOR pathway are two major pathways 
downstream of multiple RTKs, many inhibitors targeting these pathways have been 
developed and are currently in clinical trials (Tan et al., 2017). However, compensatory 
activation of alternative signaling cascades leading to drug resistance to targeted therapy 
has remained the main obstacle in the success of these kinds of treatments. For instance, 
in breast cancer, a highly specific MEK inhibitor-PD0325901, in addition to inhibiting 
the MEK/ERK pathway, caused an upregulation of PI3K pathway to sustain the 
oncogenic signaling (Hoeflich et al., 2009). In addition, inhibition of AKT or MEK in 
breast cancer cell-lines, was responsible for increased transcription and phosphorylation 
of multiple RTKs by alleviating feedback loop inhibition in cancer cells (Duncan et al., 
2012, Chandarlapaty et al., 2011). Therefore, targeting a single molecule may not be an 
effective strategy also in schwannomas and meningiomas, instead a combination therapy 
that targets the RTK as well as downstream targets could be a more logical approach to 
inhibit schwannoma and meningioma growth.  
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Fascinatingly, UNC2025 and BGB324 successfully inhibited not only their respective 
kinases but also down-stream signaling molecules such as ERK, AKT and JNK. These 
signaling pathways are not only downstream of TAM receptors but also of several other 
receptors such as PDGFR, EGFR, IGFR1, VEGFR and integrins which all are highly 
expressed and activated in both schwannoma and meningioma tumours (Ammoun et al., 
2014, Hilton et al., 2016). These results further emphasize the importance of targeting 
TAM family receptors in schwannoma and meningioma tumours. However, experiments 
investigating the effect of these drugs on signaling pathway inhibition must be performed 
for longer incubations (72 hrs or more) to see whether there is any risk of compensatory 
mechanisms.    
5.2 Is it wise to target Gas6 in Merlin-deficient schwannoma and 
meningioma tumours? 
In addition to directly targeting TAM kinases, more of an indirect approach of inhibiting 
TAM receptors by targeting their ligand has been gaining an attention recently. In 
pancreatic ductal carcinoma cells, Gas6 neutralizing antibody GMAB1 and GMAB2 
successfully blocked Gas6-mediated autocrine activation of AXL (Moody et al., 2016). 
Anti-coagulant factor warfarin has also recently shown the efficiency in reducing 
metastatic growth of lung and pancreatic cancer by inhibiting Gas6-mediated activation 
of TAM receptors through blocking y-carboxylation of Gas6  (Paolino and Penninger, 
2016, Kirane et al., 2015). Since schwannomas and meningiomas overexpress and release 
Gas6 (Figure-3.3 and Figure-3.4) that can activate TAM signaling in an autocrine or in a 
paracrine loop, targeting Gas6 in these tumours could be an interesting therapeutic 
approach. However, so far very few studies have used this approach to successfully target 
Gas6 in cancer and none of the aforementioned therapies have been successful enough to 
enter into clinical trials. In addition, there is adequate evidence of ligand-independent 
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activation of TAM receptors as well as the discovery of several new ligands for TAM 
receptors would further complicate any therapies targeting just one TAM family ligand 
(Caberoy et al., 2010, Caberoy et al., 2012, Bellosta et al., 1995, Heiring et al., 2004). 
Hence, rather than targeting a single ligand, I still believe that directly targeting TAM 
receptors is a much better strategy, at least for Merlin-negative schwannoma and 
meningioma tumours. 
5.3 The best drug candidate for Merlin-negative schwannoma and 
meningioma tumours. 
When comparing the effectiveness of UNC2025 and BGB324 in inhibiting schwannoma 
and meningioma cell growth, BGB324 was less effictive at inhibiting AXL kinase and 
reducing total cell number (IC50-14.30 µM-7 days) of schwannoma cells. However, 
BGB324 potently inhibited meningioma cell growth (IC50-3.70 µM; 72 hrs and IC50-0.13 
µM; 7 days) at lower concentrations with minimum toxicity. On the other hand, 
UNC2025 was effective reducing oncogenic growth of both schwannoma (IC50- 3.96 µM; 
72 hrs and IC50-3.09 µM; 7 days) and meningioma cells (IC50- 1.45 µM; 72hrs and IC50-
0.47 µM; 7days) at lower concentrations. Whereas BGB324 makes an ideal candidate for 
Merlin-deficient sporadic meningioma patients, NF2 patients- suffering from multiple 
schwannomas and meningiomas, often require treatment for both tumour types. In this 
context, for NF2 patients with schwannomas and meningiomas, UNC2025 is the most 
potent candidate.  Originally designed as type-II pan-TAM inhibitor, BMS-777607 
unfortunately failed to reduce both schwannoma and meningioma cell growth at 
concentrations below 100 µM and therefore is not an ideal candidate to take forward in a 
clinical trial for NF2-related tumours. 
Importantly, UNC2025 is a MERTK/FLT3 dual kinase inhibitor (Zhang et al., 2014). In 
addition, an elegant study published last year established that BGB324, which has long 
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been believed as an AXL-specific kinase inhibitor, also targets FLT3 with an equal 
potency (Myers et al., 2018). Whereas developing a highly specific kinase inhibitor has 
often remained a priority, most of the inhibitors involve a certain degree of cross-
reactivity with other protein kinases, especially RTKs due to high homology within the 
kinase domain. TAM family receptors share a striking similarity in kinase domain not 
just among each other but also with other RTK families such as FLT3, RON, MET and 
Aurora A/B, In AML, AXL and FLT3 co-immunoprecipitate and AXL siRNA or soluble 
AXL chimeric protein (AXL-Fc) diminishes FLT3 phosphorylation  (Park et al., 2013). 
The role of FLT3 is not well researched in brain tumours, however, a preliminary study 
carried out by Eßbach et al showed the expression of FLT3 at mRNA level in 87% of 
astrocytic tumours and in GBM (Essbach et al., 2013). The expression of FLT3 was also 
confirmed in all grades of meningiomas (Andrae et al., 2012). BGB324 and UNC2025 
both successfully inhibited phosphorylation of FLT3 (supplementary figure S1 and S2) 
along with AXL and MERTK respectively. In this case, it is highly likely that the anti-
tumour activity of these inhibitors in reducing schwannoma and meningioma cell growth 
may have been enhanced due to their effect on this additional kinase.  
5.4 Potential use of TAM inhibitors as immune-modulators in Merlin-
negative schwannoma and meningioma tumours  
There has been a growing recognition of a complex cross-talk between tumour cells and 
stromal immune cells. Tumour cells can modulate stromal cells to facilitate the growth 
and development of tumours (Loges et al., 2010) and TAM receptors may play an 
important role in mediating this cross-talk. As previously described, TAM receptors are 
also expressed by tumour-infiltrating leukocytes such as macrophages and dendritic cells 
and, more importantly, expression of AXL and MERTK is restricted to anti-inflammatory 
M2 type macrophages (Chiu et al., 2015, Zizzo et al., 2012). Strong staining of MERTK 
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and the presence of AXL in M2 macrophages was also observed in this study 
(Supplimentary chapter 7.3, Figure- S3). TAM signaling is known to play a vital role in 
suppressing the production of pro-inflammatory cytokines such as IL-12 therefore, 
inhibiting the anti-tumour immune response by macrophages and dendritic cells (Cook et 
al., 2013). Moreover, there is evidence that TAM-overexpressing tumour cells can 
instruct macrophages to overexpress and secret elevated levels of Gas6 within the tumour 
microenvironment. This enhances TAM receptor signaling and create a positive feedback 
loop, further enhancing tumour growth (Loges et al., 2010). Secretion of Gas6 from the 
tumour microenvironment has been shown to be responsible for enhanced tumorigenic 
growth of GBM, breast cancer and colon cancer (Schoumacher and Burbridge, 2017). 
Targeting the immuno-suppressive effect of TAM receptors provides an excellent 
opportunity to enhance the effectiveness of anti-cancer treatment. One study reported 
increased serological levels of pro-inflammatory cytokines and higher numbers of CD8+ 
T lymphocytes in MERTK-/- mice compared to wild type (Cook et al., 2013). Additional 
studies suggest a role of MERTK in regulating immune checkpoint signaling through PD-
L1 and PD-L2. PD-L1 and PD-L2 bind to PD-1 on tumour-infiltrating T cells, rendering 
them inactive and inducing apoptosis of tumour-reactive T cells therefore, suppressing 
anti-tumour immune response (Dong et al., 2002, Blank et al., 2004). Expression of PDL-
1, PDL-2 and/or PD-1 is a prognostic factor in several cancers (Konishi et al., 2004, 
Yamamoto et al., 2008). Constitutively activated MERTK increased the expression of 
PD-L1 and PD-L2 in epithelial cells and genetic knock-down of MERTK in the 
aggressive breast cancer cell-line MDA-MB 231 reduced the expression of PD-L1 
compared to control (Nguyen et al., 2014). Although the exact mechanism of how 
MERTK inhibits PD-L1 and PD-L2 signaling is not known yet, recent study also showed 
that inhibition of MERTK using the small molecule MERTK inhibitor MRX-2843, 
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decreased the expression of PD-1 on CD4+ and CD8+ T cells as well as Treg cells in 
leukemia (Lee-Sherick et al., 2018).   
Similarly, inhibition of AXL by BGB324 in prostate cancer reduced the activity of tank-
binding kinase 1 (TBK1) that resulted in decrease of immunosuppressor chemokines 
CCL11, IL-7, IL-1β, and IL-6 as well as tumour-associated macrophages (Ludwig et al., 
2018). In the mammary adenocarcinoma 4T1/Balb/C syngeneic mouse model, treatment 
of BGB324 (50 mg/kg bid) enhanced the responsiveness to anti-CTLA-4/anti-PD-1 
treatment (10 mg/kg of each, 4 doses) by increasing CD8+ T cell tumor infiltration 
(Research, 2016 January). Moreover, two out of four -AML patients treated with BGB324 
for three weeks in a clinical trial showed enhanced T cell clonal population and anti-
tumour immune response (Sonja, 2016).  
In addition, another study reported the potential of targeting TAM receptors to enhance 
ani-tumour response by activation of NK cells. The authors showed that all three TAM 
receptors are expressed by natural killer (NK) cells in vitro and binding of TAM receptors 
to Gas6 inhibits the proliferation of NK cells and production of interferon gamma (IFN-
y). The inhibition of TAM receptors using TAM specific inhibitor LDC1267 in vivo 
resulted in release of NK cells and killing of tumour cells (Paolino et al., 2014, Sonja, 
2016). These results are encouraging for future research into TAM receptors and their 
link to immunological signaling as targeting TAM receptors may promote anti-tumour 
immunity in cancer treatments.  
Since schwannomas and meningiomas also show high infiltration of macrophages, 
targeting TAM receptors in these tumours may enhance anti-tumour immune response. 
Very preliminary work carried out in this project also showed a correlation between level 
of MERTK and macrophage infiltration in meningiomas (Supplimentary chapter 7.3, 
Figure S4). However, so far little is known about the mechanism and importance of 
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macrophages in NF2-related tumours, furthermore, the effect of TAM signaling in 
mediating immune cell–tumour cell interaction may be tumour specific. Future 
experiments should be conducted to study the importance of high MERTK level in 
macrophages along with on tumour cells and to study the effect of MERTK inhibition on 
anti-tumour immune response and to compare the effectiveness of MERTK inhibition in 
tumours with high and low macrophage infiltration. 
5.5 Concerns of using TAM inhibitors 
While the role of TAM receptors as oncogenes and immune suppressors in several cancers 
makes the inhibition of TAM receptors an impressive strategy on one side, 
counterproductive results of TAM inhibition in other systems present a paradox regarding 
the use ofTAM inhibitors. Li Q and colleagues showed that TAM triple knock-out mice 
developed systemic autoimmunity which resulted in an increased production of 
proinflammatory cytokines such as TNF-α and disruption of the blood brain barrier 
(BBB). Moreover, increased neuronal cell death in these mice, probably due to increased 
neuroinflammation, raises concerns for the development of neurodegenerative disorders 
such as Alzimer’s and Parkinson’s disease in long term (Li et al., 2013). Interestingly, 
TAM receptors and their ligand Gas6 seem to play a tumour suppressor role in colitis-
colorectal cancer as opposed to the usual oncogenic role demonstrated in many other 
cancers. Chronic inflammation caused by colitis increases the risk of colorectal cancer 
and TAMs appear to reduce the inflammatory immune response in this condition, 
therefore helping to prevent the onset of related cancer. Indeed, two separate studies 
showed that Gas6-/- and AXL-/-MERTK-/- mice had larger tumour volume and 
decreased overall survival (Bosurgi et al., 2013, Akitake-Kawano et al., 2013).  
The contradictory role of TAM receptors and Gas6 emphasizes a real need to think 
thoroughly about the potential long-term effects of TAM inactivation since chronic 
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inflammation has long been associated with increased risk of cancer. In order to deal with 
this problem Bosurgi et al suggested to develop a therapeutic strategy that spare the 
macrophages population involved in regulation of local inflammation and tissue 
homeostasis from TAM inhibition (Bosurgi et al., 2013). While this approach can be of 
use for inflammation-driven cancer like the colitis-colorectal cancer mentioned 
previously, I believe that it could be little biased as activating innate immune response 
has a protective role in several other cancers. A better understanding of the cell-type and 
the tumour-type specific role of TAM signaling in inflammation setting would help in 
deciding upon the therapeutic suitability of targeting TAMs in specific cancers. 
Again, while removal of all three TAM receptors lead to development of systemic 
immunity in TAM triple knock-out mice, strikingly it did not reduce the life expectancy 
and the effects of autoimmunity were also appeared to be well-tolerated (Li et al., 2013). 
Moreover, it was complete depletion of TAMs that lead to excess immunity in these mice, 
therefore partial inhibition of TAMs or reducing TAM levels only to basal physiological 
level may provide therapeutic benefits without inducing unnecessary toxicity. AXL 
inhibitor BGB324 has proved its effectiveness at low, physiologically-safe doses in 
healthy volunteers and showed its potential to be used as a cancer immunotherapy in 
future without inducing a toxicity (Wnuk-Lipinska et al., 2014). Consistent with this 
UNC2025 has also shown promising results in pre-clinical trials and an analogue of the 
drug, MRX2843, has just entered into phase-I clinical trial (NCT03510104). Although 
there is skepticism about long-term effects of these kinase inhibitors on patient’s 
immunity, in immediate setting BGB324 and particularly UNC2025 appear to be 
promising small molecules for the treatment of NF2 patients.  
In conclusion, the development of TAM therapies for the treatment of meningioma and 
schwannomas are promising but futher investigations are required to ensure anti-
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tumourgenic effects do not have long term consequences on normal tissue maintenance 
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7.0 Supplementary data  
7.1 The inhibitory effect of UNC2025 and BGB324 on pFLT3 in meningioma 
primary cells 
Incubation of meningioma primary cells with UNC2025 for 1 hr led to reduction in 
pFLT3 from 1.0 μM. UNC2025 was even more effective at inhibiting phosphorylation of 
FLT3 at 72 hrs and it nearly completely inhibited pFLT3 at 0.3 μM. A dose-dependent 
decrease in pFLT3 was also observed on treatment of meningioma primary cells with 
BGB324 for 1 hr. Although these results are preliminary and more samples needs to be 
tested to reach to any conclusion, the results of these experiments show that both BGB324 
and UNC2025 may mediate their anti-tumorigenic effect via acting upon FLT3 in 
addition to AXL and MERTK respectively.    
 
 
Figure S1- UNC2025 and BGB324 inhibits pFLT3 in meningioma primary cells. 
A Western blot showing dose-dependent decrease in pFLT3 following treatment of meningioma 
primary cells with UNC2025 (1 hr and 72 hrs; n=1) A); and BGB324 (1 hr; n=1) B). GAPDH 
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7.2 The inhibitory effect of BGB324 on pAXL and pFLT3 in schwannoma cells 
A strong reduction in pAXL was observed at 5 μM following incubation of schwannoma 
primary cells with BGB324 for 72 hrs. Interestingly, BGB324 also completely inhibited 
pFLT3 at 5 μM after 72 hrs. Although much more work is needed to understand the 
importance FLT3 in schwannoma pathogenesis, this preliminary data provides a new 
candidate which has not yet been investigated with respect to its role in NF2 
tumorigenesis.       
 
Figure S2- BGB324 inhibits pAXL and pFLT3 in schwannoma primary cells. 
Decrease in pAXL and pFLT3 following treatment of schwannoma primary cells with BGB324 
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7.3 Macrophage infiltration in Merlin-negative human meningioma G-I tissues 
and the expression of AXL, TYRO3 and MERTK. 
Since MERTK is highly expressed by macrophages and the TAM receptors can be 
activated at the cell membrane by forming a homo or hetero-dimer with the receptors of 
the same cells or adjacent cells, I wanted to investigate whether infiltrated macrophages 
influences the expression and activity of MERTK in meningiomas. To search this, firstly 
the levels of macrophages were investigated in each meningioma tissue sample by 
performing IHC or flow cytometry, followed by examination of MERTK and pMERTK 
levels in the same samples. In addition, the level of total AXL, TYRO3 and phospho AXL 
were also searched using IHC and Western blotting. IHC on meningioma tumour samples 
was performed in collaboration with the pathologist Dr David Hilton from the 
Neuropathology Department at Plymouth Hospital NHS Trust and Flow cytometry was 
performed by Dr Claire Adams at University of Plymouth. 
IHC (Figure S3- A, B and C) and Flow cytometry (Figure S4- A and B) confirmed the 
infiltration of M2-polarized CD163+ tumour associated macrophages in meningioma 
tissues and freshly isolated meningioma cells in culture, respectively.  
IHC demonstrated strong cytoplasmic MERTK staining in macrophages (blue arrows) 
and weak variable staining in tumour cells (red arrows) (Figure-S3 D). pMERTK showed 
granular membrane and some cytoplasmic staining in endothelial cells (black arrows), 
macrophages and (blue arrows) and tumour cells (red arrows) (Figure-S3 E). AXL, pAXL 
and TYRO3 staining was mainly found in tumour cells (red arrows), however some 
staining is also observed in macrophages (blue arrows) and endothelial cells (black 
arrows) (Figure S3- F, G and H) confirming our group’s previous data (Hilton et al., 
2016). Scoring for MERTK was performed on macrophages as tumour cells displayed 
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only a weak, cytoplasmic staining. For pMERTK, pAXL/AXL and TYRO3 scoring was 
performed on tumour cells (scoring was performed by Dr David Hilton).  
No significant difference in pMERTK, pAXL, and AXL or TYRO3 staining intensity was 
observed between tissues with low macrophage infiltration and tissues with high 
macrophage infiltration (Figure-S3 I). However, meningioma tissues with high 
macrophage infiltration showed significantly stronger MERTK staining compared to 
tissue with low macrophage infiltration (Figure-S3 I). Western blotting of freshly isolated 
meningioma primary cells (p0) from the tissues with high macrophage infiltration also 
demonstrated a significant increase in MERTK expression compared to samples with low 
macrophage infiltration (Figure-S4 C), suggesting that macrophages may contribute to 
the overall MERTK expression in meningioma tissues.  
To verify that macrophages contribute to increased MERTK expression in meningioma 
tissues, freshly isolated meningioma primary cells-passage 0 (p0), were passaged to 
passage 1 (p1), followed by flow cytometry and detection of CD163+ macrophages. The 
results revealed decrease in macrophage levels from average 3.62% to average 1.20% in 
samples with low macrophage infiltration and from average 27.25% to average 16.84% 
in samples with high macrophage infiltration (Figure-S4 A and B). The same samples 
were then tested for MERTK expression by Western blotting, demonstrating a small but 
significant decrease in total MERTK levels in p1 compared to p0 cells from low 
macrophage infiltration tissues (Figure-S4 D). No difference in MERTK levels was 
observed between p0 and p1 cells from tissues with high macrophage infiltration (Figure-
S4 D) as p1 still contains a proportion of macrophages (average 16.84%) expressing 
MERTK. 
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Figure S3- IHC to detect macrophage infiltration and expression of TAM receptors. 
IHC demonstrate CD163 staining in tissues with low A) and tissue with high macrophage 
infiltration B). A scatter plot graph represents the percentage of CD163-positive cells in low (n=8) 
and high macrophage infiltrated meningioma tissues (n=8) C). IHC shows that MERTK D), 
pMERTK E), AXL F), pAXL G) and TYRO3 H); are expressed by tumour cells (red arrow), 
CD163+ macrophages (blue arrow) and endothelial cells (black arrow). The quantitative 
assessment of staining intensity for AXL, pAXL, MERTK, pMERTK and TYRO3 in tissues with 
low and high macrophage infiltration has demonstrated in a graph (n=8), I). Scale bar 50 μM. 
Unpaired two-tailed student’s t-test or two-way ANOVA with Bonferroni posttest was used to 
calculate the statistical significance; *p<0.05 and ***p<0.001. IHC staining and scoring was 
performed in collaboration with the pathologist Dr David Hilton from the Neuropathology 
Department at Plymouth Hospital NHS Trust. 
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Figure S4- The expression of MERTK is correlated with CD163+ macrophages in 
meningiomas. 
Flow cytometery demonstrates variable level of CD163+ macrophage infiltration in freshly 
isolated- passage 0 (p0) and passaged- passage 1 (p1), meningioma primary cells in culture; (p0 
and p1 for low macrophage samples (n=11) and p0 and p1 for high macrophage samples (n=6)); 
A) and B). Western blot analysis shows significantly higher expression of MERTK (n=3) but not 
of AXL (n=3) or TYRO3 (n=3) in freshly isolated meningioma primary cell samples with high 
macrophage infiltration C). The expression of MERTK is significantly reduced in low 
macrophage infiltrated samples when p0 menigioma primary cells passagd to p1 but not in 
samples with high macrophage infiltration (n=3) D). Two-way ANOVA with Bonferroni posttest 
was used for statiscal significance calculation; *p<0.05 and ***p<0.001 
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7.4 Uncropped Western blot images of each antibodies used in this project 
 
 
Figure S5- A representative uncropped Western blot images of all antibodies used in this 
project. 
Western blot images of phosphorylated and total AXL, MERTK and TYRO3 A); phosphorylated 
and total ERK, AKT, JNK, FAK, Src and Cyclin-D1 B). The bands that used for densitometry 
measurements have been marked in red box. 
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7.5 The summary of characteristics, Merlin/NF2 status and the experiments 
each clinical sample used for.  
The characteristics of all tumour samples (schwannomas and meningiomas) and in which 
particular experiments they used for, are detailed in table S1. All tumours were confirmed 
as Merlin-deficient using Western blot, performed by myself or one of my colleagues. 
The NF2 status for some of the samples were investigated by sequencing NF2 gene with 
next-generation sequencing (NGS) and multiple ligation-dependent probe amplification 
(MLPA) techniques at the Manchester Centre for Genomic Medicine, Mangen 
(Manchester Department of Clinical Genetics) depending on the project requirement and 
is summarized in table-S2. Table-S1 and table-S2 has been attached seperately as Excel 
spreadsheet.  
